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INTRODUCTION 
 Siddha system is a very ancient Medicine in the world.It is mainly occur in South India. 
Siddhars are the Indian saint in the World. They are used the Herbs, Metals, Minenals.It’s used 
for Better health and helps to live the mankind for more than Thousand of Years .Siddha 
Medicine is a preciousless medicine in the world.  
 According to Siddha physiology man is considered as the “MICROCOSM”.Universe is 
considered as the “MACROCOSM”. It shows the Human body is the replica of the Universe. 
 Siddha System of medicine is to give healthiness to an individual.Siddha system is differ  
from the other system medicine by giving absolute Physical, mental and social well being of an 
individual. 
 Siddhars advised to use herbal medicine initially to cure diseases.Siddhars are most 
beneficial Scientists, 
 In the world.The only difference appears to be that the Siddha medicine recognizes 
predominance of Vadham ,Pitham, Kabam.in childhood,adulthood and old age.According to the 
Siddha system of medicine, varios psychological and physiological functions of body are 
attributed to the combination of seven elements: 
1.Ooneer(plasma) 
2.Seneer(Blood) 
3.Oon(Muscle) 
4.Koluppu(Fatty tissue) 
5.Enbu(Bone) 
6.Enbu majjai(Bone Marrow) 
7.Sukkilam /Suronitham(Reproductive organs). 
 According to the siddha medicine System ,diet and life style play an major role in health 
and curing diseses. This concept of this siddha medicine is termed as pathiyam and apathiyam, 
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which is essentially a list of ‘’do’s and don’ts’’.Siddhars  Principle nature is man and man is 
nature.Man’s body is produced by nature. Which is a part of Universal nature.Man’s body is 
produced by nature but the power in nature is Spiritual.Therefore Spiritual is able to change a 
man’s nature response to nature call is liable to occur diseases. 
 The Uyir thathu divided in to three thodas known as Vatham, Pitham, Kabam and 
acquires 3 characters(Sathuvam, Thamo, Raso)thereby it protects and develops the Soul and 
body. 
Saiva Siddhantam is basic for siddha .Mini of siddhars were devout saivaites .The Siddha 
medicines meant for the human body are prepared , based on the theory of Panchabuthas. 
The Name Siddha medicines owes its origin to medicinal thoughts and practices of a 
classof Tamil sages called the Siddhas “ Perfected “ or “Holy immortals “ who were , and are 
still , thought to have superhuman powers. They had firm trust in the “deathless “ physical body 
being in harmony with the spiritual immortal “soul”. 
 Significantly , one of the definitions of siddha medicine is invasion of death : that which 
ensure preventive against mortality “,- Tirumular 
In Siddha system of medicine knee joint pain is classified and described underkeel vayu. 
The  word keel means the hinge joint 
The word vayu means the vali of vatham 
 Keel Vayu is classified as 10 is number . Azhal Keel Vayu is comes  under this 
Classification .Azhal keel vayu is characterized  by 
Joint Pain 
Swelling 
Tenderness  
Stiffness 
Restricted movements 
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and therefore it can be correlated with osteoarthritis of knee. 
Osteoarthritis: 
Osteoarthritis is a chronic progressive degenerative disease affecting mainly the articular 
cartilage of big weight joints of the body mainly in the aged individuals that is characterized by 
• Subchondral sclerosis 
• Osteophyte formation 
• Changes in the soft tissues including the synovial membrane joint capsule,ligaments and 
muscle, 
• Synovial inflammation 
 
Osteoarthritis figures as the second most common disease after diabetes. 
Hence osteoarthritis represents a major root of disability.It is more common in post 
menopausal women. 
 
As per Siddha literaturePanja Lavana parpam (internal) Lahu vatha kesari thylam 
(External) have  been indicated for arthritis and myalgic  pain. On the basis of our siddha text 
Osteoarthritis is intercorrelated with keelvayu and more often keelvayu comes under 80 types of 
vadha diseases.The above medicine contain ingredients which have anti inflammatory property. 
 
PANJA LAVANA PARPAM- INTERNALLY  
    (Ref – ATHMARATCHAMIRTHAM) 
LAHU VADHA KESARI THYLAM-EXTERNALLY  
    ( ReF_.)ANUBAVA VAITHIYA DEVA RAGASIYAM. 
The drugs were prepared by the author and tried in 40 cases in the OPD and IPD. 
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AIM AND OBJECTIVES 
AIM: 
Phase II clinical observation criteria based study of “AZHAL KEEL VAYU” and the 
drug choice “PANJA LAVANA PARPAM” (Internal) and “LAHU VATHA KESARI 
THYLAM”(External). 
PRIMARY    OBJECTIVE: 
 To evaluate the clinical efficiency of Siddha drugs “PANJA LAVANA 
PARPAM”(Internal) and “LAHU VADHA KESARI THYLAM”(External) in healing of 
“AZHAL KEEL VAYU” (OSTEOARTHIRITIS). 
SECONDARY OBJECTIVE: 
o To study the siddha principles neerkuri and neikuri before and after treatment. 
o To study the effect of internal and external medicine with wash in 40 subjects. 
o To evaluate the safety profile of the trial medicine. 
1.To evaluate the clinical cause of the disease Azhal keel vayu with keen study on 
the definition,Aetiology,Pathology, Diagnosis,Prognosis,Complications and the 
treatment by making apply of siddha aspects. 
2.To have an idea about the occurrence of Azhal keel vayu with orientation of 
Age,Sex, Family,History,Socio-economic status,Diet, Habit and climatic 
conditions.  
3.TO know the connection of aetiology, classification, Symptoms,diagnosis and 
line of treatment compared with osteo arthiritis. 
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4.To execute the variation of the disease under the topics of Mukkutram,Uyir 
Thathukkal,Udal thathukkal ,Envagai thervugal,Porigal,Naadi,Neerkuri,Neikuri. 
5.To formulate a clinical trial medicine PANJA LAVANA 
PARPAM(Internal),LAHU VADHA KESARI THYLAM(External) in the 
treatment of Azhal keel vayu. 
6.To apply the modern parameters in the analysis of X-ray to confirm the 
diagnosis and to follow the series of patients. 
7.To bring out the biochemical analysis and pharmacological action of the trial 
medicine. 
8.To insist Thokkanam and Otradam, Asanam exercise along with medicine  to 
achieve the good results, Which are the prominent features of Sirappu 
Maruthuvam. 
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SIDDHA LITERATURE 
Siddhars are most spiritual scientist in the world he explored. 
 The food we have take six types of taste. 
1. Sweet (-eqh<H* 
2. Sour ( Htqh<H* 
3. Salt (dh<H* 
4. Bitter (jgh<H* 
5. Pungent (giIh<H* 
6. Astringent (Kui<h<H* 
Each of it mixture of 2 basic materials, 
 -eqh<H!! .! l{<! + fQI!
! Htqh<H!! .! l{<! + kQ!
dh<H! ! .! fQI! + kQ!
jgh<H!! .! gix<X!+ Ngibl<!
giIh<H!! .! kQ! + Ngibl<!
Kui<h<H! .! l{<! + Ngibl<!
This six tastes are divided by the thiridhosam (vatham, pitham, kabam) 
Which are the pillar for support our body structure. 
 uiB! .! uikl<!
! OkB! .! hqk<kl<!
! nh<H! .! ghl<!
 These are the alteration method in the level of Thiridhosha.  It may affects the normal 
function of the body. 
 lqgqEl<!GjxbqEl<!Ofib<!osb<Bl<!F~OziI!
! utqLkzi!ou{<{qb!&e<X!!
. kqVg<Gxt<!
!
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The normal value of thiridhosa vadham, pitham, kabam – 1: ½ : ¼ 
 upr<gqb!uikl<!lik<kqjv!obie<xigqz<!
! kpr<gqb!hqk<kf<!ke<eqjz!uisq!
! npr<Gr<!ghf<kiemr<gqOb!giOzicz<!
! hqsr<gqb!sQuIg<Gh<!hqsogie<Xlqz<jzOb!
. G{uigml<!
Synonyms of the literature, Three dhosas due to irregular diet & behavior.  In the keel 
vatham disease, the chief deranged factor among the Thirithathu is the vatham. 
gQz<uiB!
Introduction 
 gQz<uiB!we<hK!&m<Mgjth<!hx<xqb!uikl</!
! In Siddha literature Azhal keel vayu comes in the topic of vatha disease. 
 Azhal keel vayu = Azhal + keel + Vayu 
 Azhal - Pitham 
 Keel - Joint 
 Vayu - Vatham 
In Agasthiyar Gunavagadam “KEEL VAYU” comes under 80 types of vatha diseases. 
 “kieig!gQz<uik!Ovigl<!Ohjv!
! Ofib<!keg<G!higqbib<!uikOvig!ole<hi<!
! Fm<hLt<t!uikOvig!ol{<hKf<!kie<!
! Nb<f<okMk<K!-kx<Gt<Ot!nmg<gl<!hiV/!
. ngk<kqbi<!G{uigml<!
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Okjvbi<!gih<hqbk<kqz<!uikl<!92!ujgbqz<!gQz<uikl<!okiGg<gh<hm<Mt<tK/!
B,gq!juk<kqb!sqf<kil{qbqz<!uikl<!91!ujgbigUl<?!
! TV sil<hsqul<hqt<jt!F~zqz<!gQz<uiB!causes “Painful inflammation with swwelling 
affecting the muscle & joints of the human body. 
Ofib<!-bz<< << << <!
! -kje!shihkq!jgObm<cz<?!
! “utqBjlf<!ke<eqjz!ogm<M!
! uzqBme<!uQg<gs<!SvLl<!gib<f<K!
! &m<Mg<gt<!OkiXl<!LMg<gqOb!ofix<K!
! &m<Mg<gt<!ke<eqz<!fQVl<!Svf<K!
! kir<ogi{i!uzqBli!ofif<kqMll<Ol”!
OuXohbi<gt<< << << <!
! sf<Kuzq?! &m<Muzq?! Olg$jz?!Lmg<GuiB?!Nluikl<?! sf<Kuikl<?! $jzg<gm<M?!
sf<kqg!sqOz]<l!Ovigl<?!uik$jz?!uiBOvigl<!
giv{!ohbi<gt<< << << <!
Ofib<giv{l<!! ! .! Olg$jz!
Lg<Gx<x!fqjz!liXhiM! .! uik$jz?!sf<kqg!sqOz]<lOvigl<?!sf<Kuikl<!
-mk<jkg<!ogi{<M! ! .! &m<Muzq?!sf<Kuzq!
GxqG{r<gjt!ogi{<M!! .! $jz!gm<M?!Lmg<G!uikl<!
Ofib<!uVl<!giv{r<gt<!hx<xq!hvvis!Osgvk<kqe<hc?< < < < < < << < < < < < << < < < < < < !
! “gi{Ou!lqgU{<miZr<!gVKhm<ceq!uqm<miZl<!
! lie<jebiI!g{<!Oliglxg<gqE!lqGf<kqm<miZl<!
!
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! N{u!lzr<gml<jl!br<gOe!uqmikkiZl<!
! uiEke<!lmfz<!ziOt!uikr<Ogi!hqg<Gr<!giOe”!
hbl<?! wz<OziiqmLl<! Ogihl<! ogit<tz<?! lqGkqbig! Ymz<?! lqGf<k!Kg<gl<?! kqeLl<!
dmzqe<Olz<!gix<Xh<hmz<!Ohie<xux<xiZl<?!
! “gizr<g{<!lixqB{<[r<!giiqbk<!kiZf<!k{<{QI!
! sizOu!bVf<kqeiZf<!sf<kqZm<!giIf<kiZl<!
! Ogizlil<!Htqh<H!ofb<jb!uVf<kqeiZl<!
! uiz<uiI!Ljz!fz<ziOt!uik!Lx<huqg<Gr<!giO{”!
. hvvisOsgvl<<<<!
“%Xolie<X!&e<Xme<!GzU!fijzf<!OkpqZl<!
! Gx<xlil<!fzk<kqEl<!ogivl<!he<eqv{<cZl<!
! OsvOu!Hke<kiXOli!sQiqbOlje!fqe<xqcz<!
! osh<ohi{ik!kQjlObiM!osb<Bl<!hs<sf<kiXl<!
! ofMf<Kg<g!lqg<guil<!fmg<gx<kiK!okipqz<kil<!
! fqk<jkbiG!gQz<hqch<H!fQM!olb<bqz<!Okie<Xlil<!
! giiqbr<gt<!Osklib<!giz<ubK!GjxBlil<!
! g{<M{If<K!g{qk!uz<Ozie<!gVk<Kme<!osh<hqeOv/!
. l{qlf<kqv!juk<<< <kqb!Ovigl<< << << <!
we<eOu!uikl<!kio{e<hkiGl<!
! -gk<kqOz!leqki<gTg<G!osb<BuiX!
! hqe<eOu!ohie<kjeOb!Osivr<!osb<K?!
! ohiqObiIgt<!hqvil{jvk<!K~%c{qk<Kl<?!
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! ue<Okux<!osik<kqx<!OsivR<!osb<K!
! liki!hqki!GVju!lxf<k!OhIg<Gl<!
! ge<eOu!Ougk<jk!fqf<jk!osb<kz<!
! gibk<kqz<!gzf<kqMOl!uikf<!kiOe”!
. B,gq!sqf<kil{qhimz<!354< << << < !
“kioee<x!gsh<OhiM!Kui<h<Hjxh<H!
sikglib<!ofR<osZs<!sjlk<k!u{<{l<!
Noee<x!uixqeK!ohisqk<kziZl<!
Ngibk<!OkxzK!Gck<kiZl<!
hioee<x!hgZvg<g!lqviuqpqh<H!
hm<ceqOb!lqgBXkz<!hivolb<kz<!
Okoee<x!olipqbiIOlt<!sqf<jkbikz<!
sQg<gqvlib<!uiklK!oseqg<Gf<!kiOe”. 
kib<?! kf<jk?! GV! -ui<gjt! lxk<kz<?! Oukk<jkh<! hpqk<kz<?! gsh<H?! Kui<h<H?!
djxh<H! Osi<f<k! d{ju! nVf<Kkz<?! Nxqe! d{ju! d{<{z<?! Okr<gqb! fQI?!
zigqiqbijegt<?! sivibl<! Gck<kz<?! hgzqz<! K~r<gq! -vuqz<! uqpqk<kqVk<kz<?! nkqglig!
hm<ceq!gqmk<kz<?!lqGf<k!Sjljbk<!K~g<Gkz<?! oh{<{qe<! Olz<! skifqjeh<Hg<! ogit<tz<!
Ngqb!giv{r<gtiz<!uikOfib<!d{<miGl</!
“utqBjlf<!ke<eqjz!ogm<M!
uzqBme<!uQg<gs<!SvLl<!gib<f<K!
&m<Mgt<!OkiXl<!LMg<gqOb!ofif<K!
&m<Mgt<!ke<eqz<!fQVl<!Svf<K!
kir<ogi{i!uzqBli!ofif<kqMll<Ol”!
. shihkq!jgObM!
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Following precipitating factors are caused the disease, 
 Increased intake of tuber 
 Wandering of chill weather 
 Drenching in Rain 
 Living in hilly region 
 Excessive sexual intercourse 
 Hereditary 
 Excessive intake of bitter, astringent, acrid taste food, intake of varagu thinai and altered 
sleep pattern also contribute to vatha disease. 
Sju!
HtqKui<!uqR<Sr<gxq!bix<H,iqg<!Gl<uil<!
ytqBui<jgh<!Ohxqz<!hqk<Ks<!sQXl<!.!gqtqolipqOb!
giIh<hq{qh<H!uqR<sqx<!ghl<uqR<S!sm<cvks<!
Osvh<!H{i<!Ofib[giOk/!
we<hkqeiz<!Htqh<H?!Kui<h<H!nkqgLt<t!d{Ugtiz<!uikl<!lqGkqh<hMl</!
d{U!
! “utqkV!gib<gqpr<G!ujvuqzi!kbqzz<!Ogijp!
! Ltqkbqi<!Ohie<lqGg<G!Ljxbqzi!U{<c!Ogimz<!
Gtqi<kV!utqbqx<!Oxgr<!Geqh<Hx!Uzuz<!oh{<ci<!
! GtqkV!lbg<gl<!ohx<OxiI!gcosbz<!gVuqbiliz<”/!
. shihkq!jgObM!
“okipqz<ohX!jgh<Hg<!giIk<kz<?!KuIk<kz<!uqR<SgqER<!OsiXl<!
hjpbkil<!uvG!lx<jxh<!jhf<kqje!bVf<kqeiZl<!
!
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wpqz<!ohxh<!hgZxr<gq!-vuqeqZxr<gtk<kiZl<!
ljp!fqgi<!GpzqeiOz!uikr<Ogi!hqg<Gr<giO{”!
. hvvis!Osgvl<<<<!
jgh<H?!Kui<h<H?!giIh<H?!hkiIk<kr<gjt!lqGkqbig!d{<{z<?!hjpb!OsiX?!uvG?!
kqj{!d{<{z<?! hgzqz<!dxr<gq! -vuqz<! uqpqk<kqVk<kz<!Ngqb!giv{r<gtqeiz<! uikl<!
lqGkqh<hMl</!
Environmental factors (Hx$p<fqjzgt<*< << << < !
! “uik!ui<k<kje!gizOlOki!oue<eqz<!
! lVUgqe<x!Neq!gx<gmliGl<!
! Nkjuh<!hsqObiM!giIk<kqjg!ke<eqz<!
! nmVOl!lx<x!likr<gt<!ke<eqz<!
! OhigOt!slqg<Ggqe<x!gizliGl</”!
! ohiVf<kqOb!bqui<!okipqz<!kie<!g{<cxk<kz<!
! gikOu!g{<&mz<!jggiz<!jsk<kz<!
! gcf<Okim<m!Lmg<goziM!fQm<moue<Oe”/!
. B,gq!sqf<kil{qhimz<< << << <!
From the month of Aani to Karthigai (June to December), vatha diseases are precipitated, 
hence the seasonal factors are involved and facilitate the vatha diseases. 
 “hKlk<jk!H,g<g!jug<Gl<!hiElqg<g!giBl<!
! LKOueq!zqx<H!uqf<fQI!Lx<Xl<!.!gKole!
! ux<Xl<!gh0Gl<!uiBlqGl<!uip<lif<kQIg<!
! Gx<x!fzqg<!Ogkqoke<!OxiK”!
. lVk<Kui<!keqh<himz<< < < << < < << < < <!
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uqtg<gl<< << << <!
! LKOueqz<! gizk<kqz<?! $iqbouh<hk<kqe<! giv{lig! ohVl<! uiiqbig!
fQINuqbig<gh<hm<M! H,lqbqz<! uxm<sq! fqzUl</! ! nKOhiz<! flK! dmzqz<! uxm<sq! Wx<hm<M!
utqOfib<!uVukx<G!WKuigqxK/!
hpg<gupg<gr<gt<< < < << < < << < < <!
! “oub<bqzqz<!fmg<jgbiZl<!lqgk<k{<{QI!
! osb<bqjp!lgtqjvs<!Osi<f<kE!huqg<jgbiZl<!
! jhbOe!d{<jlbiZl<!higx<gib<!kqe<jgbiZl<!
! jkbOz!uikOvigl<!seqg<Gole<!xxqf<K!ogit<Ot”!
. Okjvbi<!uigml<< << << <!
 $iqb!ouh<hk<kqz<!nkqg!okijzuqz<!fmk<kz<!
 nkqg!k{<{QI!Gck<kkiZl<!
 nkqgtU!higx<gib<!d{<[ukiZl<!
 nkqgtU!gill<!Kb<h<hkiZl<!utqOfib<!Wx<hMl</!
Ofib<uVl<!upq< << << < !
!
!
!
! ! !
! ! !
!
ubK!
d{U!
hpg<gupg<gl<!
 
uikl<!
uqbiee<!
nhiee<!
sliee<!
 
ghl< hqk<kl< 
sf<kqgl< sikgl<! 
npz<!gQz<uiB 
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Clinical features of keelvayu 
“hqk<k!gQz<uiB!ke<eix<!hqxr<G!gQz<&m<M!uQr<gqs<!
sqk<ki<!osz<!lVk<Kuk<KR<!sQIhmike<elk<kiz<!
kk<kX!gib<s<sz<!g{<M!sizOu!kjekie<!kf<Ok!
olk<kx!sqgqs<js!ke<eiz<!ole<Olz<!fQr<Glh<hi”!
. shihkq!jgObM!
 &m<Mgtqz<!uQg<gl<!d{<miGl<!
 &m<Mgtqz<!uzq!gi{h<hMl<!
 kQg<Gx<x!lqGkqbiz<!gQz<gtqz<!hjs!ux{<M?!hjsbx<x!gQz<!njsBl<!Ohiokz<zil<!
uzq!d{<miGl</!
 sqz! Oujtgtqz<! gQz<gt<! ohiVk<Kgt<! ye<Oxiomie<X! ym<cg<! ogi{<M! fmg<g!
Lcbilz<!gi{h<hMl</!
hq{qbxqLjxjl!
! dmjzh<!hq{qk<kziz<!Ofijbk<!!okiqf<K!ogit<Tgqe<x!yPg<gl<!weh<hMl</!
 ohixqbix<Oxi<kz<!
 Hzeizxqkz<!
 uqeikz<!
ohixqbiz<!nxqkz<< << << <!
! It means examining the patient by the physician for proper diagnosis.  “Pori” is 
considered “Five sense organs” namely, 
1. olb<!)skin) 
2. uib<!)Tongue) 
3. g{<!)Eye) 
4. &g<G!)Nose) 
5. osuq!)Ear) 
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RiOef<kqiqbr<gtqe<!Nb<U< < < << < < << < < < !
osuq! yzq!nxqb!osb<kz<! -bz<H!
olb<! dmzqz<!Dx<jx!nxqkz<! Lpr<giz<!&m<Mgtqz<!
uQg<gl<?!uzq!
g{<! ytqjb!nxqb!osb<kz<! -bz<H!
fig<G! Sjujb!nxqb!osb<kz<! -bz<H!
&g<G! uisje!Fgv!osb<kz<! -bz<H!
!
ge<Olf<kqiqbr<gtqe<!Nb<H< < < < << < < < << < < < < !
uib<! useqg<gs<osb<Bl<! -bz<H!
jg! -MkZl<?!Wx<xZl<osb<Bl<! -bz<H!
giz<! fmg<gs<osb<Bl<! Lpr<giz<!&m<Mgtqz<!uzq?!
fmg<g!sqvll<!
wVuib<! lzk<jk!gpqg<Gl<! lzs<sqg<gz<!
gVuib<! gV?!Sg<gqzk<jkg<!gpqg<Gl<! -bz<H!
 
w{<ujgk<Oki<U< < << < << < < !
“uikk<kqz<!Osk<Kl!ligqz<!uzqObiM!uQg<gL{<mil<”!
. ngk<kqbi<!fic!
“nxqf<KhiI!uikOl!keqk<kieiz<!
siqf<kqmOu!giz<!Lmg<Gl<”/!
. ngk<kqbi<!vk<kqe!SVg<gl<!
“gi{h<hi!uik!lQxqz<!giz<jggt<!ohivf<kq!OfiGl<!
uikl<?!uikhqk<kl<?!hqk<kuikl<!.!giuqbfic!
2/ ^<hiqsl<! .! hikqg<gh<hm<Mt<t!&m<M!hGkqbqz<!lqk!ouh<hligOui?!
-bz<higOui!gi{h<hMl</!
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3/ fi! ! .! -bz<H?!uikOfibqz<!fi!Kck<K!-Vg<Gl</!
4/ fqxl<! ! .! -bz<H?!lifqxl<!
5/ olipq!! .! slyzq!
6/ uqpq! ! .! -bz<H?!uikOfibqz<!uqpq!gXk<K!-jlkck<kqVg<Gl</!
7/ lzl<! ! .! hikqh<H!)lzs<sqg<gz<!gi{h<hMl<*!
8/ &k<kqvl<! .! gMh<Hme<!ogiR<slig!-xr<Gl</!
Neikkuri 
 “nVf<K!lixqvkLl<!nuqOviklkib<!
! n0gz<!nzi<kz<!ngizU,{<!kuqi<kpx<!
! Gx<xt!uVf<kq!dxr<gq!jugjx!
! Ncg<!gzsk<!kiuqOb!giKohb<!
! okiV!&%Ik<kg<!gjzg<Gm<!hMfQiqe<!
! fqxg<Gxq!ofb<g<Gxq!fqVlqk<kz<!gmOe”!
. sqk<k!lVk<Kuir<gs<SVg<gl<!
w{<o{b<< << << <!uqm<Mh<!hiIg<Gl<!fQiqe<uqpq< < < < Q << < < < Q << < < < Q < !
! fqxg<Gxqg<!Gjvk<k!fqVli{!fQiqx<!
! sqxg<g!ou{<o{b<ObiI!sqXKtq!fMuqMk<!
! oke<Xxk<!kqxf<okizq!Wgikjpk<kq!
! eqe<xkqujz!Ohil<!ofxquqpqbxqUl<!
! ose<xK!HgZR<!osb<kqjb!B{Ov!
. Ofib<fimz<!Ofib<Lkz<fimz<!hqiqU.2!
“nvoue!fQ{<ce<0Ok!uikl<!
! NpqOhix<!hvuqe<!n0Ok!hqk<kl<!
Lk<okik<K!fqx<gqe<!olipqu!oke<!ghOl!
! nvuqz<!NpqBl<!Npqbqz<!nvUl<!
nvuqe<!Lk<Kl<!Npqbqz<!Lk<Kl<”!
. sqk<k!lVk<Ku!Ofib<fimz<!Ofib<!Lkeimz<!kqvm<M!
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Neerkkuri 
 “uf<k!fQIg<giq!objm!l{l<!Fjv!wR<soz!
! jxf<kqb!Ztju!bjxGK!LjxOb”!
. sqk<k!lVk<Kuir<gSVg<gl<!
Urine is examined for the following Neerkuri 
 Niram - Colour 
 Edai - Specific gravity 
 Manam -  Smell 
 Nurai - Frothy nature 
Enjal -  Quantity of urine voided 
In Azhal Keel vaayu straw or hay coloured urine was noticed in Neerkuri. 
PARUVA KAALAM 
Siddhars are classified a year into six seasons, 
Kaalam Kutram Suvai 
Kaarkaalam   
Aavani & Purattasi 
(Aug 16 – Oct 15) 
Vatham (Vetrunilai valarchi) 
Pitham (Thanilai valarchi) 
Enippu 
Pulipu 
Uppi 
Koothirkaalam 
Iypassi & Karthigai 
(Oct 16 – Dec 15) 
Vatham (-) 
(Thanilai adaithal 
Pitham 
(Vetrunilai valarchi) 
Enippu 
Kaippu 
Thuvarppu 
Munpanikalam 
(Margazhi & Thai 
(Dec 16 – Feb 15) 
Pitham 
(Thanilai adaithal) 
Enippu 
Pulippu 
Uppu 
Pinpani kaalam 
Massi & Panguni 
(Feb 16 – Apr 15) 
Kabam 
(Thanilai valarchi) 
Enippu 
Pulippu 
Thuvarppu 
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7 dmz<!kiKg<gtqe<!Nb<U< < < << < < << < < < !
u/w{<<<<! dmz<kiKg<gt<< < << < << < <! okipqz<<<<! npz<gQz<uiBuqz<!< Q < << Q < << Q < <
gi{h<hMuK<<< !
2/! sivl<! dmjz?!lejk!Dg<gLxs<osb<kz<! hikqh<H!
3/! osf<fQi<! nxqU?! ue<jl?! ytq! osVg<G!
-jugjt!fqjzg<gosb<kz<!
-bz<H!
4/! D{<! dmzqz<!dVuk<jk!njlk<kz<?!we<jh!
uti<k<kz<!
hikqh<H!
5/! ogiPh<H! dXh<Hgt<! -br<g! nux<xqx<G! ofb<h<H!
hjs!Dm<MuK!
hikqh<H! )gQz<gtqz<!
ofb<h<H! hjs!
Gjxkz<*!
6/! wZl<H! dmz<!njsuqx<G!nch<hjmbibqVk<kz<! hikqh<H!
7/! &jt! we<Hg<Gt<! fqjxf<K! ue<jlBl<?!
ole<jlBl<!kVuK!
hikqh<H!
8/! ou{<{QI! gVOkix<xk<kqx<G!Lkzib<!fqx<hK! -bz<H!
!
In Azhal keel vayu,  
 Saaram, kozhuppu, Oon and Enbu thathukkal are chiefly affected. 
Lg<Gx<x!OuXhiM< << << < !
utqlqG!uhie!uqbie!
! ! uiBg<g!tkqg!iqg<Gl<!
-tlqg!lzfQIg<!gm<Ml<!
! ! -bl<hqb!uhiee<!osb<Bl</!
!
!
!
!
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!
uikl<<<<!
u/w{<<<<! uikl<<<<! okipqz<<<<! npz<gQz<!uiBuqz<!< Q < << Q < << Q < < hikqg<gh<hm<m!< < << < << < <
Gx<xl<< << << <!
2/! hqvi{e<! &s<S!uir<gz<!uqMkz<!
osb<Bl<!
-bz<H!
3/! nhiee<! gQp<Ofig<gq!lzk<jkk<!
kt<Tl<!
hikqh<H!)lzg<gm<M*!
4/! uqbiee<! dXh<Hgjt!fQm<c!lmg<g!
osb<Bl<!
hikqh<H!)giz<gjt!fQm<c!
lmg<gsqvll<*!
5/! dkiee<! d{uqe<!sivk<jk!
dmzqz<!fqxk<kl<!
-bz<H!
6/! sliee<! lx<x!uiBg<gjt!
siqhMk<Kl<!
hikqh<H!)lx<x!uiBg<gt<!hikqh<H*!
7/! fige<! wz<zi!gjzBl<!gx<Gl<!
hc!osb<kz<!
-bz<H!
8/! %Ile<! g{<gjt!kqxg<gUl<!
&mUl<!osb<Bl<!
-bz<H!
9/! gqVgve<! fiuqx<!gsqjuBl<!fisqbqx<!
gsqjuBl<!d{<mig<Gl<!
-bz<H!
:/! Okukk<ke<! Osil<hz<?!dmz<!Liqk<kz<!
d{<mig<Gl<!
hikqh<H!)ubK!giv{k<kiz<*!
21/! keR<osbe<! -xf<k!hqe<!&e<xil<!fit<!
kjzouck<K!outqObXl<!
.!
!
!
!
!
!
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!
!
!
hqk<kl<< << << <!
u/w{<<<<! hqk<kl<< << << <! okipqz<<<<! npz<gQz<!uiBuqz<!< Q < << Q < << Q < <
hikqg<gh<hm<m!Gx<xl<< < < < << < < < << < < < <!
2/! nex<hqk<kl<! d{<m!d{U!
ohiVjt!osiqg<Gl<!hc!
osb<Bl<!
hikqh<H!)hsqbqe<jl?!
d{U!osiqbijl*!
3/! -vR<sgl<! osf<fQjv!lqGkqhMk<Kl<! hikqh<H!)osf<fQi<!GjxU*!
4/! sikgh<hqk<kl<! uqVh<hllie!okipqjz!
osb<K!Lcg<Gl<!
hikqh<H!)giz<gjt!fQm<c?!
lmg<g!sqvll<*!
5/! NOzisghqk<kl<! g{<gTg<G!ohiVjt!
okiquqg<Gl<!
-bz<H!
6/! hqvisg!hqk<kl<! OkiZg<G!yzqjb!
ogiMg<Gl<!
-bz<H!
!
Jbl<<<<!
u/w{<<<<! ghl<<<<!
okipqz<<<<! npz<gQz<uiBuqz<!hikqg<gh<hm<m!< Q < < < < << Q < < < < << Q < < < < <
Gx<xl<< << << <!
2/! nuzl<hgl<!
lx<x!fie<G!Jbr<gTg<Gl<!
hx<X!OgimibqVg<Gl<!
hikqh<H!
3/! gqOzkgl<! osiqk<kz<! -bz<H!
4/! Ohikgl<! Sjujb!nkqgiqg<Gl<! -bz<H!
5/! kx<hgl<! g{<gTg<G!Gtqi<s<sq! -bz<H!
6/! sf<kqgl<!
gQz<gtqz<!fqe<X!-bx<jgbib<!
wz<zig<!gQz<gjtBl<!
ye<Oxiomie<X!ohiVk<kq!ktv!
osb<Bl<!
hikqh<H!)fQm<c!lmg<g!sqvll<*!
!
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Ofib<g{qh<H!uquikl<< < << < << < <!
utqg<gQz<uiB< Q << Q << Q < !
uzqg<Gk<kz<!uQg<gr<gi[l<!uib<k<oki{<jm!uxm<sq!gib<s<sz<!
kjzuzq!liIKch<Hk<!kir<ogi{i!uzq!uQg<gf<kie<!
fqzU!gir<g[g<!Gxr<G!fQM!Okit<!Lpr<jgg<!gix<gil<!
lzg<!Gmx<gm<M!Oui<ju!uikg<gQz<!uiB!uqkiOl!
. shihkq!jgObM!
nxqGxqgt<<<<!
 kir<gLcbik!uzq!
 giz<uqvz<!
 Lpr<giz<!&m<M!
 -Mh<H!&m<M!
 Lpr<jg!&m<M!
 Okit<!&m<M!
 -l<&m<Mgtqz<!uQg<gl<!
 uib<!uxm<sq?! Svl<?!kjzuzq?!hmhmh<H?!lzs<sqg<gz<?!uqbi<k<kz<!Ngqb!nxqGxqgt<!
dt<te/!
Jbg<gQz<uiB< Q << Q << Q < !
“gVkVr<!ghg<gqz<!uiB!g{<cce<!dmz<!-jtg<Gl<!
dVolzquig<Gr<!ogit<Tl<!d{<cjbs<!SVg<G!lqe<hf<!
kVKbqz<!fQr<G!Lm<cx<!fir<ogi{i!uZjubig<Gl<!
-VlOz!uqg<gz<!uif<kq?!Osijh!hi{<omPh<Hl<!hiOv/!
. shihkqjgObM!
!
!
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nxqGxqgt<<<<!
 &m<Mgtqz<!kir<gLcbik!uzq!
 dmz<olzqU!
 hsqbqe<jl!
 uqg<gz<!
 uif<kq!
 hi{<M!
4/!utqJbg<!gQz<uiB< Q << Q << Q < !
“njubl<!uikg<!ghg<gQz<!uiBuie<!uzq!lqGf<Ok!
dbr<G!fQI!Ogik<K!gQz<gt<!yiqbqe<!kjzOhix<!gi[l<!
fbr<ogit<t!Lmg<gz<!fQm<mz<!f{<{qmi!olb<Br<!giBl<?!
lbg<GX!Lxg<lqe<eil<le<eqb!ofiqgm<miOl!
. shihkq!jgObM!
nxqGxqgt<<<<!
 &m<Mg<gtqz<!uzq!
 uQg<gl<!
 gQz<gt<!
 fiqbqe<!kjzOhiz<!gi{h<hMl<!
 fQm<m!fmg<g!LcbiK/!
lVk<Kul<< << << <!
&e<xqozie<X!bi<f<kjk!Le<exqf<K!!
Lf<kqbkje!obipqk<kqm!lVf<kqM!
k{qBl<!Ofibqe<!kf<kqvlqKOu!
Oh{qg<!g{qk<kqce<!hqxuib<!hqe<G{l<!
. Ofib<fimz<!Ofib<!< < << < << < < Lkz<fimz<!)higl<< < << < << < <.2*!
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!
The treatment in siddha system includes not only the removal of signs and symptoms of a 
disease but also in total uprootment of the diseases. 
 This is achieved by normalising the deranged mukkutram there by retaining body’s 
natural health.  The recurrence of the disease is prevented by the practice of yoga.  According to 
siddha system line of the treatment is divided into 3 types. 
1. Kappu (Prevention) 
2. Neekam ( Treatment) 
3. Niraivu ( Restoration) 
1. Kappu (Prevention) 
The preventive azhal keel vayu is,  
1. Control the body weight by diet & exercise. 
2. Modify the nature of work which gives stress to a particular joint. 
3. Avoid excess intake of sour, astringent and bitter tasted food. 
In azhal keel vayu the deranged vatham and other toxic products of digestion and 
metabolism is brought to its normal state by purgation (uqOvsel<*!
uqOvsek<kiz<!uikf<kiPl<< < < << < < << < < <!
15ml of vellai ennai is given the luke warm water at early morning before starting the 
treatment with trial drug. 
a. Internal Medicine 
Panja  Lavana parpam - 5 gm in two divided doses/day after food. 
Adjuvant  - Asaefotida and Honey 
b. External medicine 
Lahu vadha kesari thylam – External application over the affected joints. 
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3. Complementary therapies 
Apart from other department, Sirappu Maruthuvam department gives equal importance to 
complementary therapies in siddha system of medicine along with its internal & external 
medicines. 
 There are several complementary therapies followed in siddha system of medicine such 
as Kattu, Pattru, Nasiyam, Attai vidal, Thokkanam, Ottradam, Varmam Asanam, Vedhu etc. 
Complementary therapies which are taken into account for this study are: 
uqOvsek<kiz<!uikf<kiLl<< < < << < < << < < <!
! 15 ml of vellai email is given with like luke warm water at early morning (single dose) 
before starting the treatment with trial drug.  
a) Panjalavana parpam – 5.1gm in two divided doses / day after food  
b) Lahu vadha kesari thylam – External application over the affected joints.  
c) Complementary therapies: )Kj{!lVk<Kul<* 
Apart from other department, sirappu maruthuvan department gives equal importance to 
complementary therapies in Siddha system of medicine along with its internal and 
external medicines. There are several complemtary therapies followed in Siddha system 
of medicine such as kattu, patttu, Nasiyam, Attai, Vidal, Thokkanam, Ottradam, 
Varmam, Asanam, Vedhu etc.  
 
I. Varmam 
II. Thokkanam and ottradam  
ui<ll<< << << <!
! leqk!dmzqz<!sqz!Gxqh<hqm<m! )n*!wz<zi!Ofvk<kqZl<!Gxqh<hqm<m!Ougk<kqz<!gibl<!
Wx<hm<M!osbzqpk<kz<!Ofib<!Okie<xz<?!lbg<gl<!lx<Xl<!lv{l<!Wx<hMgqxK/!-KOu!ui<ll<!
weh<hMl</!
!
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ui<ll<!219< << << < !
2/ hMui<ll<! .! 23!
3/ okiMui<ll<! .! :7!
Varmam points 
 Varmam is a branch of siddha medicine.  It is one of the Tamilnadu priceless living 
heritage.  Varma is a point where prana exists.  An equillibrium of this points contributes to good 
health.  If any varma points are deranged or affected the related limbs or part of the body get 
affcicated causing particular problem. 
&m<Muzq!kQVukx<gie!sqxh<H!ui<l!Ht<tqgt<< Q < < < < << Q < < < < << Q < < < < <!
2/ &m<M!uIll<!
3/ sf<kq!ui<ll<!
4/ olipqohiVk<K!ui<ll<!
5/ njs!kqiqg{<[!uIll<!
6/ hjkh<H!ui<ll<!
7/ sqvm<jm!ui<ll<!
2/&m<<<<Mui<ll<< << << <!
Location:  Anterior surface of the knee joint 
2. sf<kq!ui<ll<< < << < << < <!
Location: On either side of the mootu varmam 
3. olipq!ohiVk<K!ui<ll<< < << < << < <!
Location: Posterior surface of the patella 
4. njsU!kqiqg{<[!ui<ll<< < << < << < <!
Location: In the anterior surface, 2 finger breadth side wards to the knee joint.  
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5. hjkh<H!ui<ll<< < << < << < <!
Location: Either side of the patella at the posterior surface 
6. sqvm<jm!ui<ll<< < << < << < <!
Location: Present at the patella bone. 
SIRAPPU MARUTHUVAM FOR AZHAL KEELVAYU 
1.THOKKANAM 
2. OTTRADAM 
THOKKANAM  
 Thokkanam is the siddha way of touch therapy.  it is the physical manipulation of the 
body usually done with or without oil application.  It is very effective for neurological and 
musculoskeletal problems.  It also promotes mental and physical fitness.  According to siddha, 
disease in the body occur due imbalance of three humours that is vatham, pitham and kapham 
which in turn are governed by five fundamental elements – Akayam (Space, vayu (air), Theyu 
(fire), Appu (water and Mann (Earth.  Thokkanam is one of the 32 types of external medicines 
mentioned in siddha literature.  In this technique, the physician uses his hands on the body of the 
patient in 9 different unique ways with or without using medicated oil with acurative or palliative 
point of view.  The 9 different techniques in thokkanam which makes siddha medicine unique in 
all aspects.  They are 
 
1. Thattal or patting technique 
2. Irukkal or tightening 
3. Pidithal or holding 
4. Murukkal or twisting 
5. Kattal or tying 
6. Azhuthal or pressing 
7. Izhuthal or pulling 
8. Mallathuthal or supinating 
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Benefits of Thokkanam 
 Helps to cure vatha disease even without internal medicines. 
 Chronic disease like spondylosis, lumbago, disc prolapse, hemiplegia, neurological 
conditions etc are managed well through thokkanam. 
 Improve circulation 
 Treats obesity 
 Helps in pain relief 
 Removes indigestion, constipation and flatulence 
 Induce sleep 
 Helps maintain normal blood pressure 
 Restores vatham, pitham and kapham in normal ratio 
 Regulates vatha humour. 
 Delays the aging process 
 Helps to rejuvenate the body. 
 Helps to increase the quantity of oxygen in the cells. 
 Helps to prevent wrinkles and maintain the complexion of the skin. 
 Tones the muscles 
 Helps to keep the joint flexible 
 Improves the complexion of the skin 
 Improves energy and mental alertness. 
 
Introduction 
 External remedies in siddh are classified as 32 in number.  The unique remedy of its kind 
among all and which is subdivided into nine more procedures in thokkanam.  Initially these 
procedures were used only for royal families to enhance rejuvenation and latter turned into a 
therapeutic application. 
 Thokkanam as a whole focuses on treating disease caused by aggravation of ‘VATHAM’ 
the kinetic force of the body.   The humoral theory of siddha states that vatham is the acitve force 
responsible for the physiological functioning of neuromuscular as well as musculo skeletal 
systems.  
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 Thokkanam is also useful in disease where pitham as well as kapham is deranged.  A 
simple thokkanam session wipes of sedentary feel which is a kapham aggravation. 
Toning the skin, muscles and nerves where vatham lives.  It is synonymously called as 
Marthanam.  Marthanam is performed by mallars (wrestlers) in older days.  As per siddha basic 
principles the meeting points of muscles, nerves, joints and skin including hair roots are places of 
flow of vital vatham energy.  A depletion of vatham vital energy may lead to vatham 
derangements such as pain, altered tone, power, twitching, spasticity, rigidity numbness and 
neuritis. 
Three humour theory and thokkanam 
 To have a sound knowledge in application of thokkanam clinically it is mandatory to 
know about three humour theory.  Vatham is the force of creation.  Pitta is the force of 
maintenance, and kapham is the force of destruction. 
 Vatham takes care of bodily funciton as below 
1. Respiration  - Uyirkal (Pranan) 
2. Excretion  - Keel nokku kaal (Abanan) 
3. Circulation - Paravukal (Vyanan) 
4. Digestion - Nadukkal (Samanan) 
 
Thattal – Friction and Percussive strokes 
  Thattal covers more than 40% of techniques of Marthanam. 
 Friction strokes are used in joints, muscles and in tendons.  Friction strokes are usually 
relaxing when applied gently.  Therapist should not exceed the toleratble and pleasurable 
pressure. 
 Percussive strokes are sub divided into hacking, cupping and pinching – plucking. In 
hacking palms are open and faces each other.   
Cupping is performed effectively in larger areas like trunk, back and abdomen. 
 Lifting little flesh in fingers and sliding them is pinching/plugging. 
Benefits 
1. Improves circulation 
2. Release muscle tension. 
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Precautions 
 Precussive strokes directly on spine is to be avoided.  Therapist hands and wrist should be 
held relax. 
Irukkal 
 Irukkal is squeezing type of pressure.  Irukkal is applied in conditions where a good 
nourishment to muscles and nerves is deficit.  It is also called as wringling.  It is usually 
performed across body and limbs.  Wringing is usually applied in the end hours of Thokkanam.  
Squeeze and roll the muscle between your neck and shoulder.  It’s hard to tell from the photo 
that he’s doing anything other than squeezing the muscle, But you should in addition to 
squeezing your muscle also pull or roll the muscle between your fingers.  Try it.  first squeeze 
the muscle, just like you did above.  Then pull it a little and roll it in a small circle of back and 
forth.  Try 7 slow squeeze and rolls on your trapezius muscle varying the intensity of each 
stroke.  Let your muscles relax. 
 
Purpose 
 Squeezing and Rolling increases your circulation and warms your muscles.                 
 It also gives your fingers a good workout. 
 
Ilutthal 
Ilutthal is pulling.  In this type of thokkanam, strokes are used to pull and stretch the 
muscles of the trunk and legs.  Pulling is performed before wringing or along. 
 
Murukkal 
 Murukkal is kneading.  It is performed to release muscle tension and to improve 
circulation kneading is performed in areas which are fleshy.  Action similar to that of kneading 
dough is to be performed here. 
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Pidithal 
 Both pressing and draming is performed in this variety.  Press the muscle areas gently 
and drain them slowly.  Draining is performed usually using the heel of the hand for larger areas 
and thumbs for smaller areas.  Pidithal improves circulation and relaxes the muscles. 
Aluthal 
 Aluthal is the combination of gliding and gentle pressing.  Usually these two procedures 
initiates massage and repeatedly performed in the whole session gliding is the technique used to 
apply oil all over the body.  Gentle pressing all over the body following gliding.  Gliding can be 
done in longitudinal or circular motion. 
Purpose 
 Gliding is a good beginning for every massage.  It warms your skin and sends a message 
to your body that a massage is coming. 
 
Tips 
 Velocity, volume and intensity are three variables you can use to change the effect each 
stroke has on you. 
 
Volume 
 Try covering more skin with each stroke by spreading your fingers wide or make a with 
your hand 
 
Velocity 
 Try varying the speed of your strokes 
 
Intensity 
 Try varying the intensity of each stroke 
 
Squeezing 
 Try it interlace your fingers.  Rest the heels of your hands on either side of your thigh and  
squeeze your hands into your thigh muscles.  Try 7 slow quad squeezes, slightly vary the 
location and intensity of each squeeze.  Now try it on your other leg. 
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Purpose 
 Squeezing warms muscles, increases circulation and speeds recovery. 
 
Stroke description 
 Bring pressure to bear on a muscle.  Try squeezing your left biceps with your right hands.  
It really is a simple as squeezing the muscle.  It should feel good. 
Squeezing & Rolling 
 Try it: Squeeze and roll the muscle between your neck and shoulder.  It’s hard to tell 
from the photo that he’s doing anything other than squeezing the muscle.  But you should in 
addition to the muscle.  Just like you did above.  Then pull it a little and roll it in a small circle of 
back and forth.  Try 7 slow squeeze and Rolls on your trapezius muscle varying the intensity of 
each.  Stroke let your muscles relax. 
Purpose 
 Squeezing and Rolling increases your circulation and warms your muscles.  It also gives 
your fingers a good workout. 
Pressing 
 Try it.  Take off your shoes and socks and give your foot a poke, press your thumb into 
the bottom of your foot and your other four fingers into the top of your foot.  Try 7 slow presses.  
Experiment by varying intensity and moving your fingers slowly over your foot.  Try it on your 
other foot. 
Purpose 
 The press is powerful because it activates acupoints triggers trigger points,  jump starts 
circulation, and sends endorphin cocktails flowing to every cell. 
Pressing and Rolling 
 Try it: Starting at your solarplexus.  Press and roll your abs.  Perform a series of small 
circular rolls with your first moving clockwise, until.  You’ve covered your entire belly with 
your first slightly vary the intensity of each stroke.  Alternately, relax and flex your abs.  Feel the 
difference between pressing  and pressing and rolling your abs.  It’s like night and day. 
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Purpose 
 Pressing and Rolling activates, acupoints triggers trigger points, jump starts circulation 
and sends endorphin cocktails cruising to stimulate every cell in your body. 
Drumming 
 Try it: Drum your quads, use the sides of your hands to tap your thighs.  Slightly vary the 
location of each stroke.  Let your leg relax.  focus on the rhythm and feeling of each stroke. 
 
Purpose 
 Drumming is an energizing, stimulating stroke, used to get you moving. 
Note 
 Massage therapists call this stroke trapotement  It means drumming. 
 When you need to target a specific area of your body, switch over to manual mode.  
Customize your massage and choose from several programs to suit your needs for both upper 
and lower body.  The upper body massages. 
 The thadavu murai is classified into two main parts.  They are 
1. Podhu thadaval murai 
2. Uzhl thadaval murai 
The pothu thadaval murai methods do proper alignment of the nerves, blood vessels, bones 
and muscles.  With the help of medicated oils we should do the techniques.  After that we have 
to realign the sara ottam and jeeva ottam in all varma points.  By this we can give good health to 
the patient. 
 After doing this, we should check whether the patient needs uzhlthadaval murai or not.  It 
it is needed we have to align and stimulate the tissues and internal organs.  
 In the first three days of treatment we should only do podhu thadaval methods, then in the 
4th and 5th day podhu thadaval is done followed by uzhlthadaval. 
 Usually the treatment takes seven days.  In the 6th and 7th day.  We should only do podhu 
thadaval. 
 At the end of the thadaval murai in all the days of the treatment. 
 We have to give otradam, after that the patient should take hot water bath.  After that the 
patient should take chukku kanji.  The patient may take their food after an hour of these 
treatment methods.  During the treatment days the patient must avoid sleep in the day time. 
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  The patient should follow the following food restrictions after the thadaval murai.  
Chicken, uriddhal, small gram and tamarind during the treatment days.  Because it may lower the 
effects of the treatment. 
 The patient should take 3 months rest after the treatment.  Importantly he/she should not 
have sexual contact and severe exercises during the rest periods. 
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 Done for sternocleidomastoid muscles. 
 The treatment normally starts with applying the medicated oil on the affected area.  It 
directly acts on lymphatic, muscular, nervous and vascular system. 
 Strengthens muscle and skin 
 Relaxes whole body 
 Regulates nerve function 
 Improve blood circulation 
 Improve sleep 
Through massage, the medicated oil applied permeates through the skin and reaches the 
tissues under them.  It releives pain and tension by stimulation the sensory and motor nerves. 
Benefits 
 It reduces the production of some hormones such as cortisol and nor epinephrine which 
are responsible for stress. 
 Brings fresh oxygen to the affected tissues. 
 Swelling and thickening of tissues are reduced. 
FOEMENTATION 
Definition 
A fomentation consists of a local application of moist heat to the body surface.  A 
fomentation is usually made of blanket material.  50% wool to retain heat and 50% cotton to 
retain moisture and be more durable. 
Physiologic effect 
1. Promotes increase in circulating white blood cells. 
2. Increases blood flow to the skin, thereby relieving internal congestion. 
3. Relieves muscle spasm by increasing circulation and releasing muscle tension. 
4. Relieves pain in muscles and joints by counter-irritation and de congestion. 
5. Reflexly relieves pain from internal organs. 
6. Increases elimination by promoting sweating 
7. Stimulates or sedates according to the temperature of the application. 
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Indications 
1. Joint pain 
2. Neuralgia and Neuritis pain 
3. Muscle tension 
4. Insomnia 
5. To warm the tissues in preparation for massage. 
6. To prepare for cold procedures. 
 
Contra indications and cautions 
1. Loss of skin sensation due to unconsciousness paralysis of the part legs and feet of 
diabetic 
2. Leg or feet oedema, varicose veins, advanced vascular disease. 
3. Malignancy 
4. Tendency to bleed (haemorrhage) 
5. Stomach or bowel ulcers. 
6. Omit cold in extreme pain such as pleurisy, Renal colic and dysmenorrhoea. 
 
yx<xml<< << << <(Fomentation) 
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 It is also one of the 32 external theraphies of siddha medicine by application of hot 
medicated packs. 
 The medicated pouches are made up of leaves that contains. 
 Pelonex elata )uik!fivib{e<!-jz* 
 Tamarindus indicus )Htqbqjz* 
 Vitex negundo )ofis<sq* 
 Cleodendrum phlomoidis )kPkijp* 
Uses 
 Increases blood circulation and reduces pain. 
 
 
36 
 
The treatment in siddha system includes not only the removal of signs and symptoms of a 
disease but also in total uprootment of the diseases. 
 This is achieved by normalising the deranged mukkutram there by retaining body’s 
natural health.  The recurrence of the disease is prevented by the practice of yoga.  According to 
siddha system line of the treatment is divided into 3 types. 
4. Kappu (Prevention) 
5. Neekam ( Treatment) 
6. Niraivu ( Restoration) 
1. Kappu (Prevention) 
The preventive azhal keel vayu is,  
4. Control the body weight by diet & exercise. 
5. Modify the nature of work which gives stress to a particular joint. 
6. Avoid excess intake of sour, astringent and bitter tasted food. 
In azhal keel vayu the deranged vatham and other toxic products of digestion and 
metabolism is brought to its normal state by purgation )uqOvsel<* 
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MODERN  ASPECT OF OSTEOARTHIRITIS 
Anatomy of the knee joint 
  Knee is the largest and most complex joint of the body .It is chiefly a condyloid 
type of synovial joint. It is formed by the result of fusion of three joint in one. The original three 
joint included the lateral femoro tibial, medial femoro tibial and femoropatellar. 
TYPE: 
It is a compound synovial joint, incorporating two –condylarjoint between the condyles 
of femur and tibia and one saddle joint between femur and patella. 
ARTICULAR SURFACES: 
 Knee joint is formed by 
1.Condyles of femur. 
2.Condyles  of tibia. 
3.The patella. 
 The femoral condyles articulate with tibial condyles below and behind and with the 
patella in front.Structurally,Knee is a weak joint because the articular surfaces are not congruent. 
The tibial  condyles are too small and shallow to hold the large, convex femoral condyles. The 
femoropatellar articulation is also quite in secure because of their shallow surfaces, and also the 
outward between the axis of thigh and leg. The stability of the joint is maintained by various 
ligaments. 
Ligaments:  
Knee joint is supported by various ligaments . they are  
1. Fibrous capsule . 
2. Ligamentum patellae 
3. Tibial collateral ligaments  
4. Fibular collateral ligament 
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5. Obligue popliteal ligament 
6. Arcuate popliteal ligament 
7. Anterior cruciate ligament 
8. Posterior cruciate ligament 
9. Medical meniscus  
10. Lateral meniscus 
11. Transverse ligament 
 
1.Fibrous capsule: 
The fibrous capsule is very thin. Superiorly the capsule is attached to the borders of 
articular surface of condyles of the femur and inter condylar notch. 
 
Inferiorly the capsule is attached to the articular borders of the condyles of the tibia  
 Anteriorly   - capsule is deficient the opening synovial membrane of the joint extend above             
the patella.This is called supra patellar bursa. 
 The lateral side- capsule has an opening for the passage of the tendon of popliteus. 
Posteriorly –oblique popliteal ligament.medial and lateral patellar retinaculae are strengthening 
the capsule on the sides. 
2.Ligamentum Patellae:  
 It is strong , flat, about 8cm in length, it is situated in the anterior side of 
the knee joint , it is attached proximally the the apex of patella and distally to the tibial tuberosity 
. it is separated from the synovial membrane by the infrapatellar pad of fat. 
3.Tibial collateral (medical) ligaments: 
It is a broad and fiat ligament, situated in the medical side of the knee joint. Superiorly it is 
attached to 
the medical epicondyle of femur .Inferiorly, it divides into the anterior and posterior parts . 
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Anterior part is attached to the medical surface of the shaft of the tibia . Posterior part is attached 
to the medical condyle of tibia . it is connected to the medical meniscus .It prevents the 
abduction of knee and limits extension of the leg.  
4.Fibular collateral ( lateral) ligaments:  
This ligament is  strong and cord like . It is situated in the lateral side of the knee joint. 
Superiorly It is attached to the lateral epicondyle of the femur and inferiorly to the head of fibula 
,It prevents adduction of the knee and limits extension of the leg. 
5.Oblique popliteal ligaments:  
It extends from the tendon of semimembranosus to the lateral part of the intercondylar line and 
lateral condyle of femur. 
6.Arcuate popliteal ligament: 
It is a “Y” shaped ligament. The stem is attached to the head of the fibula. The stem divides into 
anterior and posterior bands .  The posterior band is attached to the posterior aspect of inter 
condylar area of tibia. The anterior band is attached to the lateral condyle of femur. 
7.Cruciate ligaments:  
They are very strong. They are  termed cruciate because they cross anterior and posterior from 
their tibial attachements. They are named as anterior and posterior according to their attachement 
on the tibia. 
8.Anterior cruciate ligaments:  
 It is attached between anterior part of inter condylar area of tibia , and medial surface of lateral 
condyle of femur. 
9.Posterior cruciate ligament: 
This ligament is attached between  posterior part of intercondylar area of tibia to the lateral 
surface of the medial condyle of femur. 
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Menisci ( semilunar cartilage) 
Menisci are two (medical and lateral ) fibrocartilagenous cresents , which try to deepen the 
articular surfaces of the condyles of tibia ,  They are acting like a buffer cushion .  
10.Medial meniscus : 
 It is nearly semi circular , it has anterior and posterior horns, They are attached to the 
intercondylar eminence of the tibia. 
11.Lateral meniscus : 
 It is nearly circular and smaller than medial meniscus , it has anterior and posterior ends 
attached to the lateral tubercle of the intercondylar eminence of tibia .   
12.Transverse ligaments: 
It connects the anterior ends of the medial and lateral menisci. 
Blood supply to the knee joint –  
1. Genicular branches of popliteal artery 
2. Desending branch of laterial circumflex femoral artery 
3. Two recurrent branch of anterior tibial artery 
4. Circumflex fibular branch of posterior tibial artery 
 
Nerve supply  
1. Femoral nerve 
2. Sciatic nerve 
3. Obturator nerve 
Knee Joint Muscles 
 
The knee joint consists of the femur (thigh bone), tibia and fibula with the patella or kneecap. 
Muscles producing joint actions at the knee joint are the quadriceps muscles (vastus medialis, 
vastus lateralis, vastus intermedius and rectus femoris at the front, with the hamstring muscles 
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(semitendinosis, semimembranosus and biceps femoris) at the back along with the 
popliteusmuscle. 
 
The Hamstring Muscles 
The hamstring muscles at the back of the thigh consist of the biceps femoris, semitendinosus and 
semimembranosus. 
 
Vastus Medialis 
Vastus Medialis is the most medially (inner) located of the quadricep muscles. The portion of the 
muscle just above the knee is known as VMO (vastus medialis oblique). This is important in 
stabilising the knee joint and often becomes inhibited following injury. 
 
Vastus Lateralis 
Vastus Lateralis is the most lateral (outer) of the four quadriceps muscles and is felt on the 
outside top of the thigh. 
 
VastusIntermedius 
Vastus Intermedius is one of four quadricep muscles, located deep in the thigh underneath the 
Rectus Femoris muscle. 
           
Movements of knee joint  
Active movements at the knee are 
1.Flexion 
2.Extension 
3.Medial Rotation 
4.lateral Rotation 
 Flexion and extension are the chief movements of much greater range than rotations. 
These are permitted in the upper compartment of the joint , above the menisci. Flexion and 
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extension take place in transverse axis. During extension the axis moves upwards and forwards, 
During flexion the axis moves downwards and backwards. 
Movements of the knee joint: 
 Flexion and extension are the main knee movements, some  rotations occur when the knee 
flexed. 
Locking and unlocking of the knee (conjunct rotation): locking 
It is defined as medical rotation of femur on tibia during terminal stages of extension of the 
knee, when feet are supporting the body weight, when knee is  locked , it is completely rigid 
and all ligaments of the joint are taut. 
Unlocking : 
It is defined as lateral rotation of femur on tibia during initial stages of flexion of the knee, 
when feet are supporting the body weight , It is brought about by popliteus, It can be flexed 
by the hamstrings .  
Adjunct rotation : (or) Independent active rotation:  
 It can occur only in flexed knee. They contribute to the twisting movements of the body 
when feet are fixed. 
Accessory or Passive movements: 
   It can be performed in a partially flexed knee , These movements include. 
1. A wider range of rotaion  
2. Anteroposterior gliding of tibia on femur 
3. Some adduction and abduction 
4. Some Separation of tibia from femur. 
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OSTEOARTHRITIS 
 It is a non- inflammatory degenerative disorder of joints  characterized by 
progressive deterioration of articular cartilage and formation of new bone (osteophytes), It is 
called primary when the actiology is unknown of secondary when it follows some known 
cause Ex-  trama , injection , r.a etc 
     It is more common in weight bearing its such as Hip & knee . It is also seen in spine 
Metacarpal joint of thumb & distal interphalangeal joint. The concept is wear & tear is  
generally attributed as a cause of osteoarthiritis . 
CLINICAL FEATURES  
 Pain is the pain presenting sympotom , Initially the pain occur usually on or 
after weight bearing activity . The joint become swollen due to synorittis stiffness gradually 
set in following severe pain 4 capsular contracture . 
 In late stage of the disease the joint become defermed , A common example is gence varum 
deformity at the knee ,  It may due to caused by ligamentous instability , capsule contractures 
or muscle imbalance . 
Narrowing of joint Space. 
Osteophytes at the margins of articular cartiage. 
Sclerosis and cysts in Sub condralbone. 
PATHOPHYSIOLOGY OF OSTEOARTHRITIS 
 Osteoarthritis (OA) is the most frequent cause of disability in the United 
States, with the medial compartment of the knee being the most commonly affected.1 The 
initiation and progression of knee OA is influenced by many factors including kinematics. In 
response to loading during weight bearing, cartilage in healthy knees demonstrates spatial 
adaptations in morphology and mechanical properties. These adaptations allow certain 
regions of the cartilage to respond to loading while other regions are less well suited to 
accommodate loading. Alterations in normal knee kinematics shift loading from those 
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cartilage regions adapted for loading to regions less well suited. This leads to the initiation 
and progression of degenerative processes consistent with knee OA. Kinematic variables 
associated with the development, progression and severity of knee OA are the adduction 
moment (Madd) and tibiofemoral rotation. Due to its strong correlation with disease 
progression and pain, the peak Madd during gait has been identified as a target for treatment 
design. Gait modification offers a non-invasive option for seeking significant reductions. 
Gait modification has the potential to reduce pain and slow the progression of medial 
compartment  knee OA. 
Keywords: kinematics, knee, osteoarthritis, gait 
  Osteoarthritis (OA) is condition with a multifaceted etiology and afflicts 
both load bearing and non-weight bearing joints. The risk of developing OA substantially 
increases with each decade after the age of 45 years.2 Among reported upper and lower 
extremity sites, the most common region for OA to manifest is the medial compartment of 
the knee, and the knee will serve as the model for discussion in this review.1 The initiation 
and progression of knee OA involves mechanical, structural, genetic and environmental 
factors. During growth and development, the tibial and femoral cartilage adapt over time to 
cyclic loading during walking; 3 cartilage remodeling to loading also applies to other joints 
such as the hip.4 Knee cartilage thickens in the areas of greatest loading in both the anterior-
to-posterior and medial-to-lateral regions.3 The tibiofemoral mechanics and loading patterns 
during walking, therefore, have a significant influence on the regional development of 
articular cartilage. Disruption of normal gait mechanics with trauma, acute injury, 
ligamentous laxity, weight gain and improper footwear can shift the loading patterns during 
weight-bearing to cartilage regions not well adapted to accept those loads. 3, 5–10 Although 
normal healthy cartilage responds positively to loading and increases regional thickness, 
diseased or injured cartilage degenerates and decreases regional thickness. 
  While there are several potential biomechanical alterations that may 
contribute to the onset and progression of knee OA, increased internal tibiofemoral rotation 
and peak knee adduction moment (Madd) during load bearing may be two factors that are of 
particular interest. The Madd is recognized as a clinically important measure to study medial 
compartment knee OA,11,12 and is a surrogate for medial contact force,13 disease severity 
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and progression, 14,15 and pain severity. 16 Normal tibiofemoral loading may be altered in 
knees with either anterior cruciate ligament (ACL) deficiency or OA, and may shift the 
weight bearing stressors to cartilage regions not previously adapted for load bearing.5 The 
loading of these non-adapted regions leads to cartilage fibrillation and local degenerative 
changes.3, 5, 17, 18 Correcting abnormalities of tibiofemoral rotation and/ or decreasing the 
Madd are clinically relevant for management of OA symptoms and progression. 
             This review will provide evidence regarding the potential roles of the separate and 
combined roles of tibiofemoral rotation and the Madd in the development and progression of 
knee OA. Emerging methods that favorably change these two parameters and thereby OA 
symptoms will be presented.Setting the Stage.  With normal aging, cartilage breakdown 
begins in joint areas with little or no contact. As destruction advances, it moves gradually 
into the more heavily loaded areas. At this point, biomechanical factors such as loading 
patterns, tibiofemoral contact time and motions about the joint generate shear and frictional 
stresses.4 Cartilage softens and fibrillates. Aging or injury to the knee joint increases joint 
laxity and permits excess or aberrant motion about the knee, a process that exacerbates 
progression of OA. 
ETIOLOGY: 
  Osteoarthritis is the most common disease of joints in adults around the 
world (1). Felson et al. reported that about one-third of all adults have radiological signs of 
osteoarthritis, although Andrianakos et al., in an epidemiological study, found clinically 
significant osteoarthritis of the knee, hand, or hip in only 8.9% of the adult population (2, 3). 
Knee osteoarthritis was the most common type (6% of all adults). The likelihood of 
developing osteoarthritis increases with age. Studies have shown that knee osteoarthritis in 
men aged 60 to 64 is more commonly found in the right knee (23%) than in the left knee 
(16.3%), while its distribution seems to be more evenly balanced in women (right knee, 
24.2%; left knee, 24.7%) (3, 4). The prevalence of osteoarthritis of the knee is higher among 
70- to 74-year-olds, rising as high as 40% (e2). When the diagnosis is based on clinical signs 
and symptoms alone, the prevalence among adults is found to be lower, at 10% (e3). The 
radiological demonstration of typical signs of osteoarthritis of the knee is not correlated with 
symptoms: Only about 15% of patients with radiologically demonstrated knee osteoarthritis 
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complain of knee pain (e4). The incidence of the disorder among persons over 70 is 
estimated at 1% per year.  
  Epidemiological studies have revealed that there are both endogenous and 
exogenous risk factors for osteoarthritis (table 1). Genetic factors unquestionably play a role. 
In a clinical study involving female twins, Spector et al. showed an effect of heredity on the 
development of osteoarthritis of the hip and knee (e6). In only very few cases, however, can 
osteoarthritis be attributed to the effect of a single gene. Its development and progression are 
more likely due to an interaction among multiple genes, in combination with further risk 
factors. Cross-sectional studies have shown that the risk of knee osteoarthritis is 1.9 to 13.0 
times higher among underground coal miners than in a control population (e7– e9); 
presumably, the main risk factor in this occupational group is frequent work in the kneeling 
or squatting position. Construction workers, too, particularly floorers, have a significantly 
elevated prevalence of knee osteoarthritis (e10). In another epidemiological study, Grotle et 
al. found a significant dose-effect relationship for overweight (BMI >30) as a risk factor for 
knee osteoarthritis, but not for hip osteoarthritis  
OSTEOARTHIRIS OF KNEE: 
     In osteoarthiristis of the knee major problems are pain , stiffness , Instabilty 
, Deformity and Functional inadequacy 
1.Pain :- Pain is assessed for its character degree, posture and duration pain in O A 
usually noticed when the degenerated it is exposed to compressive forces , hyper 
vascularisation of the neighboring bone.  
2.Tenderness and effusion :- The site and degree recorded 
3. Range of Movements:- passive ROM inclueding the end – feel is recorded . 
4.Deformity :- It is nature and extent are assed at HIP ,Knee , Ankle & foot during total 
weight        bearing. 
5.Stability :- The it is Assessed in supine & with weight bearing affected knee 
alone.Strengh, endurance  & Hamstrings , Glutei should be recorded. 
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Efficancy of performing functional activities  
  The pattern of gait & other ambulatory para meter are evaluated knee rating 
scale is ideal to assess pain & functional status. 
Physical demands: -  
    Physical demand of the patient daily routine need to be evaluated in relation to the degree 
of involvement. 
Knee Rating  Scale for Pain & Function 
   Pain free standing & long walk 50 mild pain ,Painless walking up to 1km 40 considerable 
pain on long standing / walking  pain free upto less than 1/2km 20 considerable pain 
,walking confined to indoor only. 
Severe pain on standing /walking or even at rest.Unable to walk 
Radiographic classification  
Stage  I – Bony Spurs only 
Stage II – Narrowing of joint space  less than half of normal joint space. 
Stage III- Narrowing of joint space more than half of normal joint space. 
Stage IV- Obliteration of joint space or bone attrition under 1 gm 
Stage V – Major bone attrition more than 1gm sub luxnation or secondary lateral arthrosis. 
COMPLICATION: 
Possible complications of osteoarthritis include: 
Rapid, complete breakdown of cartilage resulting in loose tissue material in the joint 
(chondrolysis). 
Bone death (osteonecrosis).Stress fractures (hairline crack in the bone that develops 
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gradually in response to repeated injury or stress).Bleeding inside the joint.Infection in the 
joint.Deterioration or rupture of the tendons and ligaments around the joint, leading to loss of 
stability.Pinched nerve (in osteoarthritis of the spine). 
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MATERIALS   AND METHODS 
 Phase II clinical observation criteria based study of siddha formulation “PANJA 
LAVANA PARPAM” (INTERNAL)”,LAHU VADHA KESARI THYLAM”(EXTERNAL) in 
“AZHAL KEEL VAYU” (OSTEOARTHIRITIS) was carried out at post graduate department of 
Sirappu maruthuvam, GOVT. Siddha medical college  hospital palayamkottai under the 
observation and guidance of the head of the department. In this study 20 cases were admitted in 
IN patient ward and other 20 cases were seen in OUT patient ward . 
SELECTION OF CASES: 
INCLUSION CRITERIA:  
1.AGE:30-60Yrs. 
2.SEX:Both Male and female. 
3.Patients having symptoms of joint pain of both knee joint swelling, tenderness,   
stiffness, crepitations, restricted movements of both knee joints. 
4.Patients who are willing to give blood samples for laboratory investigation.  
5.Patients who are willing to take X-ray before and after treatment. 
6.Patient who are willing to participate in this study with the knowledge of potential 
risks. 
EXCLUSION CRITERIA: 
• Systemic illness of the Patient 
• Rheumatoid arthritis 
• Use of narcotic drugs 
• Pregnancy and lactation  
• History of trauma 
• Carcinoma patient 
• Tuberculosis 
• Immuno compromised patients 
• Clinically significant abnormal laboratory values 
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DIAGNOSIS: 
  The diagnosis was made by following Siddha diagnosis methods  
1. Pulanal arithal  
2. Poriyal arithal 
3. vinaathal  
4. Mukkutra Nilaigal  
5. Udal Thathukal Nilai  
6. Envagai thervugal  
7. Neer kuri  
8. Neikuri  
the diagnosis of azhalkeel vayu were obtained which correlated with diagnosis of osteo arthritis  
by the X-Ray findings. 
UNIVERSAL PAIN  SCALE ASSESSMENT:
 
A.   0    : No Pain  
B. 1 -3  :  Mild pain 
C. 4-6  :  Moderate pain 
D. 7-10 :  Severe pain 
 Reference: Clinical Manual for Nursing Practice. (National Institute of Health Warren Grant 
Magnuson Clinical Center) 
GRADATION OF MOVEMENTS: 
Grade 1 : Fit for all activities to do their work without  
 support (Normal). 
Grade 2          :  Mild Pain and Mild restriction of Movements. 
Grade 3 : Moderate Pain with or without radiation to lower limbs  
and  Moderate restriction of Movements. 
Grade 4 :  Severe Pain with or without radiation to lower limbs  
and Severe  restriction of Movements. 
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Investigation: 
 The following investigations were done in all selected patients in the laboratory of 
Government Siddha Medical College, Palayamkottai.  
 
LABORATORY INVESTIGATIONS: 
Blood: 
• TC 
• DC 
• ESR 
• Hb 
 
• Blood Sugar 
  Fasting 
  Random  
Post prandial 
• Blood urea 
• Serum Creatinine 
• Serum Cholesterol 
• ASO Titre 
• RA-factor 
• C-RP 
Urine: 
 Albumin 
 Sugar 
 Deposits 
 
SPECIFIC INVESTIGATIONS: 
RADIOLOGICAL INVESTIGATION: 
 . X- Ray of Knee Joint  (AP  & Lateral View) 
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LINE OF TREATMENT: 
 They day before the internal medicine started, vellai ennai-15ml was 
given at early morning for purgation to correct the deranged vatham to 
all the patients.from the second day onwards the trail drugs were  
administrated. 
TREATMENT  
INTERNAL MEDICINE : ”  PANJA LAVANA PARPAM “ 
 Ref:  Athmaratchamirtham 
DOSAGE :  5.1 gram 
ADJUVANT/VEHICLE      :          ¼ Perungayam added to Honey  
DURATION : 12 days to 24 days 
EXTERNAL MEDICINE : ”LAHU VADHA KESARI THAILAM”  
            Ref: Anubava Vaithiya Dhevaragasiam 
DOSAGE : Required Amount. 
 1.PANJA LAVANA PARPAM  as internal medicine 5.1 gm two times a day after food 
2. LAHU VADHA KESARI THYLAM as external medicine  
 The above oil was given only for external use only affected joint 
 All the patient were advised to maintain dietary regiment(or) pathiyam to avoid interaction witn 
drugsome complementary therapies like Thokkanm and varmam were manipulated. 
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A.CLINICAL ASSESMENTS: 
# Pain and swelling in both knee joints 
# Stiffness in Knee Joint 
# Crepitus 
# Tenderness 
# Warmth 
# Restricted movements of knee joints  
B) RADIOLOGICAL INVESTIGATIONS  
X- ray of knee joint  (AP -  Lateral  view) 
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RESULTS AND OBSERVATION 
1. AGE DISTRIBUTION 
Table 1. Illustrates the age distributions 
S.no Age No. Of patients Percentage(%) 
1 16 – 20 - - 
2 21 – 30 - - 
3 31 – 40 3 7.5 
4 41 – 50 8 20 
5 51 - 60 29 72.5 
 Total 40 100 
 
 
Inference 
 The prevalence of the disease was found to be higher in the age group 51-60 years.
 31-40 age had 7.5%, 41-50 age group had 20%.   
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2. SEX DISTRIBUTION  
Table 2. Illustrates sex distributions in relative percentage. 
S.no Sex No. Of cases Percentage(%) 
Op Ip 
1.  Male 13 12 62.5 
2.  Female 7 8 37.5 
3.  Total 20 20 100 
 
 
Inference 
 Among the 40 patients male are 62.5%  affected. Female 37.5 affected.   
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3. RELIGION 
Table 3.  Illustrates the religion 
S.no Religion No. Of patients Percentage(%) 
1 Hindu 36 90 
2 Christian 4 10 
3 Muslim 0 - 
 
 
Inference 
 Above the religion hindu religion 90% affected. Chrisitan 10% affected.   
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4.KAALAM 
Table 4.  Illustrates the kaalam 
S.no kaalam No. Of patients Percentage(%) 
1 Vatha kaalam(1-33yrs) - - 
2 Pitha kaalam(34-66yrs) 40 100 
3 Kaba kaalam(67-100yrs) - - 
 
 
Inference 
  40 patients are reported in pitha kaalam.  
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5. THINAI (THE HABITAT OF THE PATIENTS) 
Table 5. Illustrates the thinai 
S.no Thinai or Land No. Of patients Percentage(%) 
1 Kurinji - - 
2 Mullai - - 
3 Marutham 40 100 
4 Neithal - - 
5 paalai - - 
 Total 40 100 
 
 
Inference 
 Among the 40 patient, 40 cases were from the marutham.  
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6. Paruvakalam 
Table 6. Illustrates the Paruvakalam 
S.no Paruvakalam Month No. Of patients Percentage(%) 
1 Kaarkalam 
Avani-puratasi 
(15 aug – 14 oct) 
3 7.5 
2 Koothirkaalam 
Ippasi-karthigai 
(15 oct – 14 dec) 
3 7.5 
3 Munpanikaalam 
Margazhi-thai 
(15 jan – 14 feb) 12 30 
4 Pinpanikaalam 
Maasi-panguni 
(15 mar – 14 apr) 
13 32.5 
5 Elaveenirkaalam 
Chitthirai-vaigasi 
(15 may – 14 jun) 5 12.5 
6 Muthuvenirkaalam 
Aani-aadi 
(15 jul– 14 aug) 4 10 
 
 
Inference 
 Among the 40 cases Munpanikaalam 30% cases, Pinpanikaalam 32.5% cases affected. 
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7. Distribution based on etiological factors 
Table 7. Illustrates etiological factors 
S.no Precipitating factors No. Of patients Percentage(%) 
1 Obesity 5 12.5 
2 Menopause 5 12.5 
3 Occupation 25 62.5 
4 Hereditary 5 12.5 
 total 40 100 
 
 
Inference 
Among the 40 cases 25cases are occupationally affected. Obesity 5 patients affected. Menopause 
5 patients affected. Heediatary 5patients affected.   
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8. Socio - Economical status 
Table 8. Illustrate socio-economical status 
S.no Socio - Economical 
status 
No. Of patients Percentage(%) 
1 Low class 20 50 
2 Middle class 15 37.5 
3 High class 5 12.5 
 Total 40 100 
 
 
Inference 
 Among the 50%  low socio – encomic status, 37.5% Middle Class, 12.5% High class  
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9. Occupation  
Table.9 Illustrates occupation 
S.no Occupation No. Of patients Percentage(%) 
1 Agricultural labours 14 35 
2 House wives 16 40 
3 Watchman 1 2.5 
4 Hotel worker 1 2.5 
5 Teacher 3 7.5 
6 Weight lifters 2 5 
7 Tailors 3 7.5 
 
 
Inference 
35% agriculatrual labours, 40% Housewives, 2.5%  watchman & Hotel workers, 7.5% Teacher 
& Tailors, 5% Weight lifters.  
  
35
40
2.5 2.5
7.5
5
7.5
0
5
10
15
20
25
30
35
40
45
P
e
rc
e
n
ta
g
e
 (
%
)
OCCUPATION
63 
 
10. Clinical manifestation 
Table 10.  Illustrates the clinical manifestation 
S.no Udal kattukal No. Of patients Percentage(%) 
1 Pain 36 90 
2 Swelling 18 45 
3 Tenderness 36 90 
4 Morning stiffness 23 57.5 
5 Crepitation 36 90 
6 Deformity 0 0 
7 Restricted movement 35 87.5 
8 Muscle wasting 4 10 
9 Sleeplessness 15 37.5 
 
 
Inference 
 Among the 40 cases, pain 36 patients, swelling 18 patients, tenderness 36 patients, 
Crepitation 36 patients, restricted movement 35 patients, sleeplessness 15 patients affected. 
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11. Distribution according to the duration of illness 
Table 11. Illustrates Distribution according to the duration of illness 
S.no Duration of illness 
(in months) 
No. Of patients Percentage(%) 
1 0 - 1 12 30 
2 1 - 3 10 25 
3 3 - 6 10 25 
4 6 - 12 4 10 
5 12 - 24 4 10 
6 24 - 36 - 0 
 
 
Inference 
 Among the 40 cases, 0-1 month 30%affected, 1-3 month 25% affected, 3-6 months 25% 
affected, 6-12 months 10% afftected, 12-24 months 10% afftected.  
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12. Disturbance in vatham 
Table 12. Illustrates disturbance in vatham 
S.no Vatham No. Of patients Percentage(%) 
1 Piranan 0 0 
2 Abanan 20 50 
3 Viyanan 40 100 
4 Vudhanan 0 0 
5 Samanan 40 100 
6 Naagan 0 0 
7 Koorman 3 7.5 
8 Kirukaran 0 0 
9 Thevathathan 15 37.5 
10 Thananjayan 0 0 
 
 
Inference 
 Among the 40 cases, Abanan 20 cases are affected, Viyanan, Samanan 40 cases are 
affected, Thevathathan 15 cases are affected. 
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13. Disturbances in pitham 
Table 13. Illustrates disturbances in pitham 
S.no Pitham No. Of patients Percentage(%) 
1 Anarpitham 14 35 
2 Ranjagapitham 15 37.5 
3 Sathagapitham 40 100 
4 Aalosagapitham 2 5 
5 Pirasagapitham 0 0 
 
 
Inference 
 Among the 40 cases Sathagapitham 40 cases are affected, Anarpitham 14 cases are 
affected, Ranjagapitham 15 cases are affected. 
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14. Disturbances in kabam 
Table 14.  Illustrates  disturbances in kabam 
S.no kabam No. Of patients Percentage(%) 
1 Avalambagam 15 37.5 
2 Kilethagam 8 20 
3 Pothagam 0 0 
4 Tharpagam 0 0 
5 Santhigam 40 100 
 
 
Inference 
 Among the 40 cases Avalambagam, Santhigam 40 cases are affected, Kilethagam 8 cases 
are affected. 
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15. Involvement of udal kattukal 
Table 15. Illustrates the involvement of udal kattukal 
S.no Udal kattukal No. Of patients Percentage(%) 
1 Saaram 40 100 
2 Senneer 15 37.5 
3 Oon 3 7.5 
4 Kozhuppu 40 100 
5 Enbu 40 100 
6 Moolai 30 75 
7 Sukkilam / suronitham 0 0 
 
 
Inference 
 In all the cases Saaram, Kozhuppu, Enbu affected, Moolai 30 patients affected, Senneer 
15 patients affected, Oon 3 patients affected. 
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 16. Condition of envagai thervugal
Table 16. Illustrates the condition of envagai thervugal
S.no Envagai thervugal 
1 Naa 
2 Niram 
3 Mozhi 
4 Vizhi 
5 Malam 
6 Moothiram 
7 Naadi(thontha naadi) 
8 Sparisam 
Inference 
 Among the 40 cases, Naadi 40 cases affected
10 cases, vizhi 3 cases are affected.
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, malam 20 cases, Moothiram 15 cases, Naa 
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 17. NAADI 
Table 17. Illustrates the  pulse reading (naadi)
S.no parameters 
1 Vatha pitham 
2 Pitha vatham 
3 Kaba vatham 
 
Inference 
Among the 40 cases, Vathapitham 2
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No. Of patients Percentage(%)
25 
15 
0 
5 cases are affected, Pitha vatham 15 cases are affected.
Pitha vatham Kaba vatham
No. Of patients
Pitha vatham Kaba vatham
 
62.5 
37.5 
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 18 NEIKURI 
Table 18. Illustrates the neikuri analysis
S.no Inference 
1 Spreading like snake 
2 Spreading like ring 
3 Stants like a pearl 
4 Others 
5 Total 
 
Inference 
 Among the 40 cases 30 cases are vathaneer, 10 cases are pithaneer.
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No. Of patients Percentage(%)
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Table 19.  Progressive chart 
 
S.no 
 
 
Clinical feature 
Before treatment After treatment 
No.Of 
cases 
Percentage No.Of 
cases 
percentage 
1 Pain 40 100 36 90 
2 Swelling 22 55 18 45 
3 Tenderness 30 75 28 70 
4 Morning stiffness 26 65 23 57.5 
5 Crepitation 40 100 36 90 
6 Deformity 2 5 2 5 
7 Restricted movement 30 75 25 62.5 
8 Muscle wasting 4 10 4 10 
9 Sleeplessness 8 20 15 37.5 
 
 
 
Inference 
 Among the 40 cases, all of them had pain, tenderness, crepitation. restricted movement 
30 patients, 22 patients had swelling, 26 patients had morning stiffness, 2 patients had deformity, 
4 patients had muscle wasting and 8 patients had sleeplessness.  
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Table 20.  Provocative  chart 
 
 
S.no 
 
 
Clinical feature 
Before treatment 
No.Of cases Percentage 
1 Pain 40 100 
2 Swelling 22 55 
3 Tenderness 30 75 
4 Morning stiffness 26 65 
5 Crepitation 40 100 
6 Deformity 2 5 
7 Restricted movement 30 75 
8 Muscle wasting 4 10 
9 Sleeplessness 8 20 
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Table 21 Asesment of results outcome assessment scale 
Clinical efficaly of the trial drugs were assessed by the following scales univers pain assessment 
scale Mccaffiry et at.1993. 
a) 0- No pain 
b) 1-3 Mild Pain 
c) 4-6 Moderate pain 
d) 7-10 Severe pain 
A. Assesment of curative effects in knee osteoarthiritis patients treated with Trial Drugs (Internal 
and external medicine) 
Symptoms Initial reading Finisal reading 
No. of cases Precentage No. of cases Precentage 
No pain 0 0 10 50 
Mild 5 25 6 30 
Moderate 6 30 2 10 
Severe 9 45 2 10 
 
Inferance: 
Among the patients who were selected for treating alone with drugs. 9 of them had severe 
symptoms and remaining 5 patients hadmid symptoms. But after treatment only 2 had severe 
symptoms, 2 had moderate symptoms. 6 had mild symptoms and 10 had no clinical 
masiferstaion.  
 
 
  
   
No pain
0
10
75 
Mild Moderate Severe
5
6
9
6
2 2
Initial reading Finisal reading
 
  
Table 22. Assessment of curative effects in Osteo arthritis patients treated with trail drugs 
along with complimentary therapy (Thokkanam)
symptoms Initial readings
No of patients
No pain 0 
Mild 2 
Moderate 4 
severe 4 
 
Inference 
 Among the 40 patients, who wre selected for treatin both trial drugs and Thokkanam 4 of 
them senere symptoms, 4 had moderate symptoms and the remaining 2 patients had mild 
symptoms. But after treatment 7 
remaining 2 had moderate symptoms no cases reported to have severe symptoms.
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 Final readings
 percentage No of patients Percentage
0 7 
10 1 
40 2 
40 0 
had no clinical manifestation 1 had only mild symptoms and 
Mild Moderate severe
2
4 4
1
2
0
Initial readings Final readings
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 Table 23.  Effect of trail drug along with complementary 
S.no Effect of therapy 
1 Marked effect 
2 Moderate effect 
3 Mild effect 
4 No effect 
 
Inference 
 By treating both trial drug & complementary theraphy 60% had good improvement, 20
of patients had moderate improvement and 20% had mild improvement no were reported Nil.
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 Table 24. Comparison between 
 
S.no 
 
 
Effect of therapy
1 Good 
2 Moderate 
3 mild 
4 No 
 
Inference 
From the above results it clearly shows that trial drug with external therapy gives a best when 
compared to give trial drug above.
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effective of trail drug and trail drug with complementary 
therapies 
 
Trail drug alone Trail drug with 
external therapy
No.Of 
cases 
percentage No.Of 
cases 
10 50 13 
6 30 3 
2 5 4 
2 5 0 
 
Moderate mild No
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Table 25. Effect of therapy 
S.no Effect of therapy No. Of patients Percentage(%) 
1 Marked effect 26 65 
2 Moderate effect 8 20 
3 Mild effect 4 10 
4 No effect 2 5 
 
 
Inference 
 Among the 40 cases, 65% are marked effect, 20% are moderate effect, 10% are mild 
effect, 5% had no effect.  
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MEASURMENT OF THE KNEE JOINT 
S.NO OP NO/IP NO NAME AGE/SEX RT LT RT LT 
1 11024 PACKIYAM 50/F 34 32 32.5 29 
2 24849 VALLIAMMAL 58/F 31 34 31 31.5 
3 31395 GOPALDURAI 49/M 34 36 30.5 32 
4 66178 LATHA 55/F 33 31.5 31 30 
5 26435 DANIEL 60/M 37.5 35 33 33 
6 24852 MURUGAN 59/M 39 36.5 36 34 
7 22203 JANAKI 52/F 34 32 31.5 29.5 
8 110409 LAKSHMI 60/F 37 36 33.5 34 
9 31372 SAKUNTHALA 56/F 35 38 32 32 
10 67248 CHITRA KOMU 38/F 33 31 30 29 
11 3307 ESAKKI THE VAR 60/M 31 31 29 29 
12 3104 SUBBIAH 60/M 39 40 39 39 
13 478 VANAMAMALAI 60/M 30 32 30 31 
14 918 MADATHI 60/M 38 37 36 35 
15 3308 PONTHAI 57/F 35 35.5 34 34.5 
16 919 CHELLAMMAL 45/F 39 38 37 38.5 
17 3318 GOWRI 60/F 33 33.5 32 32 
18 398 VASUKI 39/F 35 35 34 34.5 
19 374 MUNIYANDI 60/M 38 37 36 35 
20 3256 LAKSHMANAN 58/M 33 33.5 32 32 
21 27 MANNICKAVEL 60/M 31 30 30.5 29 
22 506 MARY 54/F 29 32 29 30 
 
 
INFERENCE  
 Knee joint swelling is reduced opproximately 1-2cm after treatment  
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OP CASES CLINICAL IMPROVEMENT 
S.N
O 
OP 
NO NAME 
AGE/
SEX 
OCCUPAT
ION 
DATE OF 
ADMISSON 
DATE OF 
DISCHARGE 
TOTAL NO OF DAYS 
TREATED RESULTS 
1 
2220
3 JANAKI 52/F 
HOUSE 
WIFE 06-03-2018 28-03-2018 22 DAYS GOOD 
2 
3530
0 KAMALAM 60/F 
HOUSE 
WIFE 18-04-2018 09-05-2018 23 DAYS GOOD 
3 
1102
4 PACKIYAM 50/F TEACHER 13-12-2017 17-01-2018 34 DAYS 
MODERA
TE 
4 
2658
0 
SUBBULAK
SHMI 45/F TEACHER 19-03-2018 11-04-2018 22 DAYS GOOD 
5 
6724
8 
CHIDHRAK
OMU 38/F TAILOR 07-08-2017 28-08-2017 21 DAYS GOOD 
6 2053 
KANNAMA
L 53/F 
HOUSE 
WIFE 05-01-2018 05-02-2018 31 DAYS MILD 
7 
1104
04 
GANESHW
ARI 45/F TAILOR 14-12-2017 19-01-2018 35 DAYS MILD 
8 
3137
2 
SAKUNDA
LA 56/F TEACHER 04-04-2018 26-04-2018 23 DAYS GOOD 
9 
1104
09 LAKSHMI 60/F 
HOUSE 
WIFE 14-12-2017 11-01-2018 27 DAYS GOOD 
10 
6617
8 LATHA 55/F 
HOUSE 
WIFE 03-08-2017 21-08-2017 18 DAYS GOOD 
11 
2484
9 
VALLIAM
MAL 58/F 
HOUSE 
WIFE 14-03-2018 05-04-2018 20 DAYS GOOD 
12 
2003
4 
ARULAPPA
N 50/M FARMER 02-03-2018 27-03-2018 25 DAYS 
MODERA
TE 
13 
2960
8 
GURUSAM
Y 60/M FARMER 29-03-2018 20-04-2018 28 DAYS GOOD 
14 
2643
5 DANIEL 60/M 
WEIGHT 
LIFTER 19-03-2018 13-04-2018 24 DAYS GOOD 
15 
6724
9 
SUBRAMA
NIAN 52/M FARMER 07-08-2017 28-08-2017 22 DAYS GOOD 
16 1500 
PERIYASA
MY 60/M FARMER 04-01-2018 31-01-2018 27 DAYS 
MODERA
TE 
17 
2485
2 
MURUGA
N 59/M FARMER 14-03-2018 05-04-2018 21 DAYS GOOD 
18 
3139
5 
GOPALDU
RAI 49/M FARMER 04-04-2018 26-04-2018 22 DAYS GOOD 
19 
1120
31 
CLARAMA
RY 43/F 
HOUSE 
WIFE 09-12-2017 22-01-2018 43 DAYS 
NO 
REACTIO
N 
20 
1122
99 RAMA 54/F 
HOUSE 
WIFE 20-12-2017 24-01-2018 34 DAYS 
MODERA
TE 
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IP CASES CLINICAL IMPROVEMENT  
S.N
O 
IP 
NO NAME 
AGE/ 
SEX 
OCCUPATI
ON 
DATE OF 
ADMISSION 
DATE OF 
DISCHARGE DAYS 
RESULT
S 
1 
330
7 ESAKKITHEVAR 60/M FARMER 18-12-2017 11-01-2018 
24 
DAYS GOOD 
2 
325
6 LAKSHMANAN 58/M 
WEIGHT 
LIFTER 12-12-2017 24-12-2017 
12 
DAYS GOOD 
3 
308
9 MADASAMY 56/M 
HOTEL 
WORKER 20-11-2017 12-12-2017 
22 
DAYS GOOD 
4 
310
5 POOLIAH 55/M FARMER 22-11-2017 11-12-2017 
20 
DAYS 
MODER
ATE 
5 
310
4 SUBBIAH 60/M FARMER 22-11-2017 11-12-2017 
20 
DAYS GOOD 
6 718 ADAIKALAM 55/M FARMER 15-03-2018 10-04-2018 
26 
DAYS 
MODER
ATE 
7 611 MURUGAN 60/M FARMER 07-03-2018 05-04-2018 
29 
DAYS 
MODER
ATE 
8 478 
VANAMAMALA
I 60/M FARMER 21-02-2018 16-03-2018 
24 
DAYS GOOD 
9 432 SHANMUGAM 45/M TAILOR 17-02-2018 09-03-2018 
21 
DAYS GOOD 
10 27 MAANIKAVEL 60/M 
WATCH 
MAN 04-01-2018 02-02-2018 
29 
DAYS 
MODER
ATE 
11 374 MUNIYANDI 60/M FARMER 13-02-2018 28-02-2018 
16 
DAYS GOOD 
12 918 MADATHI 60/F 
HOUSE 
WIFE 05-04-2018 24-04-2018 
20 
DAYS GOOD 
13 919 CHELLAMAL 45/F 
HOUSE 
WIFE 05-04-2018 24-04-2018 
20 
DAYS GOOD 
14 
330
8 PONTHAI 57/F 
HOUSE 
WIFE 18-12-2017 06-01-2018 
20 
DAYS GOOD 
15 
331
8 GOWRI 60/F 
HOUSE 
WIFE 19-12-2017 28-12-2017 
10 
DAYS 
MODER
ATE 
16 
339
1 THANGAMMAL 60/F 
HOUSE 
WIFE 30-12-2017 18-01-2018 
20 
DAYS GOOD 
17 338 VASUKI 39/F 
HOUSE 
WIFE 15-02-2018 14-03-2018 
28 
DAYS 
MODER
ATE 
18 506 MARY 54/F 
HOUSE 
WIFE 25-02-2018 16-03-2018 
20 
DAYS GOOD 
19 665 
SHANMUGASU
NDARI 32/F 
HOUSE 
WIFE 12-03-2018 27-03-2018 
16 
DAYS GOOD 
20 
211
4 MUNIYASAMY 60/M FARMER 25-07-2017 10-08-2017 
16 
DAYS GOOD 
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BLOOD INVESTICATION BEFORE AND AFTERTREATMENT-OP & IP PATIENTS 
 
S.NO IP.NO 
                 TC DC ESR 
     BL.SUGAR 
BI. UREA Se.Cr 
F PP 
BT AT 
N L E Hb 
BT AT BT AT BT AT BT AT BT AT 
BT AT BT AT 
B
T 
AT BT AT 
1 3307 8600 8500 65 66 28 28 7 5 12 12.5 11l22 15l25 89 92 83 105 25 27 0.5 0.9 
2 3256 7500 7400 67 65 27 29 8 6 13 15 13l27 10l20 80 95 100 103 22 20 0.8 0.8 
3 3089 8800 8500 66 66 25 27 5 3 12 11 7l18 7l20 93 85 98 95 29 31 0.5 0.9 
4 3105 6800 6600 68 65 29 28 6 7 14 15 15l30 14l25 87 85 98 90 32 33 0.2 0.2 
5 718 8600 8400 69 67 27 27 4 6 15 15 20l45 20l30 78 85 96 102 28 26 0.3 0.2 
6 3104 7800 7900 67 65 25 24 5 5 13 12 10l20 7l15 87 82 110 108 29 31 0.5 0.3 
7 611 8700 8500 65 65 28 24 5 3 10.5 9 20/35 30l40 78 82 95 105 27 28 0.3 0.2 
8 478 8800 8000 69 67 27 26 4 2 13.5 14 17l33 25l50 90 84 95 100 29 27 0.2 0.4 
9 432 7400 7300 70 66 29 28 5 6 15 16 10l20 20l40 76 87 95 93 27 24 0.3 0.3 
10 27 7200 7600 65 67 26 24 6 4 13 11..5 17l33 25l40 75 82 89 94 28 26 0.4 0.3 
11 374 7800 7600 67 69 28 27 4 3 15 14 17l30 25/30 85 89 94 92 29 30 0.4 0.3 
12 918 7600 7500 68 68 27 25 3 5 13 12 17/33 25/20 82 80 97 92 28 30 0.7 0.7 
13 919 8300 8500 64 65 29 29 4 6 11 12 35/60 28l40 74 80 85 89 26 27 0.7 0.6 
14 3308 8400 8700 63 62 28 29 5 3 13 12 20/35 20/15 86 84 90 95 28 25 0.6 0.7 
15 3318 8200 8300 67 65 24 28 3 4 14 13 23/44 20/40 85 78 93 87 27 26 0.6 0.6 
16 3391 8600 7600 65 62 26 29 4 2 14 11 27/32 22/35 79 83 94 85 29 30 0.8 0.7 
17 398 6800 6700 66 66 26 27 8 5 13 14 2o/35 20/40 80 95 98 87 31 27 0.8 0.8 
18 506 7800 7900 68 65 26 25 5 6 13 15 13/27 25/30 93 85 98 102 28 26 0.7 0.6 
19 665 7400 7600 69 67 29 28 6 7 14 16 23/30 25/30 87 82 93 98 28 27 0.5 0.9 
20 2114 7400 7300 68 65 28 27 5 4 10.5 9 20/35 30/40 90 85 95 105 25 27 0.4 0.8 
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BLOOD INVESTICATION BEFORE AND AFTERTREATMENT-OP & IP PATIENTS 
 
21 22203 7800 7600 67 69 28 27 4 3 15 14 17l30 20/30 85 89 94 92 29 30 0.4 0.6 
22 35300 6800 6600 68 65 29 28 6 7 14 15 15l30 14l25 87 85 97 90 30 33 0.6 0.4 
23 11024 8400 8700 63 62 28 29 5 3 13 12 20/35 20/15 86 84 90 95 28 25 0.6 0.5 
24 26580 8800 8500 66 66 25 27 5 3 12 11 7l18 7l25 93 85 90 95 29 31 0.5 0.4 
25 67248 7600 7500 68 68 27 25 3 5 13 12 17/33 25/20 90 82 97 92 28 30 0.6 0.7 
26 2053 7200 7600 65 67 26 24 6 4 13 11..5 17l33 25l40 75 82 89 94 28 26 0.6 0.7 
27 110404 8200 8300 67 65 24 28 3 4 14 15 35/60 28l40 74 80 85 89 26 27 0.6 0.7 
28 31372 8300 7900 64 66 29 29 4 6 11 12 35/60 28l40 74 82 85 89 26 27 0.9 0.6 
29 110409 7800 8000 69 67 27 26 4 2 13.5 14 17l33 25l50 90 84 95 100 29 27 0.9 0.8 
30 66178 7400 7300 70 66 29 28 6 7 15 16 10l25 20l40 76 87 95 93 27 24 0.8 0.7 
31 24849 6800 6700 66 66 26 27 8 5 13 14 2o/35 20/40 80 95 98 87 31 27 0.9 0.6 
32 20034 7800 7900 68 65 26 25 5 6 13 15 13/27 25/30 93 85 98 102 28 26 0.3 0.5 
33 29608 7400 7600 69 67 29 28 6 7 14 16 24/30 25/30 87 82 93 98 28 27 0.6 0.7 
34 26435 7600 7300 70 67 29 28 5 6 15 16 10l20 20l40 76 87 95 93 27 24 0.5 0.8 
35 67249 8400 8700 63 62 28 29 5 3 13 12 20/35 20/15 86 84 90 95 28 25 0.4 0.6 
36 1500 7600 7500 68 68 27 25 3 5 13 12 17/33 25/20 90 82 97 92 28 30 0.6 0.5 
37 24852 7200 7900 65 68 26 24 5 4 13 11..5 17l33 25l40 75 82 89 94 28 26 0.5 0.4 
38 31395 8800 8500 67 66 25 28 5 3 12 11 7l18 7l25 90 85 92 95 29 31 0.3 0.5 
39 112031 7800 7600 67 69 28 27 4 3 15 14 17l30 20/30 85 89 94 92 29 30 0.8 0.7 
40 112299 6800 6600 68 65 29 28 6 7 14 15 15l30 14l25 87 85 97 90 30 33 0.4 0.6 
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URINE AND MOTIONS EXAMINATION BEFORE AND AFTER TREATMENT- OP&IP PATEINTS 
                    
S.NO IP.NO 
URINE 
BEFORE TREATMENT AFTER TREATMENT 
ALBUMIN SUGAR 
DEPOSITS 
ALBUMIN SUGAR 
DEPOSITS 
PUS 
CELLS 
EPI 
CELLS 
PUS 
CELLS 
EPI 
CELLS 
1 3104 NIL NIL NAD NAD NIL NIL NAD NAD 
2 3307 TRACE NIL 1--3 2--3 TRACE NIL 0-1 0-1 
3 3256 NIL NIL NAD NAD NIL NIL NAD NAD 
4 3089 NIL NIL NAD NAD NIL NIL NAD NAD 
5 3105 NIL NIL NAD NAD NIL NIL NAD NAD 
6 506 NIL NIL NAD NAD NIL NIL NAD NAD 
7 718 NIL NIL NAD NAD NIL NIL NAD NAD 
8 611 NIL NIL NAD NAD NIL NIL NAD NAD 
9 478 TRACE NIL 2--3 1--2 TRACE NIL 0-1 0-1 
10 432 NIL NIL NAD NAD NIL NIL NAD NAD 
11 27 NIL NIL NAD NAD NIL NIL NAD NAD 
12 374 NIL NIL NAD NAD NIL NIL NAD NAD 
13 918 NIL NIL NAD NAD NIL NIL NAD NAD 
14 919 NIL NIL NAD NAD NIL NIL NAD NAD 
15 3308 NIL NIL NAD NAD NIL NIL NAD NAD 
16 3318 NIL NIL NAD NAD NIL NIL NAD NAD 
17 3391 NIL NIL NAD NAD NIL NIL NAD NAD 
18 398 NIL NIL NAD NAD NIL NIL NAD NAD 
19 665 NIL NIL NAD NAD NIL NIL NAD NAD 
20 2114 TRACE NIL 2--3 4--5 NIL NIL NAD NAD 
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S.NO OP.NO 
URINE 
BEFORE TREATMENT AFTER TREATMENT 
ALBUMIN SUGAR 
DEPOSITS 
ALBUMIN SUGAR 
DEPOSITS 
PUS 
CELLS 
EPI CELLS 
PUS 
CELLS 
EPI 
CELLS 
21 22203 NIL NIL NAD NAD NIL NIL NAD NAD 
22 35300 NIL NIL NAD NAD NIL NIL NAD NAD 
23 11024 NIL NIL NAD NAD NIL NIL NAD NAD 
24 26580 TRACE NIL 2--3 3--4 NIL NIL NAD NAD 
25 67248 NIL NIL NAD NAD NIL NIL NAD NAD 
26 2053 NIL NIL NAD NAD NIL NIL NAD NAD 
27 11O404 NIL NIL NAD NAD NIL NIL NAD NAD 
28 31372 NIL NIL NAD NAD NIL NIL NAD NAD 
29 110409 NIL NIL NAD NAD NIL NIL NAD NAD 
30 66178 TRACE NIL 2--3 1--2 TRACE NIL 0-1 0-1 
31 24849 NIL NIL NAD NAD NIL NIL NAD NAD 
32 20034 NIL NIL NAD NAD NIL NIL NAD NAD 
33 29608 NIL NIL NAD NAD NIL NIL NAD NAD 
34 26435 NIL NIL NAD NAD NIL NIL NAD NAD 
35 67249 NIL NIL NAD NAD NIL NIL NAD NAD 
36 1500 NIL NIL NAD NAD NIL NIL NAD NAD 
37 24852 TRACE NIL 1--2 1--2 NIL NIL NAD NAD 
38 31395 NIL NIL NAD NAD NIL NIL NAD NAD 
39 112031 NIL NIL NAD NAD NIL NIL NAD NAD 
40 112299 NIL NIL NAD NAD NIL NIL NAD NAD 
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DISCUSSION 
Osteoarthritis is a chronic progressive degenerative degenerative disease affecting mainly 
the articular cartilage of the big weight bearing joints of the body. It is the most common form of 
arthritis characterized by subchondral selerosis and changes in thesoft tissues including the 
synovial membrane joint capsule ,ligaments and musle , synovial inflammation.Knee pain is the 
activities and drives them to consult a doctor . 
Osteoarthritis is a major funder to functional impairment and reduced independence  in older 
adaults so with this background , the disease osteoarthritis in knee taken for the study. 
As a search in fulfilling the prime aim of this study the following trail drugs for treating the 
disease azhal keel vaayu were selected  
 1.PANJA LAVANA PARPAM as the internal medicine 
 2.LAHU VAADHA KESARI THYLAM as the external medicine 
Age distribution 
The statistical study shows high incidence of Azhal Keel vayu in the age group between 
31-60 years as it is one of the degenerative disease. 
Kaalam Disdribution 
Most of the patients belong to pithakalam. 
This information is bestowed by our siddhars as the wordings. 
“Ou{<mi!Jl<hkil<!ubKke<eqz<!
uqjvf<KhqVkquqbqz<!nh<HOlUl<!hiOv”/!
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The target sites affected in azhal keel vayu  are generally bones, muscles, nerves, hairs, 
blood, urine, fat which are the components of appu and prithiviboothas (Appu+ prithivi = 
kabam  responsible for destruction).  Hence they begin to degenerate above fifty. 
Sex distribution 
There is a slight variation in the male and female ratio and it is noted obviously in the 
study. From the above mentioned tabulation among the 40 patients. 25 patients male and 15 
patients were female . 
Thinai 
About 100% of patients from maruthanilam.  It may be due to altered food, 
lifestyle,habits etc. 
Seasonal distribution 
Most of the patients came during, Pinpani kaalam, Munpani kaalam. 
Etiological factors 
Majority of patients of the Azhal keel vaayu was caused mainly (62.5%) due to the nature 
of occupation, obesity 12.5% menopause condition 12.5% Hereditary 12.5%. 
Socio-economic status 
During the study, 95% of cases were middle class and 5% of lower class. 
Occupational status 
The rate of incidence is higher in occupational group which includes Agricultural labour 
(35%) and house wifes(40%) Teacher(7.5%), Tailors(7.5%), Weight lifters(5%), 
others(5%).  Due to house wife  are mostly affected. 
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Clinical Manifestations 
From the tabulated data all the patients had pain, tenderness,crepitation were their 
predominating symptoms, Then morning stiffness (70%) were found to be predominant next to 
the above symptoms. 
Duration of illness 
Most of the patient with the disease Azhal keel vadham reflected its symptoms over a 
period of 0-1 month which was confirmed during the history taking while 30% of the patients 
reported the data. 
Derangement in vatham 
Viyanan and Samanan was affected in all 40 cases (100%).Abanan affected in 20 cases 
20% 
 Disturbances in Pitham 
Mostly Sathagapitham was affected in all 40 cases (100%). 
Disturbances in Kabham 
Almost Santhigam was affected in all 40 cases (100%). 
Udal Thathukkal 
In this study the patients was affected with seven thathus are affected. 
 Envagai Thervugal 
In this study thontha naadi was noted in all 40 cases, malam was affected in 20% of cases 
and In naadi 60% were vatha pitha naadi, 40% were pitha vatha naadi. 
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Investigation 
Laboratory investigations were done in all the cases before and after treatment.  The 
significant variation occurs in parameters like ESR and HB, while other parameters have 
insignificant variation. 
Pre clinical studies 
The Bio chemical analysis of “PANJA LAVANA PARPAM” contains Calcium, 
Sulphate, Chloride, ferric iron, Ferrous iron,  Unsaturated compound,  Amino acid. 
 The phytochemical study of “PANJA LAVANA PARPAM” had revealed the presence of 
calcium, ferrous iron, tannic acid, unsaturated compound, reducing sugar. 
 Pharmacological studies 
The pharmacological studies done in PANJA LAVANA PARPAM revealed the presence 
of actions such as 
1. Anti – inflammatory action 
2. Analgesic activity. 
Toxicity studies 
Acute toxicity studies in rats for “PANJA LAVANA PARPAM “ revealed that it has no 
toxicity effect. 
Treatment 
The treatment was aimed to retain the dearranged thoshas and providing relief from 
symptoms.  Before treatment the patients were advised to take vellai ennai 15ml with hot water 
during morning for first day of treatment.From the second day onwards Internal medicine 
PANJA LAVANA PARPAM  5gm two times a day after food and LAHU VADHA KESARI 
THYLAM is given as external. 
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At the time of treatment the patients were advised to follow pathiyam and specifically 
advised to avoid foods which increase vadha. Along with the course of treatment the 
complementary therapies like Thokkanam and Ottradam therapy were given additionally to some 
of the patients. 
The outcome of this study is mainly assessed by reduction in pain in Knee 
joint.  Increased range of reduction of restricted movements and improvement in quality of life 
universal pain assessment scale was also used to detect proper outcome.  No adverse effect was 
noted for both internal and external medicine along with the course of treatment. 
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SUMMARY 
40 cases with Azhal keel vayu were diagnosed clinically based on yugi 800 and admitted 
in the inpatient ward and outpatient ward of post graduate department of sirappu maruthuvam, 
Government Siddha Medical College Hospital, palayamkottai and treated by the trial medicines. 
• Laboratory diagnosis of Azhal keel vayu was done by siddha diagnostic principles and 
endorsed by modern methods of investigations. 
• The various siddha aspects of examination of the disease were carried out and were 
recorded in the proforma. 
• The trial medicine chosen for both internal and external treatments were Panja lavana 
parpam – 5.1 gms days in two divided doses for Twenty four days as per the severity of 
the diseases,Lahu vadha kesari thylam (External) 
• Before starting the treatment careful detailed history was carried out and recorded for the 
forty selected cases. 
• During the period of treatment all the patients were put under pathiyam (A specific 
dietary regimen) 
• A periodical laboratory investigation was made for all the cases along with the 
radiological investigations. 
• The observations made during the clinical study shows that the main internal drug    
Panja lavana parpam is clinically effective. 
• Though there was appreciable clinical improvement, there was not much remarkable 
radiographic changes. 
The action of external application  Lahu vadha kesari thylam with Thokkanam and Ottradam is 
also quite remarkable. 
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CONCLUSION 
All 40 patients (20 OPD and 20 IP) 10 patients with trial medicines and Massage, 10 with 
ottradam along with trial medicines). were treated for this dissertation work with Panja lavana 
parpam 5gm/day in two divided doses and Lahu vadhakesari thylam (externally) 
In the pre clinical study pharmacological evaluation of the trial drug shows. 
• Significant analgesic effect 
• Significant Anti inflammatory effect (Internal medicine) 
In the preclinical study toxicity study of “PANJA LAVANA PARPAM” shows that the trial 
drug had no acute toxicity. 
The overall effect of the clinical trial drug are  
Marked effect  - 65% 
Moderate effect – 20% 
Mild effect  - 10% 
No effect  - 5% 
This result of the clinical trial illustrates the marked effect of the drugs and 
complementary therapy. 
The trial drug PANJA LAVANA PARPAM and external Lahu vadha kesari thylam is 
effective.  No adverse effects were noticed during the treatment period.  So the trial medicine is 
safe and easily preparable medicine.   
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ANNEXURE –I 
STANDARD OPERATING PROCEDURE FOR PREPARATION OF PANJA LAVANA 
PARPAM  & LAHU VATHA KESARI THYLAM 
SOURCE OF RAW DRUGS: 
 the required drugs for preparation  of PANJA LAVANA PARPAM  (INTERNAL) & 
LAHU VATHA KESARI THYLAM (External) are purchased from well reputed country shop 
and Raw drugs are authenticated by Medical botanist of govt. Siddha Medical College, 
Palayamkottai, then purified and the meicines are prepared in the Gunapadam laboratory of 
Govt. Siddha Medical College, Palaymkottai.  
PROPERTIES OF THE TRIAL DRUG 
INTERNAL MEDICINE: 
1.    PANJA LAVANA PARPAM 
INGREDIENTS: 
 
1. PURIFIED KALL UPPU                                                          -    8.75 gram 
2. PURIFIED KARI UPPU                                                    -    8.75 gram 
3. PURIFIED INDUPPU                                                               -    8.75 gram 
4. PURIFIED VALAYAL UPPU                                                  -    8.75 gram 
5. PURIFIED VEDI UPPU          -    8.75 gram 
 
S.NO DRUG NAME BOTANICAL NAME PART USED 
1 PIRANDAI CISSUS QUADRANGULARIS STEM 
2 MURUNGAI MORINGA OLEIFERA BARK 
3 KUPPAIMENI ACALYPHA INDICA WHOLE PLANT 
4 NOCHI VITEX NEGUNDO LEAVES 
5 KUMARI ALOE VEERA STEM 
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METHODS OF PURIFICATION 
PURIFICATION OF RAW DRUGS: 
1.KALL UPPU: 
   Kallu uppu dissolved in kaadi and filtered then dried in sunlight. 
2.KARRIUPPU: 
   Karri uppu is dissolved in seven share of water or kaadi water is dissolved 
and filtered then dried and mix with lemon juice or butter milk and then dried in sunlight. 
 3.INDUPPU: 
Induppu dissolved in kaadi and filtered then dried in sunlight. 
4.VALAYALUPPU: 
   Valayal uppu dissolved in kaadi filtered then dried in sunlight. 
5.VEDIUPPU: 
Vedi uppu dissolved in kaadi filtered then dried in sunlight. 
PIRANDAI : 
Pirandai dissolved in Salt with Butter Milk filtered and dried in sunlight. 
MURUNGAI: 
Remove  outer bark layer. 
KUPPAIMENI : 
   Wash with river water. 
NOCHI : 
   Wash with river water. 
KUMARI: 
   Remove the horns and wash with river water. 
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METHOD OF PREPARATION 
Purified salt are taken, pirandai, Murungai pattai, Nochi, Kuppaimeni, Kumari are herbal 
juice taken and mix to grind in kalvam for three hours. Then prepare that in villai form na done 
the seelai mann. Then burn with 10 varates pudam.  
 
DOSE   : 1 kazhanju (5.1 gram) 
DURATION   : 12 days to 24 days 
ADJUVANT   : ¼ Perungayam with Honey     
REFERENCE : Athmaratchamirtham (page no – 511) 
DRUGS STORAGE : 
 Parpam is mixed with ¼ perungayam with Honey is formation of mezhugu stored in a 
clean and dry container and it is dispensed to the patient in packets.    
! !
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dh<hqe<!ujggt<< < << < << < <!
2/ gz<Zh<H!
3/ -f<Kh<H!
4/ gxqBh<H!
5/ ujtbZh<H!
6/ oucBh<H!
dh<hqe<!ohiKg<G{l<< < < << < < << < < <!
“ntk<kqZjx!fz<Zh<!hez<uikl<!lix<Xr<!
gtk<KOfib<!ke<jeg<!gjtBr<!.!gqjtk<kgh!
NSjmb!uz<jz!Ofib<!n]<Ge<lLl<!Ohig<Gr<!
gtsqeqBt<!liOk!gpX”!
uqtg<gl<< << << <!
dh<hqeiz<!hqk<kuikl<?!g{<mg<!gpjz?!ghl<?!gz<zQvz<!Ofib<?!w{<ujgg<Ge<ll<!kQVl</!
gz<Zh<H< << << < !
-K!gmx<GVuq!we<Xl<!upr<gh<hMl</!
-u<Uh<H?!gmZg<Gt<!ljzOhizg<!gm<cbib<h<!hijxbib<!uti<f<K!fqx<Gl</!
Sk<kq<<< !
! gic! k{<{Qiqz<! hqSxq?! hqxG! =vk<jkk<! K{qbqz<! Kjmk<K! oubqzqz<! dzi<k<kqg<!
ogit<tOu{<Ml</!
ohiKg<G{l<< << << <!
! JblXR<$jz!bOvisqhqk<kR<!sk<kqObiM!
! oub<bhq{q!bm<mGe<ll<!uqm<OmGl<!.!ohb<ujtOb!
! uiklkq!kigl<!lzg<gm<Ml<!OhiLzgqx<!
! OgikXgz<!Zh<jhg<!ogiM/!
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!
uqtg<gl<< << << <!
! ghl<?! Gk<kz<?! nVsq?! hqk<kl<?! uif<kq?! d]<{uiB?! w{<uqk! Ge<ll<?! uikOfib<?!
fiuxm<sq!kQVl</!
Action 
 Stomachachic, Anthelmintic 
-f<Kh<H< << << < !
Sodium Chloride Impura 
Rock Salt 
OuXohbi<;!jsf<kul<?!sqf<K~vl<?!sf<kqvEh<H?!lkq%Ijl?!lkqBh<H?!lqf<kis<osiz<!we<El<!
ohbi<gtiZl<!upr<gohXl</!
Sk<kq<<< !
! gicbqz<!&e<Xfit<!Dxh<ohim<M!$iqbe<!ytqbqz<!dzi<k<kq!wMg<g!Sk<kqbiGl</!
ohiKg<G{l<< << << <!
! nm<mGe<l!lf<kl<!nsqi<g<gvR<$I!sQkhqk<kf<!
! Km<mjubl<!fich<H{<!Okimr<gt<!.!ogm<mlzg<!
! gm<Muqm!uqf<jkbg<!gilqbOfib<!ue<gvh<hie<!
! uqm<Muqm!uqf<Kh<jh!uqt<!
uqtg<gl<< << << <!
• w{<uqkg<Ge<ll<!
• nzsl<!
• ghhqk<kl<!
• ghikqg<gl<!
• fvl<Hg<gqvf<kq!
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• kqiqOki]l<!
• lzhf<kl<!
• kjz?!uqpq?!fi?!kf<k&zl<?!kiK?!ge<el<?!g{<ml<?!Obieq!-u<uqmk<K!Ofib<gt<!
kQVl</!
Action 
 Carminative 
Laxative 
Stomachic 
gxqdh<H<<< !
SODIUM CHLORIDUM (OR) SODIUM CHLORIDE 
OuXohbi<;< << ! gxqBh<H?!Osix<Xh<H?!gmZh<H?!uQm<Mh<H?!-zu{l<?!sLK<kqv!zu{l</!
ohiKG{l<<<<!
! ““lf<kl<!ohiVlzXl<!uiBUl<Ohil<!kQhelil<!
! okif<kqk<k!Jbf<!okimVOli!!sf<kkLl<!
ng<gqeqbqe<!H]<c!nmVr<!gxqBh<hiz<!
! sqg<Ggqe<x!fQiqxr<GR<!osh<H”!
lf<kl<?!ubqx<Xh<ohiVlz<!kQVl<?!fQvjmh<H!kQVl</!
Chemical composition 
Chloride  -  55.1% 
Sodium  - 30.6% 
Sulphate  - 7.7% 
Magnesium  - 3.7% 
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Calcium - 1.2% 
Potassium - 1.1% 
Bicarbonate - 0.4% 
Bromide - 0.2% 
Borate  - 0.1% 
ujtbZh<H<<< !
lmuiIg<gvk<Kh<H!
Sk<kq<<< !
! Htqk<k!gicfQiqz<!yV!gizl<!Dxjuk<K!wMk<K!$iqb!ouh<hk<kqz<!dzi<k<kq!wMg<g!
-K!Sk<kqbiGl</!
ohiKg<G{l<< << << <!
! “KjtbiI!Gmz<uikk<!okif<kui!kk<Oki!
! cjtbis<!SuislX!lqe<El<!.!ujtbZh<hix<!
! Ge<luzq!$jzouh<hr<!%xih<hq!zQglqju!
! ose<ll<!uqm<OmiMolek<!OkI”!
uqtg<gl<< << << <!
! Gmz<uikl<?!uikhqk<kl<?!-jvh<H?!ubqx<Xuzq?!gQz<hqch<H?!Svl<!kQVl<!
Action 
 Laxative, Stomachic, Anthelmintic 
!
!
!
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oucBh<H!
POTASSH NITRAS (OR) POTASSIUM NITRATE SAL PETRE 
OuXohbi<<<<!
! ohim<cZh<H?!-{r<ge<?! hjmvise<?! H,lq%Ijl?! fuis<sivlqk<V!we<X! OuXohbi<gt<!
d{<M/!
Sk<kq;<<< !
dh<H! yV! hr<gqx<G?! 5! hr<G! k{<{QIuqm<M! nMh<Ohx<xq! sqXkQbiz<! wiqk<K!
ogikqg<gqtl<Hl<OhiK! 2! hr<G!dh<Hg<G! fie<G! OgipqLm<jm! ou{<gV! Osi<g<g! Ou{<Ml</!!
OlOz! nPg<Gk<kqvTl</! ! nkje! ngh<jhbiz<! upqk<K! fQg<gq?! djxBl<! hkk<kqz<!
lXsm<cbqe<! sQjzgm<c! nkqz<! uck<Kg<! gix<xqz<zi! -mk<kqz<! juk<K! lXfit<! fQjv!
uck<Kuqm<M?!$iqbytqbqz<!dh<jh!dzi<k<kUl</!!-u<uiX!WP!Ljx!osb<b!Sk<kqbil</!
ohiKG{l<<<<!
! “lz<ziV!lm<mGe<l!likVkvg<!gm<c!
! gz<zi!ljkh<HfQIg<!gm<mVg!!oz<ziiOl!
! gl<hq!gl<hqobe<Xr<!gVU{<mi!lr<gqfqe<x!
! gl<hqgl<hq!obe<Xjvg<Gr<!giz<”!
uqtg<gl<< << << <!
! w{<uqkGe<ll<?!gVh<hisbg<gm<c?!&k<kqvg<!gqiqs<svl<?!fQIs<SVg<G?!$kqgiuikl<?!uik!
SOvi{qkl<?!ohVubqX?!silieqb!uik?!hqk<k?!gh!Ge<lr<gt<?!ohVubqX?=jt!ghOkiml<!
ypqBl</!
Action 
 Diuteric, Refrigerant 
2/!Gh<jhOleq<<< !.!Acalypha indica 
OuXohbi<;!<<< niqlR<siq?!H,jeu{r<gq?!Oleq!
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Eng: Indian acalypha, cat’s struggle 
hbe<hMl<!dXh<H;< < << < << < < !-jz?!Oui<?!s&zl<!
Sju! ! .! jgh<H?!giIh<H!
ke<jl! .! ouh<hl<!
hqiqU! ! .! giIh<H!
Action 
Kbvmg<gq! ! .! Anodyne!
HPg<ogiz<zq!! .! Anthelmintic!
ohVlzl<Ohig<gq! .! Cathartic!
sqXfQIh<ohVg<gq! .! Diuretic!
uif<kqB{<mig<gq! .! Emetic!
Ogijpbgx<xq!! .! Expectorant!
$kgL{<mig<gq! .! Emmenagogue!
“kf<k&!zh<hq{qkQk<!kf<kqMH{<!si<uuqml<!
! df<KGe<ll<!uikl<!dkqv&!.!zf<kqeU!
! $zR<S!uisl<!okimi<hQ!sr<ghl<Ohil<!
! Rizr<ogit<!Oleqbk!eiz</”!
3/!gx<xijp!<<< .!Aloe Barbadensis!
OuXohbi<! ! ;!! ge<eq?!Gliq!
hbe<hMl<dXh<H! ;!lmx<OsiX?!siX?!Oui<!
Sju! ! .! sqXjgh<H?!
ke<jl! .! km<hl<!
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hqiqU! ! .! -eqh<H!
Action 
dvlig<gq! .! Tonic 
dmx<Oxx<xq! .! Alterative 
fQIlzl<Ohig<gq!.! Purgative 
VKU{<mig<gq!.! Emmenagogue 
! ! “ohiz<ziOl!gr<ghl<H!Ps<$jz!Gm<mvsl<!
! ! nz<ziIlk<!kl<hgf<k!vr<Ge<ll<!wz<zil<uqm<!
! ! OmG!liqg<G!oliqs<sx<!gqiqs<svL!
! ! liG!liqg<G!lV{<M/”!
4/!LVr<jg<<< !.!Moringa Oleifera 
OuXohbi<<<<! ;!sqg<GV!gqvR<sl<?!gqpuQ!OsihiR<sel<!
Eng  : Horse radish 
Parts used : All parts of whole plant 
Sju! ! ;! jgh<H?!Kui<h<H?!-eqh<H!
ke<jl! ;! km<hl<!
hqiqU! ! ;! -eqh<H?!giIh<H!
Action 
-squgx<xq!! ! .! Antispasmodic 
ouh<hL{<mig<gq!! .! Stimulant!
Ogijpbgx<xq!! .! Expectorant!
sqXfQIh<ohVg<gq! .! Diuretic!
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“osxqlf<kl<!ouh<hf<!okxqg<Gf<!kjzOfib<!
ouxq&Is<js!g{<O{ib<!uqzGl<!.!lxOl!
ofVr<jgbqjz!obik<kuqpq!OfiqjpOb"!fz<z!
LVr<jg!bqjzjb!olipq/”!
5/!ofis<sq<<< !.!Vitex Negundo 
OuXohbi<! ;!fqk<kqz<?!fQIg<G{<c?!ofi<g<G{<c?!sqf<Kl!sqf<Kuivl<!
4!types ;! gVofis<sq?!fQIofis<sq?!ou{<o{is<sq!
Parts used :!-jz?!H,?!Oui<?!hm<jm!
Sju! ! ;! jgh<H?!Kui<h<H?!giIh<H!
ke<jl! ;! ouh<hl<!
hqiqU! ! ;! giIh<H!
Action 
dmx<Ox<xq! .! Alterative!
HPugx<xq! .! Vermiguge!
7/ kPkijp!.Clerodendrum phlomoidis!
OuXohbi<gt<!;!! kg<giiq?!uiklmg<gq?!ff<kg<giiq!
Parts used :! !-jz?!Oui<!
Sju! ! ;! jgh<H?!Kui<h<H!
ke<jl! ;! ouh<hl<!
hqiqU! ! ;!! giIh<H!
Action 
! dmx<Oxx<xq! .! Alterative!
! Kui<h<hq! .! Astringent 
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EXTERNAL MEDICINE 
LAHU VATHA KESARI THYLAM: 
1. GINGELLY OIL -10 Palam        - 0.375 litre 
2. NALLVELAI CHARU (CLEMOE VISCOSA) – 10 Palam   -0.375 litre 
3. VELLAI POONDU ( ALLIUM SATIVUM) – 2.5 Palam   - 87.5 gram 
4. PERUNGAYAM (FERULA ASAEFOTIDA) – ½ Palam    - 17.5 gram 
5. MOOSAMBARAM (ALOE LITTORALIS) – ½ Palam   - 17.5 gram 
Method of preparation: 
 Vellai poondu mix with mooligai chaaru and add gingelly oil and give light heat  
Dosage: 
 Required amount applied externally over the affected part.  
External theraphy: 
 Varmam, Thokkanam & Ottradam  
!
External Medicine - LAHU VADHA KESARI THYLAM 
2/!ohVr<gibl<!< << << < .!ferula asafoetida!
OuXohbi<gt<!! ;!nk<kqbigqvgl<?!-r<G?!-v{l<?!gf<kq?!gibl<?!H,kfisl<?!-vilml<!
English Name  : Asafoetida 
hbe<hMl<!dXh<H! ;!! hqsqe<!
Sju! ! ! ;! jgh<H!
ke<jl! ! ;! ouh<hl<!
hqiqU! ! ! ;!! giIh<H!
Action 
ouh<hL{<mig<gq! .! Stimulant!
ngm<Muib<ugx<xq! .! Carminative!
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-squgx<xq! ! .! Antispasmodic!
Ogijpbgx<xq!! .! Expectorant!
lzlqtg<gq! ! .! Laxative!
HPg<ogiz<zq!! .! Anthelmintic!
sqXfQIh<ohVg<gq! .! Diuretic!
gill<ohVg<gq!! . Aphrodisiac!
VKU{<mig<gq!! .! Emmenagogue.!
3/giqbOhitl<!<<< .!Aloe littoralis!
OuXohbi<! ;! &sil<hvl<?!se<eqsibgl<?!-vk<kOhitl<!
English name : Small Aloe later of Indian Aives 
Sju! ! ;! jgh<H!
ke<jl! ;! ouh<hl<!
hqiqU! ! ;! giIh<H!
Action 
dvlig<gq! ! ! .! Tonic!
ouh<hL{<mig<gq!! ! .! Stimulant 
hsqk<kQk<K~{<c! ! .! Stomachic 
ohVr<gpqs<sZ{<mig<gq! .! Cathartic 
VKU{<mig<gq!! ! .! Emmenagogue.!
! “liIHuzq!uQg<gl<!ubqx<Xuzq!hg<gOfib<!
! uiIOlgg<!gm<cObiM!liuikl<!.!hiVzgqz<!
! fQtr<jg!gizqz<!fqjz$jz!Br<gXk<k!
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! Ohizqf<!kjeg<!gi{qx<!Ohil</”!
4/!fz<Oujt!<<< .!Cleome viscosa!
English Name ! ;! Dog mustard!
Parts used ! ;! !-jz?!H,?!uqjk?!Oui<!
Sju! ! ! ;! giIh<H?!
ke<jl! ! ;! ouh<hl<?!
hqiqU!!! ! ;! giIh<H!
Action 
HPg<ogiz<zq!! . Anthelmintic!
-squgx<xq! ! .! Antispasmodic!
ngm<Muib<ugx<xq!! .! Carminative!
uqbi<juohVg<gq! .! Diaphoretic!
kch<H{<mig<gq! .! Rubefacient!
“sqvOfib<!uzqGjms<sz<!kQvis<!sbqk<kqbl<!
dvOfi!bqjug!otipqBl<!.!dvOlUl<!
uqz<Oujtg<!giBl<!uqpqbib<!hsqogiMg<Gl<!
fz<Oujt!ke<je!fuqz</”!
5/!out<Tt<tq!!< << << < Allium sativum!
English  ;! Carlic!
Part used  : gqpr<G 
Sju! ! .! giIh<H!
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ke<jl! .! ouh<hl<!
hqiqU! ! .! giIh<H!
Action 
ngm<Muib<ugx<xq! .! Carminative, Stomachic, Tonic, Alterative, Stimulant, Expectorant, !
Diuretic Anthelmintic. 
“se<eqobiM!uikf<!kjzOfiU!kit<uzq!
le<equV!fQIg<Ogiju!ue<sQkl<!.!ne<eOl!
dt<Tt<tq!g{<hib<!djt&z!OvigLl<Ohil<!
out<Tt<tq!ke<eiz<!ouV{<M/”!
wt<<<<!
Sesamum indicum 
OuXohbi<! ;!kqzl<!
hbe<hMl<dXh<H! ;! -jz?!H,?!gib<?!uqjk!
Sju! ! .! -eqh<H!
ke<jl! .! ouh<hl<!
hqiqU! ! .! -eqh<H!
Action 
VKU{<mig<gq!! .! Emmenagogue!
ouh<hL{<mig<gq! .! Stimulant!
dvlig<gq! ! .! Tonic!
sqXfQIh<ohVg<gq! .! Diuretic!
hix<ohVg<gq! ! .! Galactogugue!
109 
 
lzlqtg<gq! ! .! Laxative!
wt<TlVf<! jkg<ogMg<Gl<!!wxezif<!kq{<jlkVl<!
dt<tqjzjbs<!OsIg<Gl<!dkqvk<jkk<!.!kt<TlqV!
g{<[g<!ogitqogiMg<Gr<!gisL{<mil<!hqk<kLlil<!
h{<[g<!gqmi<HiqBl<!hiI/!
!
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ANNEXURES -II 
QUALITATIVE AND QUANTITATIVE ANALYSIS 
BIO-CHEMICAL ANALYSIS OF PANJA  LAVANA  PARPAM 
(IN POWDER FORM) 
Preparation of the extract:  
 5gms of the drug was weighed accurately and placed in a 250ml clean beaker.  Then 
50ml of distilled water is added and dissolved well.  Then it is boiled well for about 10 minutes.  
It is cooled and filtered in a 100ml volumetric flask and then it is made to 100ml with distilled 
water.  This fluid is taken for analysis. 
 
QUALITATIVE ANALYSIS 
S.NO EXPERIMENT OBSERVATION INFERENCE 
1.  
TEST FOR CALCIUM 
2ml of the above prepared extract is taken 
in a clean test tube. To this add 2ml of 4% 
Ammonium oxalate solution. 
A white precipitate is 
formed. 
Indicates the 
presence of 
calcium. 
2. 
TEST FOR SULPHATE 
2ml of the extract is added to 5% Barium 
chloride solution. 
A white precipitate is 
formed. 
Indicates the 
presence of 
sulphate. 
3.  
TEST FOR CHLORIDE 
The extract is treated with silver nitrate 
solution. 
A white precipitate is 
formed. 
Indicates the 
presence of 
chloride. 
4. 
TEST FOR CARBONATE 
The substance is treated with 
concentrated HCL. 
No Brisk 
effervescence is 
formed 
Absence of 
carbonate 
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5. 
 
TEST FOR STARCH 
The extract is added with weak iodine 
solution. 
No Blue colour is 
formed. 
Absence of 
starch. 
6.  
TEST FOR FERRIC IRON 
The extract is acidified with Glacial 
acetic acid and potassium ferro cyanide. 
Blue colour is 
formed. 
Indicate 
thepresence of 
ferric iron. 
7. 
TEST OF FERROUS IRON  
The extract is treated with concentrated 
Nitric acid and Ammonium thio cyanide 
solution. 
Blood red colour is 
formed. 
Indicates the 
presence of 
ferrous iron. 
8.  
TEST FOR PHOSPHATE 
The extract is treated with Ammonium 
Molybdate and concentrated nitric acid. 
No yellow 
precipitate is formed. 
Absence of 
phosphate. 
9.  
TEST FOR ALBUMIN 
The extract is treated with Esbach’s 
reagent. 
No Yellow 
precipitate is formed. 
Absence of 
Albumin. 
10.  
TEST FOR TANNIC ACID 
The extract is treated with ferric chloride. 
No Blue black 
precipitate is formed. 
Absence of 
tannic acid. 
11.  
TEST FOR UNSATURATION 
Potassium permanganate solution is 
added to the extract. 
It gets decolourised. 
 
Indicates the 
presence of 
unsaturated 
compound. 
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12.  
TEST FOR THE REDUCING SUGAR 
5ml of Benedict’s qualitative solution is 
taken in a test tube and allowed to boil for 
2 mts and add 8-10 drops of the extract 
and again boil it for 2 minutes. 
NO colour change 
occurs. 
Absence of 
Reducing sugar. 
13.  
TEST FOR AMINO ACID 
One or two drops of the extract is placed 
on a filter paper and dried well. After 
drying, 1% Ninhydrin is sprayed over the 
same and dried it well. 
Violet colour is 
formed. 
Indicates the 
presence of 
Amino acid. 
14. 
TEST FOR ZINC 
The extract is treated with Potassium 
Ferrocyanide. 
No white precipitate 
is formed 
Absence of Zinc. 
 
Inference: 
 The given sample of “PANJA LAVANA PARPAM” contains Calcium, 
Sulphate, Chloride,Ferric iron , Ferrous iron,  Unsaturated compound, , Amino 
acid. 
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ANNEXURE -III 
EFFECT OF PANJA LAVANA PARPAM WITH ASAFOETIDA AND HONEY ON 
ACETIC ACID INDUCED WRITHING IN MICE1 
1. Kaneria MS, Naik SR, Kohli RK. Anti-inflammatory,antiarthritic and analgesic activity 
of a herbal formulation. Indian J.Experimental Biol. 2007; 45: 279. 
 
Acetic acid induced writhing method was adopted for evaluation ofanalgesic activity. Writhing is 
defined as a stretch, tension to oneside, extension of hind legs, contraction of the abdomen so 
that theabdomen of mice touches the floor, turning of trunk (twist). Anywrithing is considered as 
a positive response. 
 
MATERIAL AND METHODS 
ANIMALS: 
Healthy Swiss albino rats of either sex weighing 20-25g were usedin this study. All the animals 
were obtained from Animal house ofthe KMCH College of Pharmacy, Coimbatore. The animals 
were housed comfortably in agroup of six in a single clean plastic cage with a metal frame lid on 
itstop. They were housed under standard environmental conditions oftemperature (24±1°C) and 
relative humidity of 30-70 %. A 12:12 hlight dark cycle was followed. All animals had free 
access to waterand standard pelletized laboratory animal diet ad libitum. All theexperimental 
procedures and protocols used in this study werereviewed and approved via the Approval No. ---
-------------------------- bythe Institutional Animal EthicalCommittee (IAEC) of KMCH College 
of Pharmacy, Coimbatore (685/PO/Re/S/2002/CPSCEA Dated 21st August 2002 constituted in 
accordance with theguidelines of the CPCSEA, Government of India. 
DRUGS: 
         Acetic acid (Sigma Chemical Co. Bangalore, India) andIndomethacinwere purchased from 
(Ranbaxy, India). All drugs were dissolved in saline. The different doses of PANJA LAVANA 
PARPAMwere preparedwith ASAFOETIDA AND HONEY.The control group received vehicle as 
control. All drugs were prepared just before use. 
PREPARATION OF ACETIC ACID: 
A solution of acetic acid (1% v/v) in distilled water was prepared. 
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DOSAGE SCHEDULE: 
The required dose for mice/rat will be calculated by using the standard dose calculation 
procedure from recommended clinical dose. 
CONVERSION FORMULA: 
Human dose is 5000 mg /kg day 
Total clinical dose (a) x conversion factor (b) 0.018 = (c) per 30 gm of mice 
5000 mg x 2(a) x 0.018 (b) = 90 (c) /30 gm of mice 
90/1000x30 = 2.7 mg  
Experimental Doses Calculated as per the standard procedures are 
 
S.No 
 
Groups 
 
Dose /kg, weight 
 
Volume of administration 
 
1 Vehicle Control -- 0.5 ml 
 
2 Therapeutic Dose 2.7 mg /kg 
 
0.5 ml 
3 Middle  Dose 13.5mg/kg 0.5 ml 
4 High Dose 67.5mg/kg 0.5 ml 
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EXPERIMENTAL PROCEUDRE: 
 
GROUP 1 – CONTROL (IP injection of 0.1 ml 1% acetic acid) 
GROUP 2 -- IP injection of 0.1 ml 1% acetic acid +Indomethacin (5mg/kg, i.p) 
GROUP 3 -- 0.1 ml 1% acetic acid (ip) + PANJA LAVANA PARPAM WITH ASAFOETIDA AND HONEY 
2.7 mg /kg(PO) 
 
GROUP 4 -- 0.1 ml 1% acetic acid (ip) + PANJA LAVANA PARPAM WITH ASAFOETIDA AND HONEY 
                             13.5mg/Kg(Po) 
 
GROUP 5 -- 0.1 ml 1% acetic acid (ip) + PANJA LAVANA PARPAM WITH ASAFOETIDA AND HONEY 
67.5mg/kg(po) 
PROCEDURE: 
Wister albino mice of either sex were divided into five differentgroups each containing  
Sixanimals, the animals were markedindividually. Food was withdrawn 12 hours prior to drug 
administrationtill completion of experiment. The animals wereweighed and numbered 
appropriately. The test and standard drugswere given orally. After 60 minuteswrithing was 
induced byintra-peritoneal injection of 1% acetic acid in volume of 0.1 ml/10gbody weight. The 
writhing episodes were recorded for 30 minutes;stretching movements consisting of arching of 
the back, elongationof body and extension of hind limbs were counted. 
Anti-nociceptive activity was expressed as the percentage inhibition of abdominalconstrictions 
using the ratio:  
(Controlmean – Treatedmean) × 100/Controlmean 
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EFFECT OF PANJA LAVANA PARPAM WITH ASAFOETIDA AND HONEYON ACETIC ACID 
INDUCED WRITHING IN MICE1 
 
GROUP 
 
No of Writhing (30min) 
 
Inhibition (%) 
 
 
CONTROL 
 
 
45.33±4.807 
 
--- 
 
Indomethacin (5mg/kg, i.p) 
 
 
22.67±1.764*** 
 
49.98 % 
PLP  2.7 mg /kg (PO) 
 
 
32.67±1.764* 
 
27.92 % 
 
PLP 13.5mg/kg(po) 
 
 
19.33±1.764*** 
 
57.35 % 
 
PLP 67.5 mg/kg(po) 
 
 
17±1.528*** 
 
62.49 % 
 
 
Values are expressed as the mean ± S.D; Statistical significance (p)calculated by one way 
ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, ***P < 0.05 calculate 
by comparing treated group with CONTROL group.         
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EFFECT OF PANJA LAVANA PARPAM WITH ASAFOETIDA AND HONEYON HOT 
PLATE METHOD IN MICE1 
 
1. Turner RA. Screening methods in pharmacology. In: Turner, R., Hebborn, P. (eds.). 
Academic press, New York. 1965; 100.  
 
The paws of mice and rats are very sensitive to heat at temperatures which are not                 
damaging the skin. The responses are jumping, withdrawal of the paws and licking of the paws. 
MATERIAL AND METHODS 
ANIMALS: 
Healthy Swiss albino rats of either sex weighing 20-25g were usedin this study. All the animals 
were obtained from Animal house ofthe KMCH College of Pharmacy, Coimbatore. The animals 
were housed comfortably in agroup of six in a single clean plastic cage with a metal frame lid on 
itstop. They were housed under standard environmental conditions oftemperature (24±1°C) and 
relative humidity of 30-70 %. A 12:12 hlight dark cycle was followed. All animals had free 
access to waterand standard pelletized laboratory animal diet ad libitum. All theexperimental 
procedures and protocols used in this study werereviewed and approved via the Approval No. ---
-------------------------- bythe Institutional Animal EthicalCommittee (IAEC) of KMCH College 
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of Pharmacy, Coimbatore (685/PO/Re/S/2002/CPSCEA Dated 21st August 2002 constituted in 
accordance with theguidelines of the CPCSEA, Government of India. 
The hot plate, which is commercially available, consists ofa electrically heated surface. The 
temperature is controlled for 55° to56 °C. This can be a copper plate or a heated glass surface. 
The animals are placed on the hot plate and the time until either lickingor jumping occurs is 
recorded by a stop-watch. 
EXPERIMENTAL PROCEUDRE: 
 
        GROUP 1 – CONTROL  
GROUP 2 –Pentazocine (10mg/kg, I.P) 
       GROUP 3 -- PANJA LAVANA PARPAM WITH ASAFOETIDA AND HONEY 
2.7 mg /kg(PO) 
 
       GROUP 4 –PANJA LAVANA PARPAM WITH ASAFOETIDA AND HONEY 
                                      13.5mg/kg(po) 
 
      GROUP 5 -- PANJA LAVANA PARPAM WITH ASAFOETIDA AND HONEY 
67.5mg/kg(po) 
PROCEUDRE: 
Mice were screened by placing them on a hot plate maintained at 55±1ºC and recording 
the reaction time in seconds for forepaw licking or jumping. Only mice which reacted within 
15sec and which did not show large variation when tested on four separate occasions, each 
15min apart, were taken for the test. The time for forepaw licking or jumping on the heated plate 
of the analgesiometer maintains at 55ºC was taken as the reaction time. Prior to treatment, the 
reaction time of each mouse (licking of the forepaws or jumping response) was done at 0- and 
10-min interval. The average of the two readings was obtained as the initial reaction time (Tb). 
The reaction time (Ta) following the administration of the ---------------, Pentazocine and distilled 
water was measured at 0.5, 1, 2, and 3h after latency period of 30min. 
 
The following calculation was:  
 
Percentage analgesic activity = Ta-Tb/Tb × 100 
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EFFECT OF PANJA LAVANA PARPAM WITH ASAFOETIDA AND HONEYON HOT PLATE 
METHOD IN MICE 
 
GROUP 
 
Reaction time in seconds at time (minutes) (mean ± sem) (mean ± sem) 
 
O mints 60 mints 90 mints 120 mints 180 mints 
 
CONTROL 
 
3.215±0.235 
 
4.265±0.055 
 
3.59±0.39 
 
3.95±0.17 
 
3.885±0.005 
 
 
STANDARD 
 
3.05±0.17 
 
5.615±0.725 
 
6.555±0.08*** 
 
6.91±0.4** 
 
6.31±0.43** 
 
PLP  2.7 
mg /kg   (po) 
 
3.975±0.415 
 
7.43±0.45** 
 
8.03±0.31*** 
 
7.54±0.1*** 
 
7.905±0.02*** 
 
 
PLP 
13.5mg/kg(po) 
 
3.78±0.2 
 
7.105±0.215* 
 
7.22±0.1*** 
 
6.71±0.2** 
 
6.64±0.16*** 
 
 
PLP 67.5 
mg/kg(po) 
 
3.315±0.095 
 
6.105±0.235 
 
6.49±0.07*** 
 
6.38±0.06** 
 
5.73±0.07** 
 
Values are expressed as the mean ± S.D; Statistical significance (p)calculated by 
one way ANOVA  followed by dunnett’s ***P< 0.001, **P < 0.01,*P < 0.05 
calculated by comparing treated group with CONTROL group. 
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EFFECT OF PANJA LAVANA PARPAM  WITH HONEY/GHEE ON CARRAGEENAN-
INDUCED LOCALISED INFLAMMATORY PAIN IN RATS 
SUMMARY 
The study plan was developed based on the guidelines of Vogel1 and also it has reference to Chao Ma and 
Jun-Ming Zhang2 and Walker et al. 3,Winter CA, Risley EA, Nuss GW. Carrageenin induced edema in 
hind paw of the rat as an assay for anti-inflammatory drugs. Proc Soc Exp Biol Med. 1962;111:544–7. 
Objective 
To study the anti-inflammatory effect of PANJA LAVANA PARPAMwere prepared WITH HONEY/GHEE in 
the rat model of Carrageenan-induced localized inflammation.  
Methods: 
Test System 
Species : Rat   
Strain : Albino Wister 
Age : 6-8 weeks at the time of dosing 
Total no. of Rats : 24 
Sex : Male 
Weight                   :    150 gm 
 
 The animals were housed in polypropylene cages with stainless steel top grills having 
facilities for holding pellet food and drinking water in bottle with stainless steel sipper tube. Each 
cage contained 6 rats. All rats had free access to potable water and standard pelleted laboratory 
animal diet ad libitum. Paddy husk was used as bedding material. The animals were divided into 
5 groups (6 rats/group). Localized inflammatory pain was induced in all groups of animals by 
intraplantar injection of carrageenan (50 µl of 3% suspension).  
 
 One day before the experiment, three basal readings of hind paw in each rat were 
recorded. Group 1 received vehicle orally, Group 2 received a standard drugDiclofenac sodium 
(10 mg/kg i.p), whereas groups 3,4and 5 received PANJA LAVANA PARPAM. The doses of PANJA 
LAVANA PARPAMwere prepared WITH HONEY/GHEE, whereas Diclofenac sodiumwas dissolved in 
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normal saline.After 30 min, the rats were challenged with subcutaneous injection of 0.1 ml of 1% 
w/v solution of carrageenan into the sub plantar region of left paw. The paw was marked with 
ink at the level of lateral malleolus and immersed in mercury up to the mark. The paw volume 
was measured at 0, 1, 2, 3, 4, 5 and 6th hr after carrageenin injection using Digital 
Plethysmometer. The difference between initial and subsequent reading gave the actual edema 
volume.  
DOSAGE SCHEDULE: 
 The required dose for mice/rat will be calculated by using the standard dose calculation 
procedure from recommended clinical dose. 
CONVERSION FORMULA: 
Human dose is 6000 mg /kg day 
Total clinical dose (a) x conversion factor (b) 0.018 = (c) per 150 gm of Rat 
6000 mg x 2(a) x 0.018 (b) = 108 (c) /150 gm of Rat 
108/1000x150 = 16.2 mg  
Experimental Doses Calculated as per the standard procedures are 
 
 
S.No 
 
Groups 
 
Dose /kg, weight 
 
Volume of administration 
 
1 Vehicle Control -- 1 ml 
 
2 Therapeutic Dose 16.2 mg /kg 
 
1 ml 
3 Middle  Dose 81mg/kg 1 ml 
 
4 High Dose 405mg/kg 1 ml 
EXPERIMENTAL DESIGN: 
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Group-I:   Served as a negative control (0.1ml of 1% carrageenin) 
Group-II: Served as standard received Diclofenac sodium (10mg/kg, i.p) + 
 (0.1ml of 1% carrageenin) 
Group-III: Received PANJA LAVANA PARPAMwere prepared WITH HONEY/GHEE 
(16.2mg /kg) + (0.1ml of 1% carrageenin) 
Group IV: Received PANJA LAVANA PARPAMwere prepared WITH HONEY/GHEE 
(81 mg/kg ) + (0.1ml of 1% carrageenin) 
Group V: Received PANJA LAVANA PARPAMwere prepared WITH HONEY/GHEE 
(405 mg/kg ) + (0.1ml of 1% carrageenin) 
 
TABLE: EFFECT OF PANJA LAVANA PARPAMWITH HONEY/GHEE ON Carrageenin -INDUCED 
PAW EDEMA IN RATS (BODY WEIGHT in gms) 
 
 
Group 
 
Only 
Carrageenin 
Carrageenin + 
STD 
Carrageenin + 
L.D 
Carrageenin 
+ M.D 
Carrageenin 
+ H.D 
 
INITIAL 
BODY 
WEIGHT 
156.7±1.333 
 
142.3±28.48 
 
161±4.973 
 
166.3±2.813 
 
151.5±3.191 
 
 
Values are expressed as the mean ± S.D. Statistical significance (p) calculated by one way 
ANOVA  followed by dunnett’s. ns- not significant **P< 0.05 calculated by comparing treated group with 
control group. 
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TABLE: EFFECT OF PANJA LAVANA PARPAMWITH HONEY/GHEE ON Carrageenin -INDUCED 
PAW EDEMA IN RATS 
 
 
Group 
Mean paw 
volume before 
Carrageenin 
injection 
Paw Volume after induction with   Carrageenin 
Increase in paw volume (ml) after   Carrageenin   injection (mean ± 
SEM)/Percent   
inhibition of edema 
0 min 30 min 1h 2h 3h 4h 5h 6h 
 
Control 
 
4.105± 
0.1627 
 
7.425± 
0.1594 
 
7.483± 
0.1429 
 
8.348± 
0.2079 
 
8.39± 
0.1014 
 
7.86± 
0.0801 
 
8.283± 
0.2986 
 
7.913± 
0.2277 
 
Standard 
 
4.085± 
0.1617 
 
7.033± 
0.1053 
 
7.813± 
0.1993 
 
7.79± 
0.249 
 
7.958± 
0.2091 
 
7.788± 
0.1251 
 
6.033± 
0.1574 
 
5.663± 
0.2765 
 
LD 
 
3.698± 
0.258 
6.973± 
0.1963 
 
 
7.648± 
0.1579 
8.153± 
0.2022 
 
8.105± 
0.1269 
 
 
7.448± 
0.2509 
 
6.638± 
0.3813 
 
6.1± 
0.2967 
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Values are expressed as the mean ± S.D. Statistical significance (p) calculated by one way ANOVA  
followed by dunnett’s. ns- not significant 
**
P< 0.05 calculated by comparing treated group with control 
group. 
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control
Standard
L.D
M.D
H.D
 
MD 
 
4.283± 
0.09437 
 
7.068± 
0.1006 
 
7.488± 
0.2231 
 
7.8± 
0.1545 
 
8.16± 
0.1066 
 
7.75± 
0.03764 
 
6.235± 
0.1546 
 
5.49± 
0.1828 
HD 4.028± 
0.2623 
7.108± 
0.3236 
7.66± 
0.3129 
 
6.893± 
0.3936** 
 
7.335± 
0.2522** 
 
6.94± 
0.1685 
 
6.17± 
0.1339 
 
5.003± 
0.2594 
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FIG: EFFECT OF PANJA LAVANA PARPAMWITH HONEY/GHEE ON CARRAGEENIN-INDUCED 
PAW EDEMA IN RATS 
                     
                           GROUP – I ONLY CARRAGEENIN                                                        GROUP –II CARRAGEENIN + STD                 
                                   
                    GROUP –III CARRAGEENIN + L.D                                                         GROUP –IVCARRAGEENIN+MD                     
 
GROUP –VCARRAGEENIN+ H D 
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ACUTE TOXICITY STUDY IN FEMALE WISTER RATS TO EVALUATE TOXICITY 
PROFILE OF PANJA LAVANA PARPAM WITH ASAFOETIDA AND HONEY 
 
Table 1. Test substance details 
Name of the test substance  PANJA LAVANA PARPAM WITH 
ASAFOETIDA AND HONEY 
Colour of the test substance -Light brown 
Nature of the test substance Powder 
 
Table 2. Experimental protocol 
Name of the study Acute toxicity 
Guideline followed OECD 423 method-acute toxic class method 
Animals Healthy young adult female wister rats, 
nulliparous, non-pregnant 
Body weight 150-200 g 
Sex                       female 
Administration of dose and volume 6000 mg/kg in 200g body weight, single dose in 1 ml 
Number of groups and animals 5 groups and 3 animals in each group 1000,2000,3000,4000 and 5000mg/kg 
Route of administration Oral Cavage (po) 
Vechicle ASAFOETIDA AND HONEY 
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Table3. Housing and feeding conditions 
Room temperature 22°C  ±  3°C 
Humidity 40-60% 
Light 12 h : 12h (light : dark cycle) 
Feed 
Standard laboratory animal food pellets 
with water ad libitum 
Table 4. Study period and observation parameters 
Initial once observation First 30 minutes and periodically 24 h 
Special attention First 1-4 h after drug administration 
Long term observation Upto 14 days 
Direct observation parameters 
Tremors, convulsions, salivation, diarrhea, 
lethargy, sleep and coma. 
Additional observation parameters 
Skin and fur, eyes and mucous membrane, 
respiratory, circulatory, autonomic and 
central nervous systems, somatomotor 
activity and behavior pattern etc. 
  
The time of death, if any, is recorded. (Complete observations: annexure I). After administration 
of the drug, food is withheld for a further 1-2 hours. 
Study procedure 
Acute oral toxicity was performed as per organization for economic co-operation for 
development (OECD) guideline 423 method. The PANJA LAVANA PARPAM WITH ASAFOETIDA 
AND HONEY was administered in a single dose by tuberculin syringe. Animals are fasted 3 h 
prior to dosing (food was withheld for 3 h but not water). Following the period of fasting animals 
was weighed and test substance was administered orally at a dose of 1000,2000,3000,4000 and 
5000mg/kg. After thePANJA LAVANA PARPAM WITH ASAFOETIDA AND HONEY administration, 
food was withheld 2 h in mice. Animals are observed individually after at least once during the 
first 30 minutes, periodically during the first 24 hrs, with special attention given during the first 4 
hrs, and daily thereafter, for a total of 14 days.  
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REPORT 
Toxicological evaluation ofPANJA LAVANA PARPAM WITH ASAFOETIDA AND 
HONEY 
Table:5 Effect of PANJA LAVANA PARPAM WITH ASAFOETIDA AND HONEY on 
acute toxicity test in female rats. 
 
  
S.N 
 
 
Response 
Head Body Tail 
Before After Before After Before After 
1 Alertness Normal Normal Normal Normal Normal Normal 
2 Grooming Absent Absent Absent Absent Absent Absent 
3 Touch response Absent Absent Absent Absent Absent Absent 
4 Torch response Normal Normal Normal Normal Normal Normal 
5 Pain response Normal Normal Normal Normal Normal Normal 
6 Tremors Absent Absent Absent Absent Absent Absent 
7 Convulsion Absent Absent Absent Absent Absent Absent 
8 Righting reflux Normal Normal Normal Normal Normal Normal 
9 Gripping strength Normal Normal Normal Normal Normal Normal 
10 Pinna reflux Present Present Present Present Present Present 
11 Corneal reflux Present Present Present Present Present Present 
12 Writhing Absent Absent Absent Absent Absent Absent 
13 Pupils Normal Normal Normal Normal Normal Normal 
14 Urination Normal Normal Normal Normal Normal Normal 
15 Salivation Normal Normal Normal Normal Normal Normal 
16 Skin colour Normal Normal Normal Normal Normal Normal 
17 Lacrimation Normal Normal Normal Normal Normal Normal 
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RESULT: 
 From acute toxicity study it was observed that the administration of PANJA LAVANA 
PARPAM WITH ASAFOETIDA AND HONEYto Female Wister rats did not induce drug-
related toxicity and mortality in the animals up to 5000mg/kg in 200g female Wister rats. So No-
Observed-Adverse-Effect- Level (NOAEL) of PANJA LAVANA PARPAM WITH 
ASAFOETIDA AND HONEY is 5000 mg/kg equal to human dose 
DISCUSSION 
PANJA LAVANA PARPAM WITH ASAFOETIDA AND HONEYwas 
administered single time at the doses of 1000,2000,3000,4000 and 5000mg/kgto female 
Wister rats and observed for consecutive 14 days after administration. Doses were 
selected based on the pilot study and literature review. All animals were observed 
daily once for any abnormal clinical signs. Weekly body weight and food 
consumption were recorded. No mortality was observed during the entire period of 
the study. Data obtained in this study indicated no significance physical and 
behavioral signs of any toxicity due to administration of PANJA LAVANA PARPAM 
WITH ASAFOETIDA AND HONEYat the doses of 1000,2000,3000,4000 and 5000mg/kg 
to female Wister rats  
At the 14th day, all animals were observed for functional and behavioral 
examination. In functional and behavioral examination, home cage activity, hand 
held activity were observed. Home cage activities like Body position, Respiration, 
Clonic involuntary movement, Tonic involuntary movement, Palpebral closure, 
Approach response, Touch response, Pinna reflex, Sound responses, Tail pinch 
response were observed. Handheld activities like Reactivity, Handling, Palpebral 
closure, Lacrimation, Salivation, Piloercetion, Papillary reflex, abdominal tone, 
Limb tone were observed. Functional and behavioral examination was normal in 
all treated groups. Food consumption of all treated animals was found normal as 
compared to normalgroup. 
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SUMMARY & CONCLUSION: 
Summary: 
The present study was conducted to know single dose toxicity of PANJA 
LAVANA PARPAM WITH ASAFOETIDA AND HONEYon female Wister rats. The 
study was conducted using 15 female Wister rats. The female animals were 
selected for study of 8- 12 weeks old with weight range of within ± 20 % of mean 
body weight at the time of randomization. The groups were numbered as group I, 
II, III, IV and V and dose with 1000,2000,3000,4000 and 5000mg/kg of PANJA 
LAVANA PARPAM WITH ASAFOETIDA AND HONEY. The drug was administered 
by oral route single time and observed for 14 days. Daily the animals were 
observed for clinical signs and mortality.  
There were no physical and behavioral changes observed in Female Wister 
rats during 14 days. Mortality was not observed in any treatment groups. 
Conclusion: 
The study shows that PANJA LAVANA PARPAM WITH ASAFOETIDA AND 
HONEYdid not produce any toxic effect at dose of 1000,2000,3000,4000 and 5000mg/kg 
to rats. SoNo-Observed-Adverse-Effect-Level (NOAEL) of PANJA LAVANA 
PARPAM WITH ASAFOETIDA AND HONEY is 5000 mg/kg. 
7.0 ABBREVIATIONS 
No.   Number 
Mg  Milligram 
Kg   Kilogram 
LD50  Lethal Dose 50 
p.o  peros 
ML  Milliliter 
%   percentage 
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R&D   Research and Development 
g%   Gram percentage 
g  Gram 
NOAEL  No-Observed-Adverse-Effect-Level 
MLD   Minimum Lethal Dose 
MTD   Maximum Tolerated Dose 
OECD Organisation of Economic Co-operation and Development 
CPCSEA  Committee for the Purpose of Control and Supervision of 
Experiments onAnimals 
 
8.0 REFERENCES: 
 
1. OECD. Guideline for Testing of Chemicals 423, Acute oral toxicity (acute toxic class 
method). December 2001. 
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ANNEXURE –IV  
SUB-ACUTE TOXICITY STUDY IN WISTER RATS TO EVALUATE TOXICITY 
PROFILE OF PANJA LAVANA PARPAM WITH ASAFOETIDA AND HONEY 
Objective 
 The objective of this study is to evaluate the toxic effects, if any, as a result of the 
repeated once daily oral administration of PANJA LAVANA PARPAM WITH ASAFOETIDA 
AND HONEYto Wister Albino rats for a minimum period of 28 consecutive days. This study 
will provide information on any major toxic effects, target organs and a rationale for 
concluding the No-Observed-Adverse-Effect-Level (NOAEL) and/or No Observed Effect 
Level (NOEL) / LOEL (Low Observed Effect Level) and risk assessment in humans. 
1. Test Guidelines 
This study plan is prepared as per the following guidelines: 
Schedule – Y, Amendment version 2005, Drugs and Cosmetics Rules, 1945. 
OECD – 407 – Repeated dose 28-day Oral Toxicity Study in Rodents, Adopted 3 October, 
2008. 
1.1. Test System Details 
Species : Rat 
Strain  : Wister Albino  
Source    : Sree Venkateshwara Enterprises Pvt Ltd, Bangalore 
Age : 6-8 weeks 
Sex : Male / Female (nulliparous and non-pregnant) 
Body weight   : 160.0to 180.0 g 
1.2. Acclimatization 
Animals will be allowed to acclimatize to the experimental room conditions for five days 
prior to the commencement of dosing. During the acclimatization period, the animals will 
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be observed daily for any apparent adverse clinical signs. Prior to assignment to the study 
and commencement of treatment, a detailed physical health examination will be 
performed on all animals by a veterinarian and animals with any evidence of ill health or 
poor physical condition will not selected for the study. 
1.3. Randomization and Grouping 
On the starting day of dosing, the animals will be weighed and health examination will be 
performed by veterinarian. Animals will be randomly allocated to different groups 
according to their body weight by using MS-Excel sheet as described in the 
randomization SOP. Animals will be divided into four groups (vehicle control, low, 
intermediate, and high dose). At the initiation of the treatment, the body weight variation 
between the groups did not exceed ±20% of the mean weight of each sex. 
1.4. Animal Identification 
In each cage, animals will be identified with numbers by marking at the base of the ear. 
The cages will be identified with an attached colored cage label showing study number, 
study code, group number, sex, dose, strain, species, cage number, route of 
administration and animal number. 
2. Animal Husbandry 
2.1. Animal Welfare and approval 
The study was approved by the IAEC (SLS) and Committee for the Purpose of Control 
and Supervision of Experiments on Animals (CPCSEA registration number: 
Abc14).Their recommendations regarding animal care and handling will be followed. 
2.2. Environmental Conditions 
The temperature of the experimental room will be maintained at 22±30Cand the relative 
humidity between 30-70 %. The photoperiod will be 12 hours light and 12 hours dark 
cycles  
2.3. Housing Conditions 
Two animals will be housed in autoclaved polypropylene rat cages (Size in mm=L x W x 
H: 430 x 290 x 160) using paddy husk as the bedding material. Each cage will be fitted 
with a top grill having provision for keeping rodent pellet feed and an autoclaved 
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polypropylene water bottle with stainless steel drinking nozzle. Cages will be placed on 
3-tier racks and cage rotation will be performed every week. Cages will be changed at 
least twice a week. The cages and water bottles will be cleaned and autoclave sterilized. 
2.4. Sanitation 
Each day, the floor of the animal room will be swept and mopped. Cages and bedding 
material will be changed once in three days and water bottles will be changed daily. All 
the experimental procedures will be done in a clean environment. 
2.5. Feed 
The experimental animals will be provided with irradiated rodent pellet feed ad libitum 
supplied from Sai feeds Pvt ltd, Chennai . Feed will be withheld for four hours prior to 
blood collection and necropsy. 
2.6. Drinking Water 
Animals will be provided with filtered drinking water ad libitum  passed through water 
filter system (Aquaguard™) in autoclaved polypropylene bottles. Water bottles will be 
changed daily. Microbial analysis of water will be carried out once monthly and the 
report is maintained in the study file. 
3. Personnel Safety 
All personnel handling animals undergo regular medical examination. Protective clothing 
like apron, face mask, head cap, and gloves will be used to maintain hygienic conditions. 
4. Materials and Methods 
4.1. Preparation of Dose formulation 
The dose formulation will be prepared under aseptic conditions as per SLS, SOP.  
4.2. Route of Administration and Justification 
Administration will be by oral gavage, as it is one of the possible routes of exposure. 
4.3. Frequency and Duration of Administration 
Once daily for 28 consecutive days 
135 
 
4.4. Dosing Procedure 
The test item will be administered in once daily by oral gavage using a suitable 
intubation cannula fitted with a graduated syringe. The scheme of dosing and sacrifice 
time points are presented in the below below Table. 
4.5. Experimental Procedures 
All experimental procedures will be performed in accordance with the Study plan and 
Standard Operating Procedures (SOPs) of SLS. 
4.6 DOSAGE SCHEDULE: 
The required dose for mice/rat will be calculated by using the standard dose calculation 
procedure from recommended clinical dose. 
CONVERSION FORMULA: 
Human dose is 5000 mg /kg day 
Total clinical dose (a) x conversion factor (b) 0.018 = (c) per 150 gm of Rat 
5000 mg x 2(a) x 0.018 (b) = 90 (c) /150 gm of Rat 
90/1000x150 = 13.5 mg  
Experimental Doses Calculated as per the standard procedures are 
 
S.No 
 
Groups 
 
Dose /kg, weight 
 
Volume of administration 
1 Vehicle Control  
ASAFOETIDA AND HONEY 
1 ml 
 
2 Therapeutic Dose 13.5 mg /kg 
 
1 ml 
3 Middle  Dose 67.5mg/kg 1 ml 
 
4 High Dose 337.5mg/kg 1 ml 
 
 
136 
 
1.1.1 Experimental Design 
 
5. Observations 
Animals will be observed daily throughout the treatment period at regular intervals. During 
the treatment period, animals will be observed twice daily for any clinical signs of toxicity, 
morbidity and mortality. All the surviving animals will be sacrificed at the end of scheduled 
period and subjected to gross necropsy and histopathological evaluations. 
5.1.Clinical Signs 
All the animals will be subjected to cage-side (home-cage) observations twice a day for 
any clinical signs of toxicity, preferably at the same time each day and considering the 
peak period of anticipated effect. In addition to home cage observations, a detailed 
clinical examination will be performed once prior to dosing and weekly thereafter during 
treatment period.  
Group 
No. 
Group 
Dose                          
(mg/kg  
b.wt /day) 
No. of Animals 
Male Female 
G1 Vehicle control ASAFOETIDA AND HONEY 5 5 
G2 
Low dose of   PANJA LAVANA 
PARPAM WITH ASAFOETIDA AND 
HONEY 
13.5 mg /kg 
 
5 5 
G3 
Intermediate dosePANJA LAVANA 
PARPAM WITH ASAFOETIDA AND 
HONEY 
67.5mg/kg 5 5 
G4 
High dose PANJA LAVANA PARPAM 
WITH ASAFOETIDA AND HONEY 
337.5mg/kg 5 5 
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5.2. Morbidity/ Mortality 
All animals will be examined twice a day for mortality and signs of morbidity.  
5.3. Body Weights 
Body weights will be recorded at the beginning of acclimatization, before randomization, 
there after at weekly intervals and at the time of necropsy. 
5.4. Feed Consumption 
Feed consumption will be calculated on a weekly basis throughout the study period. 
5.5. Hematologyand Clinical Biochemistry 
Hematology and clinical biochemistry tests will be performed with terminally collected 
blood samples on day-29 from all animals. Animals will be deprived of feed overnight 
and blood samples will be collected by tapping the ear for visibility of the vein site and 
inserted the needle into the marginal ear vein and collected the blood into micro 
centrifuge tube. Approximately 0.5 ml of blood will be collected in vials containing 1% 
EDTA (20µl) as an anticoagulant for hematological analysis. 
Approximately 2 ml blood will be collected from each animal in micro centrifuge tubes 
containing 15µl of heparin (19 units) and the plasma will be separated by centrifugation 
at 4000 rpm for ten minutes at 4oC. The plasma will be stored at -20 oC ± 2 and used for 
all clinical chemistry analysis. 
5.6. Hematology 
Erythrocyte count (RBC), Total Leucocyte count (WBC), Hemoglobin (Hb), Hematocrit 
(HCT), Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin (MCH), 
Mean Corpuscular Hemoglobin Concentration (MCHC) and Platelet (PLTC). 
5.7. Clinical Biochemistry 
Glucose, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline 
phosphatase (ALP), Total protein, Albumin, Creatinine, Urea, Cholesterol, Triglycerides, 
Sodium, Potassium, Calcium, and  Chloride. 
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1.1.2 5.8 Pathology 
All animals will be euthanized by CO2 asphyxiation and subjected to necropsy under the 
supervision of the veterinary pathologist. Different tissues/organs of thoracic, abdominal 
and cranial cavities will be examined for any gross pathological changes. Tissues from 
vehicle control and high dose groups will be subjected to detailed histopathological 
analysis (Ovaries/ testes,  kidneys, liver, lungs). The organs will be fixed using Bouin’s 
(reproductive organs) and 10% neutral buffered formalin (kidneys, liver, spleen, 
lungs).Processing of tissue will be done by spin tissue processer, embedding of the tissue 
by tissue embedder. The tissues will be initially trimmed to 10-20µ thickness and later 3-
6µ to obtain thinner tissue sections by using rotary microtome. Haematoxylin and Eosin 
staining will be performed for all tissues. 
5.8. Organ Weights 
Absolute weights of adrenal glands, brain, ovaries/testes, epididymis/uterus, heart, 
kidneys, liver, spleen and lungs will be recorded for all the animals after trimming 
adherent tissue immediately after dissection from the animal. Paired organs will be 
weighed together. Relative weights of these organs against fasting animal body weights 
will be calculated and reported. 
6. Data Compilation 
Data will be summarised in a tabular form showing the number of animals, experimental 
design, dose groups, dose volume and concentrations, test item and vehicle control details. 
All findings like clinical signs, mortality and morbidity data, time of death, body weights, 
feed consumption, clinical signs, and necropsy and pathology observations will be recorded 
and given in the final report. One original copy of the final report is issued to the sponsor.  
7. Statistical Analysis 
All the parameters of treated groups of both sex, viz. body weight, feed consumption, organ 
weights (absolute and relative), biochemical parameters, and hematology parameters will be 
analyzed using SPSS software, version 16.0 by using one-way ANOVA test with multiple 
comparison (vehicle controls treated groups) in the study report, and p value < 0.05 is 
considered as statistically significant.  
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MATERIALS AND METHODS 
         ESTIMATION OF HEMATOLOGICAL PARAMETERS: 1 
Collection of blood for hematological studies 
After the treatment period the animals were anaesthetized by ketamine hydrochloride and the blood 
was collected from Retro-orbital sinus by using capillary into a centrifugation tube which contains 
EDTA for haematological parameters The haematological parameters like RBC, WBC and Hb 
percentage, Differential cell count, MCV, MCHC, Hematocrit, MCH, platelet count wereestimated by 
the following procedures. 
1. ENUMERATION OF RED BLOOD CELLS: 1Ramnic 2007) 
Reagents : RBC diluting fluid 
       Procedure: 
Using a red blood cell pipette of haemocytometer, well mixed blood was drawn up to 0.5 mark and RBC diluting 
fluid was taken up to mark II. The fluid blood mixture was shaken and transferred onto the counting chamber. The 
cells were allowed to settle to the bottom of the chamber for 2 min. See the fluid does not get dried. Using 45X or 
high power objective the RBC’s were counted uniformly in the larger corner squares.   
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The cells were expressed as number of cells x1012/l 
2. ENUMERATION OF WBC: 2    John 1972) 
      Reagents: 
 Turk’s fluid: Turk’s fluid was prepared by mixing 2ml of acetic acid with 100 ml of distilled 
water. To this 10 drop of aqueous methylene blue 3 %    w/v) was added. This solution haemolysis the red 
cells due to acidity so that counting of white cells becomes easy. 
Procedure:     
Using a white blood cell pipette of haemocytometer, well mixed blood was drawn up to 0.5 mark and WBC diluting 
fluid was taken up to mark II. The fluid blood mixture was shaken and transferred onto the counting chamber. The 
cells were allowed to settle to the bottom of the chamber for 2 min. See the fluid does not get dried. 
 Using 10X or low power objective the WBC’s were counted uniformly in the larger corner squares.  
 The cells were expressed as number of cells/10mm. 
3. DIFFERENTIAL LEUCOCYTE COUNT: 3 John 1972) 
Reagent: 
              Leishmann’s stain: 150mg of powdered leishmann’s stain was dissolved in 133ml of acetone free methanol. 
Procedure: 
 A blood film stained with leishmann’s stain was examined under oil immersion and the different types of 
WBCs were identified. The percentage distribution of these cells was then determined. Smears were made from 
anticoagulant blood specimens and stained with leishmann’s stain. The slides were preserved for counting the 
number of lymphocytes and neutrophils, per 100 cells were noted.  
 From the different Leukocyte count and WBC count, absolute lymphocyte and neutrophil count were 
calculated. 
           Number of neutrophils  
 Absolute neutrophil count =   _______________________________   x  TWBC 
                        100  
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                                                                  Number of lymphocytes  
 Absolute lymphocyte count =   _______________________________ x TWBC 
                        100 
DETERMINATION OF BIOCHEMICAL PARAMETERS: 
 
For assessment of biochemical parameters, blood samples were collected from the animals by puncturing the 
retro-orbital plexus and centrifuged. The serum collected after centrifugation was analyzed for various biochemical 
parameters like SGOT, SGPT, ALP,TC.TG,HDL All of the above biochemical parameters were estimated using 
semi autoanalyzer (Photometer 5010 V5+, Germany) with enzymatic kits procured from Piramal Healthcare limited, 
Lab Diagnostic Division, Mumbai, India. 
1. Total Cholesterol (TC) 
Principle 
Determination of cholesterol is done after enzymatic hydrolysis and oxidation. The colorimetric indicator is 
quinoneimine, which is generated from 4-aminoantipyrine and phenol by hydrogen peroxide under the catalytic 
action of peroxidase (trinder’s reaction). 
Cholesterol ester + H2O       CHE       Cholesterol + Fatty acid 
Cholesterol + O2CHO      Cholesterol-3-one +H2O2 
2H2O2  + 4- Amino antipyrine + Phenol      POD          Quinonelimine + 4 H2O2 
Method  
 CHOD-PAP: Enzymatic photometric test 
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Table 6: Reagents 
Goods buffer (pH 6.7) 50 mmol/ l 
Phenol 5 mmol/l 
4-aminoantipyrine 0.3 mmol/l 
Cholesterol estrase >  200 U/l 
Cholesterol oxidase >  100 U/l 
Peroxidase 3 KU/l 
Standard (5.2 mmol/l) 
 
Assay procedure 
a. 1 ml (1000 µl) of reagent-1 is taken in a 5 ml test tube. 
b.  Added 0.01 ml (10 µl) of serum. 
c. Mixed well and incubated at 37◦C   for 5 min. 
d. Read the test sample. 
NORMAL RANGE: <200 mg/dl in serum.  
1. Deeg R, Ziegenhorn J, Kinetic enzymatic method for automated determination of total cholesterol in serum, 
Clin. Chem., 1983, 29:1798-802. 
 
2. Triglycerides 
Principle 
Determination of triglycerides (TG) alters enzymatic splitting with lipoprotein lipase. Indicator is quinoneimine 
which is generated from 4-aminoantipyrine and 4- chlorophenol by hydrogen peroxidase under the catalytic action 
of peroxidase. 
Triglycerides              LPL           Glycerol + fatty acid 
Glycerol + ATP              GK            Glycerol-3-phosphate+ ADP 
Glycerol-3-phosphate +O2 GPO Dihydroxyaceton phosphate + H2O2 
2H2O2  + 4- Amino antipyrine + 4- chlorophenol         POD  Quinonelimine + HCL + 4H2O2 
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Method 
 Colorimetric enzymatic test using glycerol-3-phosphate-oxidase (GPO). 
Reagents 
Components and concentrations in the test Goods buffer pH 7.2, 50 mmol/ l 
Table 7: Reagents 
4-chloroPhenol 4 mmol/l 
ATP 2 mmol/l 
Mg2+ 15 mmol/l 
Glycerokinase > 0.4 Kµ/l 
Peroxidase > 2 Kµ/l 
Lipoprotein lipase > 4 Kµ/l 
4-aminoantipyrine 0.5 mmol/l 
Glcerol-3-phosphate- oxidase > 1.5Kµ/l 
Standard (2.3 mmol/l) 
 
Assay procedure 
a. 1 ml (1000 µl) of reagent-1 is taken in a 5 ml test tube. 
b. Added 0.01 ml (10 µl) of serum. 
c. Mixed well and incubated at 37◦C for 15 min. 
d. Read the test sample. 
 Normal Range: <200 mg/dl in serum. 
1. Cole T.G, Klotzsch S.G, Mcnarmara J, Measurement of triglyceride concentration, In Rifai N, Warnick G.R, 
Dominiczak M.H, Handbook of lipoprotein testing, Washington:AACC, Press, 1997, 115-26. 
3. HDL Cholestrol 
 Principle  
Chylomicrons, VLDL and LDL are precipitated by adding phosphotungstic acid and magnesium ions to the 
sample. Centrifugation leaves only the HDL in the supernatant. The cholesterol content in it is determined 
enzymatically. 
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Method 
Phosphotungstic acid precipitation method. 
Table 8: Reagents 
Phosphotungstic acid 0.55 mmol/l 
Magnesium chloride 25 mmol/l 
Assay procedure 
A.  Preparation of supernatant for the HDL-CHL estimation 
    Added 200 µl of serum to the 500 µl of HDL-Cholesterol precipitating reagent (from HDL kit) in 1.5 ml 
centrifuge tube and mixed well. Centrifuged the above solution at 4000 rpm for 10 min. 
B. Preparation of test sample for the estimation of HDL-Cholesterol 
a. Taken 1000 µl of reagent-1 (from cholesterol kit) in a 5 ml test tube. 
b. Added, 100 µl of supernatant from above centrifuged solution 
c. Mixed well and incubated at 37◦C for 15 min. 
d. Read the test sample.  
Normal Range: >60 mg/dl in serum. 
1. Friedewald W.T, Levy R.T, Frederickson D.S, Estimation of VLDL and LDL cholesterol, Clin. Chem., 
1972, 18:499-502. 
4. ESTIMATIONOFSERUMGLUTAMATEPYRUVATETRANSAMINASES(SGPT/ALT) 
1. Determination of aspartate aminotransferase (AST) 
  Aspartate aminotransferase, also known as Glutamate Oxaloacetate Transaminase (GOT)catalyses the 
transamination of L-aspartate and α keto glutarate to form oxaloacetate and L- glutamate. Oxaloacetate formed is 
coupled with 2,4- Dinitrophenyl hydrazine to form hydrazone, a brown coloured complex in alkaline medium which 
can be measured colorimetrically. 
Reagents  
Buffered aspartate  (pH 7.4); 2,4- DNPH reagent;  4N sodium hydroxide;  working pyruvate standard; solution I 
(prepared by diluting 1 ml of reagent 3 to 10 ml with purified water). 
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Procedure  
  Rietman and Frankle method was adopted for the estimation of SGOT. (Reitmann S, Frankel S, 
1957. A colorimetric method for the determination of serum oxaloacetic and glutamic pyruvate transminases. 
American Journal of Clinical Pathology.28: 56-63.The reaction systems used for this study included blank, standard, 
test (for each serum sample) and control (for each serum sample). 0.25 ml of buffered aspartate was added into all 
the test tubes. Then 0.05 ml of serum was added to the test group tubes and 0.05 ml of working pyruvate standard 
into the standard tubes. After proper mixing, all the tubes were kept for incubation at 37oC for 60 min, after which 
0.25 ml each of 2,4- DNPH reagent was added into all the tubes. Then, 0.05 ml of distilled water and 0.05 ml of 
each serum sample was added to the blank and the serum control tubes respectively. The mixture was allowed to 
stand at room temperature for 20 min. After incubation, 2.5 ml of solution I was added to all test tubes. Mixed 
properly and optical density was measured in a spectrophotometer at 505 nm within 15 min. 
The enzyme activity was calculated as:-  
AST (GOT) activity in IU/L) = [(Absorbance of test - Absorbance of control)/ (Absorbance of standard - 
Absorbance of blank)] x concentration of the standard         
 
2.  Determination of alanine aminotransferase(ALT) 
 Alanine aminotransferase, also known as Glutathione Peroxidase (GPT) catalyses the transamination of L-
alanine and α keto glutarate to form pyruvate and L- Glutamate. Pyruvate so formed is coupled with 2,4 – 
Dinitrophenyl hydrazine to form a corresponding hydrazone, a brown coloured complex in alkaline medium which 
can be measured colorimetrically. 
Reagents 
Buffered alanine (pH 7.4), 2,4–DNPH, 4N sodium hydroxide, working pyruvate standard, solution I (prepared by 
diluting 1 ml of reagent 3 to 10 ml with purified water). 
Procedure  
 Rietman and Frankle method was dopted for the estimation of SGPT. The reaction systems used for this 
study included blank, standard, test (for each serum sample) and control (for each serum sample). 0.25 ml of 
buffered alanine was added into all the test tubes. This was followed by the addition of 0.05 ml of serum into the test 
group tubes and 0.05 ml of working pyruvate standard into the standard tubes. After proper mixing, all the tubes 
were kept for incubation at 37oC for 60 minutes, after which 0.25 ml each of 2,4- DNPH reagent was added into all 
the tubes. Then, 0.05 ml of distilled water and 0.05 ml of each serum sample was added to the blank and the serum 
control tubes respectively. The mixture was allowed to stand at room temperature for 20 min. After incubation, 2.5 
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ml of solution I was added to all test tubes. Mixed properly and optical density was read against purified water in a 
spectrophotometer at 505 nm within 15 min. 
The enzyme activity was calculated as:- ALT (GPT) activity in IU/L) = [(Absorbance of test - Absorbance of 
control)/ (Absorbance of standard - Absorbance of blank)] x concentration of the standard.        
3. Determination of alkaline phosphatase (ALP) 
Alkaline phoshatase from serum converts phenyl phosphate to inorganic phosphate and phenol at pH 10.0. Phenol so 
formed reacts in alkaline medium with 4-aminoantipyrine in presence of the oxidising agent potassium ferricyanide 
and forms an orange-red coloured complex, which can be measured spectrometrically. The color intensity is 
proportional to the enzyme activity. 
Reagents: 
Buffered substrate 
Chromogen Reagent 
Phenol Standard, 10 mg% 
Procedure: 
ALP was determined using the method of Kind (Kind PRM, King EJ, 1972. In-vitro determination of serum alkaline 
phosphatase. Journal of Clinical Pathology 7: 321-22\). The working solution was prepared by reconstituting one 
vial of buffered substrate with 2.2 ml of water. 0.5 ml of working buffered substrate and 1.5 ml of purified water 
was dispensed to blank, standard, control and test. Mixed well and incubated at 370C for 3 min. 0.05 ml each of 
serum and phenol standard were added to test and standard test tubes respectively. Mixed well and incubated for 15 
min at 370C. Thereafter, 1 ml of chromogen reagent was added to all the test tubes. Then, added 0.05 ml of serum to 
control. Mixed well after addition of each reagent and the O.D of blank, standard, control and test were read against 
purified water at 510 nm. 
Serum alkaline phosphatase activity in KA units was calculated as follows  
[(O.D. Test-O.D. Control) / (O.D. Standard- O.D. Blank)] x 10 
 
4. Determination of bilirubin  
In toxic liver, bilirubin levels are elevated. Hyperbilirubinemia can result from impaired hepatic uptake of 
unconjugated bilirubin, such a situation can occur in generalized liver cell injury, certain drugs (e.g Rifampin and 
probenecid) interfere with the rat uptake of bilirubin by the liver cell and may produce a mild unconjugated 
hyperbilirubinemia. Bilirubin level rises in diseases of hepatocytes, obstruction to bilirubin excretion into 
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duodenum, in haemolysis and defects of hepatic uptake and conjugation of Bilirubin pigment such as Gilbert’s 
disease.  
Elevation of total serum bilirubin may occur due to:  
1.Excessive haemolysis or destruction of the red blood cells.Eg:Haemolytic disease of the new born. 
2.Liver diseases.Eg.Hepatitis and cirrhosis. 
3.Obstruction of the biliary tract.Eg.Gall stones. 
The method is based on the reaction of Sulfonilic acid with sodium nitrite to form azobilirubin which has maximum 
absorbance at 546nm in the aqueous solution. The intensity of the color Produced is directly proportional to the 
amount of direct or total bilurubin concentration present in the sample. 
Reagents 
1. Diazo A-(Reagent-R1) :Ready to use 
2. Diazo B-(Reagent-R2):Ready to use 
3. Bilirubin Activater :Ready to use 
Procedure 
Kind & King’s method was followed for the estimation of Bilirubin. Five hundred µl of working reagent was added 
to 50 µl of rat serum & incubated for 5 min at 37°C. Absorbance was measured AT 546 NM in semi auto analyzer 
against the standard. 
The Bilirubin content was calculated using the following equation: 
Total bilirubin (mg/dt) = Abs of the sample blank x 15. 
Direct Bilirubin(mg/dt) = Abs of sample blank x 10. 
 
5. ESTIMATION OF UREA 
Urea is the nitrogen-containing end product of protein catabolism. States associated with elevated levels of 
urea in blood are referred to as hyper uremia or azotemia.  
Method 
  Estimation of urea was done by Urease-GLDH: enzymatic UV test.  
148 
 
Principle 
Urea + 2H2O     Urease       2NH4 + 2HCO3 
2- Oxoglutarate +NH4+ +NADH      GLDH      L- Glutamate +NAD+ + H2O 
Table 14. Reagents 
 
Procedure 
a. Take 1000 µl of reagent-1 and 250 µl of reagent-2 in 5 ml test tube. 
b. To this, add 10 µl of serum. 
c. Mix well and immediately read the test sample at 340 nm Hg 334 nm Hg 365 nm optical path 1 cm against 
reagent blank (2-point kinetic). 
d. And note down the value. 
Normal range: 10 – 50 mg/dl. 
 
6. ESTIMATION OF URIC ACID 
Uric acid and its salts are end products of the purine  metabolism. In gout the most common complication 
of  hyperuricemia, ie. Increased serum levels of uric acid lead to formation of  monosodium urate crystal around the 
joints. 
Method  
  Enzymatic photometric test using  TOOS (N ethyl- N (hydroxyl -3- sulfopropyl)-m- toluidin) 
  
R 1 
TRIS pH 7.8 120  mmol/l 
2-Oxoglutarate 7 mmol/l 
ADP 0.6 mmol/l 
Urease ≥ 6 KU/l 
GLDH ≥ 1 KU/l 
R 2 NADH 0.25 mmol 
R 3 Standard 40 mg/dl 
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Principle  
Uric acid + H2O + O2       uricase         Allantoin +CO2 +H2O2 
TOOS + 4 aminoantipyrine + 2H2O2POD       Indamine + 3H2O 
Table 15.reagents 
R1 Phosphate buffer pH 7.0 100mmol/l 
TOOS 1mmol/l 
Ascorbate oxidase ≥1 KU/l 
R2 Phosphate buffer pH 7.0 100mmol/l 
4- amino antipyrine 0.3mmol/l 
K4 (Fe( CN)6) 10µmol/l 
Peroxidase ≥1KU/l 
Uricase ≥50U/l 
Procedure 
a. Take 800µl of  reagents -1 in a2ml centrifuge tube. 
b. To this add 20µl of serum. 
c. Mix well and incubate at 30°c for 5 minutes. 
d. Then add 200µl of reagent2 
e. Mix well incubate for 5min at 37°c 
f. Measure the not down the values. 
Normal range: 1.9-8.2mg/dl 
7. ESTIMATION OF CREATININE:  
Principle: 
Creatinine forms a coloured complex with picrate in alkaline medium.  
The rate of formation of the complex is measured.  
Reagents: 
Reagent 1    Standard Creatinine (2mg/100ml) 
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Reagent 2    Picric acid solution. 
Reagent 3     sodium hydroxide solution  
Procedure: 
 Take 500 µl of reagent -2 and 500 µl of reagent -3 in a 5ml test tube. To this add 100 µl of serum. Mix well 
and immediately read the test sample at Hg 492 nm 1cm light path and note down the values.  
Normal range is 0.6 -1.1 mg/dl. 
 
TABLE:1EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF PANJA LAVANA PARPAM WITH 
ASAFOETIDA AND HONEY ON BODY WEIGHT IN Gram (PHYSICAL PARAMETER) 
 
GPs Control Low Dose Middle Dose High Dose 
 Male Female Male Female Male Female Male Female 
1stwk 137.3±3.
528 
139.3±2.
404 
146.7±2.9
06 
141.3±1.7
64 
132±2.30
9 
135.3±2.4
04 
145.3±1.7
64 
142.3±2.7
28 
2ndwk 142.7±2.
906 
143.7±2.
603 
150.7±1.7
64 
150±4.16
3 
138±2.64
6 
139.7±2.1
86 153±1.732 
148±2.88
7 
3rdwk 151.7± 
3.844 
152±4 
 
154± 
3.055 
156.7± 
1.764 
146.7± 
1.453 
147.3± 
2.963 
157±1.528 
 
154.3± 
2.728 
 
4thwk 
162± 
2.082 
162.7± 
3.528 
163.3± 
3.48 
166.3± 
0.8819 
157.7± 
0.8819 
158.7± 
2.603 166±2.082 
162± 
2.646 
Values are expressed as the mean ± S.D 
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EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF PANJA LAVANA PARPAM WITH ASAFOETIDA AND 
HONEY ON FOOD INTAKEIn Gram 
Effect Of Sub Acute Doses (28 Days) 0fPANJA LAVANA PARPAM WITH ASAFOETIDA AND HONEYONFOOD INTAKE 
IN Gram 
Groups Control Low Dose Middle Dose High Dose 
 
DAY Male Female Male Female Male Female Male Female 
Day 1 
34 28 15 10 18 60 12 24 
DAY2 
38 62 56 31 28 80 8 58 
DAY3 
38 30 44 52 66 32 34 14 
Day 4 
56 18 34 24 18 22 42 22 
DAY5 
34 10 18 6 44 58 38 26 
Day 6 
60 12 58 68 32 38 58 64 
DAY7 
50 14 61 88 58 34 62 74 
DAY8 
32 44 18 40 26 64 58 62 
Day 9 
80 56 22 60 48 56 56 64 
DAY10 
74 62 45 56 64 74 24 58 
Day 11 
44 54 68 58 30 62 70 56 
DAY12 
54 60 38 62 56 64 62 48 
DAY13 
72 56 38 44 57 74 54 78 
Day 14 
38 19 54 50 16 74 72 56 
DAY15 
48 36 64 71 82 56 56 28 
Day 16 
56 78 54 42 56 80 56 77 
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DAY17 
56 78 64 58 44 56 56 74 
DAY18 
45 52 34 56 72 64 62 54 
Day 19 
50 48 62 56 88 64 64 58 
DAY20 
16 35 20 75 35 56 72 34 
DAY21 
34 56 64 68 56 64 45 62 
Day 22 
56 34 18 58 64 78 56 42 
DAY23 
46 28 64 56 67 58 18 34 
DAY24 
54 42 34 78 46 64 30 68 
Day 25 
40 80 55 44 88 80 34 64 
DAY26 
64 42 56 64 52 46 58 56 
DAY27 
68 45 32 38 56 80 56 58 
DAY28 
88 36 58 34 24 74 62 61 
 
Values are expressed as the mean ± S.D 
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EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF PANJA LAVANA PARPAM WITH ASAFOETIDA AND 
HONEY ON WATER INTAKE IN ml 
Effect Of Sub Acute Doses (28 Day) 0f PANJA LAVANA PARPAM WITH ASAFOETIDA AND HONEYonWater 
Intake in ml 
Groups Control Low Dose Middle Dose High Dose 
 
DAY Male Female Male Female Male Female Male Female 
Day 1 
70 75 85 140 70 100 50 70 
DAY2 
105 60 85 60 50 85 140 105 
DAY3 
130 60 85 60 70 150 165 130 
Day 4 
70 90 40 55 80 100 90 70 
DAY5 
130 210 60 70 130 70 75 60 
Day 6 
50 70 90 50 65 60 70 85 
DAY7 
70 80 50 130 60 70 90 55 
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DAY8 
130 60 50 70 75 50 70 55 
Day 9 
110 40 80 55 130 20 130 85 
DAY10 
65 130 40 130 70 50 60 70 
Day 11 
80 60 55 70 60 60 70 30 
DAY12 
70 60 75 40 45 80 60 40 
DAY13 
50 60 40 65 55 50 30 60 
Day 14 
40 40 65 60 85 65 20 70 
DAY15 
60 65 20 60 65 80 60 70 
Day 16 
45 60 50 65 30 70 60 40 
DAY17 
80 60 40 70 30 60 20 55 
DAY18 
60 80 65 60 40 90 170 140 
Day 19 
70 115 125 120 20 95 185 140 
DAY20 
70 90 95 50 65 60 75 50 
DAY21 
70 60 85 130 90 50 95 85 
Day 22 
140 40 60 105 70 60 90 60 
DAY23 
60 95 60 65 80 95 70 50 
DAY24 
110 90 75 60 70 50 60 70 
Day 25 
130 60 125 110 85 60 70 60 
DAY26 
70 110 90 60 50 70 110 40 
DAY27 
70 90 50 70 40 110 60 140 
DAY28 
65 50 110 60 85 75 60 125 
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Values are expressed as the mean ± S.D 
 
EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF PANJA LAVANA PARPAM WITH 
ASAFOETIDA AND HONEYON ORGAN WEIGHT in gm 
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WATER INTAKE
F
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M
GROUP CONTROL 
 
Low Dose 
 
Middle Dose 
 
High Dose 
LIVER  WEIGHT 7.472±0.356 6.59±0.415
ns 
7.678±0.788
ns 
6.721±0.241
ns 
KIDNEY 
WEIGHT 
L 0.704±0.0114 0.574±0.019** 0.596±0.00145* 0.515±0.0018*** 
R 0.666±0.0180 0.607±0.0354 0.560±0.0078** 0.493±0.0043*** 
HEART WEIGHT 0.745±0.0565 0.715±0.0343 0.660±0.0190 0.79±0.0517 
LUNGS  WEIGHT 1.728±0.122
ns 
1.33±0.0596
ns 
1.663±0.1328
ns 
1.627±0.03301
ns 
TESTIS WEIGH 2.357±0.01615 2.281±0.07202 1.739±0.1249* 1.89±0.179 
 0.6793±0.0594 0.605±0.04431 0.5553±0.06623 0.5967±0.03567 
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Values arae expressed as mean ± SEM Statisticalsignificance (p) calculated by one way 
ANOVA followed by dunnett’s (n=6); nsp>0.05, *p<0.05, **p<0.01, ***p<0.001, calculated by 
comparing treated groupswith control group.  
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EFFECT OF SUB ACUTE DOSES (28 DAY) 0FPANJA LAVANA PARPAM WITH ASAFOETIDA AND 
HONEYON HAEMATOLOGICALPARAMETERS 
Effect Of Sub Acute Doses (28 Day) 0fPANJA LAVANA PARPAM WITH ASAFOETIDA AND HONEYOn 
Haematological Parameters 
Groups Control Low Dose Middle Dose High Dose 
Rbc (X103/µl)  
 
5.33±0.8585 6.403±0.289 5.96±0.2173 6.213±0.3619 
Wbc(X106/µl)  
 11.17±0.8762 11.87±0.8212 13.73±0.636 13.3±0.3606 
 
Hb (g/dl) 
 
16.4±1.29 
 
16.37±1.707 
 
13.5±0.3055 
 
14.37±0.977 
 
 
Values are expressed as the mean ± S.D; Statistical significance (p)calculated by one way 
ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, ***P < 0.05 calculate 
by comparing treated group with CONTROL group.         
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EFFECT OF SUB ACUTE DOSES (28 DAY) 0FPANJA LAVANA PARPAM WITH ASAFOETIDA AND 
HONEYON BIOCHEMICAL PARAMETER (LIVER PROFILE) 
Groups Control Low Dose Middle Dose High Dose 
Total 
Bilirubin(mg/dl) 
 
0.625±0.125 
 
 
0.865±0.195 
 
 
0.79±0.06 
 
 
1.015±0.055 
 
 
 
Values are expressed as the mean ± S.D; Statistical significance (p)calculated by one way 
ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, ***P < 0.05 calculate 
by comparing treated group with CONTROL group.         
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EFFECT OF SUB ACUTE DOSES (28 DAY) 0FPANJA LAVANA PARPAM WITH ASAFOETIDA AND 
HONEYON BIOCHEMICAL PARAMETER (LIVER PROFILE) 
Groups Control Low Dose Middle Dose High Dose 
 
SGOT (U/L) 
 
85.95±9.25 
 
133.2±37.95 
 
77.9±14.9 
 
81.35±3.05 
 
SGPT (U/L) 69.79±15.72 
 
45.4±3.8 
 
48.15±21.85 
 
38.15±3.95 
 
ALP (U/L) 308.2±24.55 
 
321.8±15.75 
 
247.8±10.55 
 
267.3±1.9 
 
 
Values are expressed as the mean ± S.D; Statistical significance (p)calculated by one way 
ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, ***P < 0.05 calculate 
by comparing treated group with CONTROL group.         
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EFFECT OF SUB ACUTE DOSES (28 DAY) 0FPANJA LAVANA PARPAM WITH ASAFOETIDA AND 
HONEYON BIOCHEMICAL PARAMETER (KIDNEY PROFILE) 
Groups Control Low Dose Middle Dose High Dose 
Urea (mg/dl) 26.03±1.01 
 
33.45±0.25 
 
39.08±1.18 
 
26.74±1.13 
 
Uric acid (mg/dl) 1.615±0.135 
 
1.2±0.04 
 
1.31±0.07 
 
1.64±0.1 
 
Creatinine 
(mg/dl) 
0.33±0.05 
 
0.275±0.005 
 
0.23±0.02 
 
0.29±0.09 
 
 
Values are expressed as the mean ± S.D; Statistical significance (p)calculated by one way 
ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, ***P < 0.05 calculate 
by comparing treated group with CONTROL group.         
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EFFECT OF SUB ACUTE DOSES (28 DAY) 0FPANJA LAVANA PARPAM WITH ASAFOETIDA AND 
HONEYON BIOCHEMICAL PARAMETER (LIPID PROFILE) 
Groups Control Low Dose Middle Dose High Dose 
Total cholesterol 
(mg/dl) 
34.3±3.6 
 
44.85±0.75 
 
44.95±8.05 
 
41.2±1.1 
 
Triglycerides 
(mg/dl) 
101.3±5 
 
71.55±4.85 
 
68.28±2.48 
 
80.4±3.8 
 
HDL-
Cholesterol 
(mg/dl) 
10.12±0.185 
 
6.625±1.945 
 
6.65±2.05 
 
3.9±0.7 
 
 
Values are expressed as the mean ± S.D; Statistical significance (p)calculated by one way 
ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, ***P < 0.05 calculate 
by comparing treated group with CONTROL group.         
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RESULTS: 
    CLINICAL SIGNS: 
All animals in this study were free of toxic clinical signs throughout the dosing   period 
of 28 days. 
 Mortality: 
All animals in control and in all the treated dose groups survived throughout the dosing 
period of 28 days. 
 Body weight: 
Results of body weight determination of animals Table-1 from control and different dose 
groups exhibited comparable body weight gain throughout the dosing period of 28 days. 
Food consumption: 
During dosing and the post-dosing recovery period, the quantity of food consumed by 
animals from different dose groups was found to be comparable with that by control animals. 
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Organ Weight: 
Group Mean Relative Organ Weights (% of body weight) are recorded in Table No.4 
Comparison of organ weights of treated animals with respective control animals on day 29 was 
found to be comparable similarly. 
Hematological investigations: 
The results of hematological investigations (Table 4) conducted on day 29 revealed 
following significant changes in the values of different parameters investigated when compared 
with those of respective controls; however, the increase or decrease in the values obtained was 
within normal biological and laboratory limits or the effect was not dose dependent. 
Biochemical Investigations: 
Results of Biochemical investigations conducted on days 29 and recorded in Table 2 
revealed the following significant changes in the values of hepatic serum enzymes studied. When 
compared with those of respective control. However, the increase or decrease in the values 
obtained was within normal biological and laboratory limits. 
Histopathology: 
In histopathological examination, revealed normal architecture in comparison with 
control and treated animal. 
 DISCUSSION: 
1)  All the animals from control and all the treated dose groups up to 500 mg/kg survived 
throughout the dosing period of 28 days. 
2)  No signs of toxicity were observed in animals from different dose groups during the dosing 
period of 28 days. 
3)  Animals from all the treated dose groups exhibited comparable body weight gain with that of 
controls throughout the dosing period of 28 days. 
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4) Food consumption of control and treated animals was found to be comparable throughout the 
dosing period of 28 days 
5)   Haematological analysis conducted at the end of the dosing period on day 29, revealed no 
abnormalities attributable to the treatment. 
6) Biochemical analysis conducted at the end of the dosing period on day 29 no abnormalities 
attributable to the treatment. 
7) Organ weight data of animals sacrificed at the end of the dosing period was found to be 
comparable with that of respective controls. 
8) Histopathological examination revealed normal architecture in comparison with control and 
treated animal. 
 
SUMMARY AND CONCLUSION:  
In conclusionPANJA LAVANA PARPAM WITH ASAFOETIDA AND HONEYcan 
be considered safe, as it did not cause either any lethality or adverse changes with general 
behavior of rats and also there were no observable detrimental effects (100 to 300 mg/kg body 
weight) over a period of 28 days. Our results have demonstrated that the PANJA LAVANA 
PARPAM WITH ASAFOETIDA AND HONEYis relatively safe when administered orally in 
rats. 
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9.0 ABBRVIATION 
No.   Number 
Mg  Milligram 
Kg   Kilogram 
LD50  Lethal Dose 50 
p.o.  peros 
mL  Milliliter 
%   percentage 
R&D   Research and Development 
EDTA  Ethylene Diamine Tetra Acetic Acid 
M   Male 
g%   Gram percentage 
g  Gram 
NOAEL  No-Observed-Adverse-Effect-Level 
MLD   Minimum Lethal Dose 
MTD   Maximum Tolerated Dose 
OECD  Organisation of Economic Co-operation and Development 
CPCSEA  Committee for the Purpose of Control and Supervision of Experiments on 
Animals 
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HISTOPATHOLOGY   -  TOXICITY STUDY 
SPECIMEN     : A) Liver.    Group –    :  Panja lavana parpam 
 
                                                       
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MICROSCOPIC APPEARANCE:  
 Section from liver shows lobular architecture with interface hepatitis. Individual Hepatocytes shows 
reactive atypia. Portal triad shows no significant pathology. Central vein and Sinusoids show dilatation. 
10x shows mild altered architecture with 
peripotal inflammation 
10x shows sinusoidal dilatation 
40x shows bile duct hyperplasia 40x shows central vein congestion 
40x shows central vein dilated 40x shows interface hepatitis 
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SPECIMEN    :  B) spleen. 
Group – :  Panja lavana parpam 
               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MICROSCOPIC APPEARANCE:  
Section studied from spleen shows normal white pulp and red pulp. Red pulp shows pigment laden 
macrophages and congested vessels. White pulp shows lymphocytic infiltrates forming germinal centre. 
The pencillar artery shows normal morphology. Megakaryocytes 
10x shows normal spleen with red and white pulp 40x show slymphocytic infiltrates 
40x shows  red pulp shows pigment laden 
macrophages 
40x shows normal red and white pulp 
40x shows normal white pulp 40x shows red and white pulp 
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SPECIMEN  :  C)  Kidney. 
Group – :  Panja lavana parpam 
               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MICROSCOPIC APPEARANCE: 
 
Section from kidney shows both cortex and medulla. Glomeruli and tubules shows no significant 
pathology. Interstitium shows no significant pathology. Blood vessels show congestion. There is no 
evidence of toxic changes. 
  
10x shows cortex and medulla 10x shows normal cortex and medulla 
10x shows normal interstitium 
40x shows normal glomeruli 
40x shows normal tubules 
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SPECIMEN  :  D) Testis 
Group – :  Panja lavana parpam 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MICROSCOPIC APPEARANCE:  
Section from testes with seminiferous tubules showing maturation arrest with lacking of 
spermatogenesis.  
10x shows focal maturation arrest 40x shows normal maturation 
40x shows spermatogenesis 40x shows tubular  spermatogenesis 
40x shows tubular maturation arrest 
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Name   : 
Ref. No. : [H0 334A/18] 
 
 
Rec.On :  25/03/2018 
Rep.On :  18/04/2018 
 
HISTOPATHOLOGY 
              TOXICITY STUDY            
 
SPECIMEN                   : A) Liver. 
    
Group –                   : Nasiya banu- P.L.P. 
 
GROSS APPEARANCE: 
 
                     Received a specimen of liver measuring 3.6x2.5x1.6cms.                     
  
(PE): Two bits – One block. 
 
MICROSCOPIC APPEARANCE:  
 
                     Section from liver shows lobular architecture with interface hepatitis. Individual hepatocytes 
show no significant pathology. Portal triad shows bile duct hyperplasia. Central vein shows dilated and 
congestion. Sinusoids show dilatation. 
    Dr.C.R.Ajeethkumar.M.D. (Path). 
             
Consultant pathologists: 
Dr.S.Kalyani.M.D. (Path),   Dr. C.R.Ajeeth kumar.M.D. (Path), 
Checked 
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Name   : 
Ref. No. : [H0 334B/17] 
 
Rec.On :  25/03/2018 
Rep.On :  18/04/2018 
 
HISTOPATHOLOGY 
         Toxicity study                
 
SPECIMEN                   :  B) spleen. 
    
Group –                   : Nasiya banu- P.L.P. 
 
GROSS APPEARANCE:  
 
                     Received a specimen of spleen measuring 2.4x0.8x0.4cms. 
 
 (PE): Two bits – One block. 
 
MICROSCOPIC APPEARANCE:  
 
                     Section studied from spleen shows normal white pulp and red pulp. Red pulp shows pigment 
laden macrophages and congested vessels. White pulp shows lymphocytic infiltrates forming germinal 
centre. The pencillar artery shows normal morphology.  
 
                                                                                     
                                                                                Dr.C.R.Ajeeth kumar. M.D. (Path), 
Consultant pathologists: 
Dr.S.Kalyani.M.D. (Path), Dr. C.R.Ajeeth kumar.M.D. (Path), 
Checked 
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Name   :   
Ref. No. : [Ho 334C/18]                      
 
Rec.On :  25/03/2018 
Rep.On :  18/04/2018 
 
HISTOPATHOLOGY 
                                 Toxicity study 
SPECIMEN                          : C) Kidney. 
 
Group –                   : Nasiya banu- P.L.P. 
 
GROSS APPEARANCE    : 
 
Received specimen of kidneys each measuring 1.4x0.7x0.5cms and 1.3x0.6x0.4cms. 
 
PE : Two bits – One block.                                                            
 
MICROSCOPIC APPEARANCE:  
 
                     Section from kidney shows both cortex and medulla. Glomeruli and tubules shows no 
significant pathology. Interstitium shows no significant pathology. Blood vessels show congestion. There 
is no evidence of toxic changes. 
 Dr. C.R.Ajeeth kumar.M.D. (Path). 
 
Consultant pathologists: 
Dr.S.Kalyani.M.D. (Path),   Dr. C.R.Ajeeth kumar.M.D. (Path), 
 
Checked 
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Name   :   
Ref. No. : [Ho 334D/18]                      
 
Rec.On :  25/03/2018 
Rep.On :  18/04/2018 
 
HISTOPATHOLOGY 
                                 Toxicity study 
SPECIMEN                          : D) Testis. 
 
Group –                   : Nasiya banu- P.L.P. 
 
GROSS APPEARANCE    : 
 
Received specimen of both testis measuring each 1.2x0.7x0.5cms and 1.0x0.5x0.4cms. 
 
PE : Two bits – One block.                                                            
 
MICROSCOPIC APPEARANCE:  
 
                     Section from testes with seminiferous tubules showing normal spermatogenesis. Sertoli 
cells, leydig cell and interstitium shows normal morphology. No evidence of toxic changes. 
 
Dr. C.R.Ajeeth kumar.M.D. (Path). 
Consultant pathologists: 
Dr.S.Kalyani.M.D. (Path),   Dr. C.R.Ajeeth kumar.M.D. (Path), 
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ANNEXURE –V 
ASSESSMENT FORMS 
 
FORM I  : Screening and Selection Proforma 
FORM I A  : History Proforma on Enrollment 
FORM II  : Clinical assessment on enrollment 
FORM II A  : Clinical assessment during and after trial 
FORM III  : Laboratory Investigation on enrollment and conclusion  of trial 
FORM IV  : Consent Form 
FORM IV B  : Withdrawal form 
FORM IV C  : Patient information sheet 
FORM IV D  : Dietary Advice form 
FORM IV E  : Adverse Reaction form 
FORM IV F  : Discharge proforma 
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GOVERNMENTSIDDHAMEDICALCOLLEGE& HOSPITAL 
POST GRADUATE DEPARTMENT 
PALAYAMKOTTAI, TIRUNELVELI – 627002 
BRANCH – III SIRAPPU MARUTHUVAM 
 
A PILOT STUDY TO EVALUATE THE THERAPEUTIC EFFICACY OF SIDDHA 
FORMULATION “PANJA LAVANA PARPAM” INTERNAL & “LAHU VATHA KESARI 
THYLAM” EXTERNAL IN “AZHAL KEEL VAYU” (OSTEOARTHRITIS). 
 
FORM I – SCREENING & SELECTION PROFORMA 
 
1. OP / IP NO    : ___________ 
2. NAME   : ___________ 
3. RELIGION    : H / C / M / O 
4. AGE / GENDER  : ___________ 
5. OCCUPATION  : ___________ 
6. INCOME   : ___________ 
7. CONTACT NO  : ___________ 
8. INCLUSION CRITERIA :  
INCLUSION CRITERIA: 
• Age   :  between 30 -60 years  
• Sex  : Both  
• Joints pain : 1 joint 
• Swelling   
• Stiffness  
• Restricted movements in affected joint.  
• Willing for admission and study in IPD for 40 days or willing to attend OPD 
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EXCLUSION CRITERIA: 
• Systemic illness of the Patient 
• Rheumatoid arthritis 
• Use of narcotic drugs 
• Pregnancy and lactation  
• History of trauma 
• Carcinoma patient 
• Tuberculosis 
• Immuno compromised patients 
• Clinically significant abnormal laboratory values 
 
 
ADMITTED TO TRIAL: 
    YES  NO 
If Yes Serial Number : 
 
Date  :  
Station: 
Signature of the Investigator : 
Signature of the Lecturer :    Signature of the HOD 
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GOVERNMENTSIDDHAMEDICALCOLLEGE& HOSPITAL 
POST GRADUATE DEPARTMENT 
PALAYAMKOTTAI, TIRUNELVELI – 627002 
BRANCH – III SIRAPPU MARUTHUVAM 
A PILOT STUDY TO EVALUATE THE THERAPEUTIC EFFICACY OF SIDDHA 
FORMULATION “PANJA LAVANA PARPAM” INTERNAL & “LAHU VATHA KESARI 
THYLAM” EXTERNAL IN “AZHAL KEEL VAYU” (OSTEOARTHRITIS). 
 
FORM I A – HISTORY PROFORMA 
1. SL.NO     : ___________ 
2. OP / IP NO     : ___________ 
3. NAME    : ___________ 
4. RELIGION     : H / C / M / O 
5. AGE / GENDER   : ___________ 
6. OCCUPATION   : ___________ 
7. INCOME    : ___________ 
8. CONTACT NUMBER  : ___________ 
9. MARITAL STATUS   : Married / Unmarried 
10. COMPLAINTS & DURATION : 
 
11. PERSONAL HISTORY: 
PERSONAL HABITS YES NO IF YES SPECIFY DURATION 
Smoking    
Tobacco Chewing    
Alcohol    
Narcotic Drug Addiction    
12. DRUG HISTORY: 
 Whether the Patient has underwent any allopathic Treatment  
1. Yes    2. No. 
 If yes specify the nature of the drug and treatment duration _____ 
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13. FAMILY HISTORY: 
 Whether this problem runs in family? 
1. Yes  2. No 
If yes, mention the relationship of affected person(s) 
1. ___________ 
2. ___________ 
14. DIETARY HABITS : 
 
   1. Pure vegetarian 
   2. Non-Vegetarian 
 
Date  :  
Station: 
Signature of the Investigator : 
Signature of the Lecturer :    Signature of the HOD 
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GOVERNMENTSIDDHAMEDICALCOLLEGE& HOSPITAL 
POST GRADUATE DEPARTMENT 
PALAYAMKOTTAI, TIRUNELVELI – 627002 
BRANCH – III SIRAPPU MARUTHUVAM 
A PILOT STUDY TO EVALUATE THE THERAPEUTIC EFFICACY OF SIDDHA 
FORMULATION “PANJA LAVANA PARPAM” INTERNAL & “LAHU VATHA KESARI 
THYLAM” EXTERNAL IN “AZHAL KEEL VAYU” (OSTEOARTHRITIS). 
 
FORM II AND II-A  CLINICAL ASSESSMENT ON ENROLLMENT AND ON VISITS 
 
1. OP / IP No     :  
2. BED No    :  
3. SL. NO    : 
4. NAME    : 
5. AGE     : 
6. GENDER    : 
7. OCCUPATION   : 
8. SOCIAL STATUS   : 
9. DATE OF ADMISSION  : 
10. DATE OF DISCHARGE  : 
11. POSTAL ADDRESS   : 
12. COMPLAINTS & DURATION : 
13. HISTORY OF PRESENT ILLNESS : 
14. PAST HISTORY   : 
15. FAMILY HISTORY   : 
16. MENSTRUAL HISTORY (If Applicable): 
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17. HABITS: 
1. Smoker    : 
2. Alcoholic    : 
3. Tobbaco chewer   :  
4. Betel nut chewer   : 
5. Non-Vegetarian   : 
6. Drug addiction   : 
 
18. GENERAL EXAMINATION: 
1. Body weight (Kg)   : 
2. Height (Cm)   :  
3. Body Temperature (F)  :  
4. Blood Pressure (mmHg)  : 
5. Pulse Rate (/min)   : 
6. Heart Rate (/min)   : 
7. Respiratory Rate (/min)  :  
8. Pallor    :  
9. Jaundice    : 
10. Clubbing    : 
11. Cyanosis    : 
12. Pedal Oedema   :  
13. Lymphadenopathy  :  
14. Jugular venous pulsation  : 
 
19. CLINICAL EXAMINATION: 
I. INSPECTION: 
1. Attitude    : 
2. Muscular spasm   : 
3. Muscle wasting – Proximal :  
4. Muscle wasting – Distal  : 
5. Minor Joint Swelling  : 
6. Major Joint Swelling  : 
7. Nodules    : 
8. Deformity    : 
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II. PALPATION: 
1. Swelling    : 
2. Tenderness   :  
3. Joint Stiffness   : 
4. Muscle wasting   : 
5. Local heat    : 
6. Local Lymphadenopathy  : 
7. Pitting Oedema   : 
8. Nodules    : 
 
III. MOVEMENTS: 
Restriction of joint movements 
1. Neck              :            Full            Partial    
2. Shoulder  : 
3. Elbow joint  : 
4. Knee joint  : 
5. Ankle joint  : 
6. Hip joint  : 
7. Minor joints  : 
IV. PAIN: 
1. Onset :   Sudden : Gradual : 
2. Early morning stiffness :  Present  : absent  : 
3. Nature of pain:  Mild  : Moderate :     Severe: 
4. Aggravating factor –Movements  : 
5. Relieving factor – rest   : 
6. Stiffness     : 
7. Tenderness    :  
 
V. CLINICAL ASSESSMENT :  
1. Arthritis of three or more Joints  : 
2. Arthritis of hand joints   : 
3. Morning Stiffness    : 
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4. Fever     : 
5. Anorexia     : 
6. Anaemia     : 
7. Spindle appearance of fingers  : 
8. Restricted movements   : 
9. Rheumatoid Nodules   : 
10. Numbness     : 
20. EXAMINATION OF OTHER SYSTEMS:  
1. CVS    : 
2. RS     : 
3. CNS    : 
4. ABDOMEN   : 
5. GENITO – URINARY  : 
 
EXAMINATION – SIDDHA ASPECTS 
1. NILAM: 
 1. Kurinji 2. Mullai 3. Marutham 4. Neithal 5. Paalai 
2. KAALAM: 
 1. Kaar Kaalam 2. Koothir Kaalam 3. Munpani Kaalam 
 4. Pinpani Kaalam 5. Elavenir Kaalam 6. Mudhuvenir Kaalam 
3. YAAKKAI:  
 1. Vatham   2. Pitham   3. Kabam 
 4. Vathapitham  5. Pithavatham  6. Kabavatham 
 7. Vathakabam  8. Pithakabam   9. Kabapitham 
4. GUNAM:  
 1. Sathuvam   2. Rasatham   3. Thamasam 
 
5. KANMENDHIRIUM / KANMAVIDAYAM 
 1. Kai   : 
 2. Kaal   : 
 3. Vaai   : 
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 4. Eruvaai  : 
5. Karuvaai  : 
 
6. UYIR THATHUKKAL: 
I. VATHAM: 
1. Piraanan  : 
2. Abaanan  : 
3. Viyaanan  : 
4. Uthaanan  : 
5. Samaanan  : 
6. Naagan  : 
7. Koorman  : 
8. Kirukaran  : 
9. Devathathan : 
10. Dhananjeyan : 
II. PITHAM : 
1. Analagam  : 
2. Ranjagam  : 
3. Saathagam  : 
4. Aalosagam : 
5. Praasagam  : 
III. KABAM: 
1. Avalambagam : 
2. Kilethagam : 
3. Pothagam  : 
4. Tharpagam : 
5. Santhigam  : 
7. UDAL THAATHUKKAL: 
1. Saaram  : 
2. Senneer  : 
3. Oon  : 
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4. Kozhuppu  : 
5. Enbu  : 
6. Moolai  : 
7. Sukkilam / Suronitham: 
8. ENVAGAI THERVUGAL: 
1. Naadi  : 
2. Sparisam  : 
3. Naa  :  
4. Niram  : 
5. Mozhi  : 
6. Vizhi  : 
7. Malam :  
i. Niram:  ii. Thanmai: iii. Irugal: iv.Ilagal: 
8. Moothiram : 
 
I. NEERKURI: 
 a. Niram : 
 b. Manam : 
 c. Edai  : 
 d. Nurai : 
 e. Enjal : 
 
II. NEIKURI: 
 Vatha Neer  :  Pittha Neer   :    Kaba Neer : 
  
Date  :  
Station: 
Signature of the Investigator : 
Signature of the Lecturer :    Signature of the HOD 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
POST GRADUATE DEPARTMENT 
PALAYAMKOTTAI, TIRUNELVELI – 627002 
BRANCH – III SIRAPPU MARUTHUVAM 
A PILOT STUDY TO EVALUATE THE THERAPEUTIC EFFICACY OF SIDDHA 
FORMULATION “PANJA LAVANA PARPAM” INTERNAL & “LAHU VATHA KESARI 
THYLAM” EXTERNAL IN “AZHAL KEEL VAYU” (OSTEOARTHRITIS). 
 
FORM III – LABORATORY INVESTIGATION 
1. BLOOD: 
1. TC   : (Cells / Cumm) 
2. DC (%)  : N : L : M : E : 
3. ESR (mm)  : ½ hr : 1 hr : 
4. Hb   : 
5. Blood Sugar : a) Fasting : b) Post Prandial : 
6. Renal function tests: 
Blood Urea:  Serum creatinine: 
7. Lipid profile : 
HDL:   LDL:  VLDL: 
Total Cholesterol : TGL : 
8. Liver Function tests: 
Serum Bilirubin :  Total  Direct  Indirect 
 
SPECIFIC INVESTIGATIONS 
 RA factor   : 
 ASO titre   : 
 C-Reactive Protein  : 
 SGOT    : 
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SGPT    : 
 Serum albumin & globulin : 
 Total protein   : 
II. URINE: 
1. Albumin   : 
2. Sugar   : 
3. Epithelial cells  : 
4. Pus cells   : 
5. Red blood cells  : 
6. Casts / Crystals  : 
III. MOTION: 
1. Ova   : 
2. Cyst   : 
3. Occult blood  : 
4. Pus cells   : 
IV. X-RAY FINDINGS 
 
 
 
Date  :  
Station: 
Signature of the Investigator : 
Signature of the Lecturer :    Signature of the HOD 
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GOVERNMENTSIDDHAMEDICALCOLLEGE& HOSPITAL 
POST GRADUATE DEPARTMENT 
PALAYAMKOTTAI, TIRUNELVELI – 627002 
BRANCH – III SIRAPPU MARUTHUVAM 
A PILOT STUDY TO EVALUATE THE THERAPEUTIC EFFICACY OF SIDDHA 
FORMULATION “PANJA LAVANA PARPAM” INTERNAL & “LAHU VATHA KESARI 
THYLAM” EXTERNAL IN “AZHAL KEEL VAYU” (OSTEOARTHRITIS). 
    
FORM IV A – CONSENT FORM 
 
CERTIFICATE BY INVESTIGATOR 
 I certify that I have disclosed all the details about the study in the terms readily 
understood by the patient. 
Signature ______________ 
Date      ______________ 
Name    ______________ 
CONSENT BY PATIENT 
 I have been informed to my satisfaction, by the attending physician, the purpose of the 
clinical trial, and the nature of drug treatment and follow-up including the laboratory 
investigations to be performed to monitor and safeguard my body functions. 
 I am aware of my right to opt out of the trial at any time during the course of the trial 
without having to give the reasons for doing so. 
 I exercising my free power of choice, hereby give my consent to be included as a subject 
in the clinical trial of “PANJA LAVANA PARPAM” (Internal drug) and “LAHU VATHA 
KESARI THYLAM” (External drug) for the treatment of “AZHAL KEEL VAYU” 
(OSTEOARTHRITIS)”. 
 
Place :        Signature  :  
Date :         Name  : 
        Witness Signature: 
        Name  :  
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murpdH rpj;j kUj;Jtf; fy;Yhhp kw;Wk; kUj;Jtk; ; ; ; ; ; ;; ; ; ; ; ; ;; ; ; ; ; ; ; id 
ghisaq;Nfhl;il; ;; ;; ;  
gl;lNkw;gbg;G rpwg;G kUj;Jtj;Jiw; ; ; ; ; ;; ; ; ; ; ;; ; ; ; ; ;  
 
‘gQ;rytz gw;gk;; ; ;; ; ;; ; ;” kw;Wk; ‘; ;; ;; ; ,yF thj Nfrhp ijyk;;;;” ,tw;wpd; ghpfhpg;Gj; jpwidf; ; ; ; ; ;; ; ; ; ;; ; ; ; ;
fz;lwpAk; kUj;Jt Ma;T xg;Gjy; gbtk; Ma;thsuhy; rhd;wspf;fg;gl;lJ.; ; ; ; ; ; ; ; ; ; ; ; ;; ; ; ; ; ; ; ; ; ; ; ; ;; ; ; ; ; ; ; ; ; ; ; ; ;  
 
ehd; ,e;j Ma;itf; Fwpj;j midj;J tpguq;fisAk; Nehahspf;F GhpAk; 
tifapy; vLj;Jiuj;Njd; vd cWjpaspf;fpNwd;. 
 
Njjp  :        ifnahg;gk;: 
,lk; :        ngaH: 
Nehahspapd; xg;Gjy;; ; ;; ; ;; ; ; 
 vd;dplk; ,e;j kUj;Jt Ma;tpd; fhuzj;ijAk; kUe;jpd; jd;ik kw;Wk; 
kUj;Jt topKiwiag; gw;wpAk; njhlHe;J vdJ cly; ,af;fj;ij fz;fhzpf;fTk;> 
mjidg; ghJfhf;fTk; gad;gLk; kUj;Jt Ma;Tf;$l ghpNrhjidfs; gw;wpAk; jpUg;jp 
mspf;Fk; tifapy; Ma;T kUj;Jtuhy; tpsf;fpf; $wg;gl;lJ. 
 ehd; ,e;j kUj;Jt Ma;tpd; NghJ fhuzk; vJTk; $whky; vg;nghOJ 
Ntz;LkhdhYk; ,e;j Ma;tpypUe;J vd;id tpLtpj;Jf; nfhs;Sk; chpikia 
njhpe;jpUf;fpd;Nwd;. 
 ehd; vd;Dila Rje;jpukhfj; NjHT nra;Ak; chpikiaf; nfhz;L moy; ;;;
fPy;thAP ;P ;P ; vd;Dk; Neha;f;fhd gQ;rytz gw;gk; ;; ;; ; ;kw;Wk; ‘,yF thj Nfrhp ijyk;;;;” 
Mfpatw;wpd; ghpfhpg;Gj; jpwidf; fz;lwpAk; kUj;Jt Ma;tpw;F vd;id cl;gLj;j 
xg;Gjy; mspf;fpNwd;. 
 
Njjp :       ifnahg;gk;: 
,lk; :       ngaH :  
     
       rhl;rpf;fhuH ifnahg;gk;: 
       ngaH : 
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GOVERNMENTSIDDHAMEDICALCOLLEGE& HOSPITAL 
POST GRADUATE DEPARTMENT 
PALAYAMKOTTAI, TIRUNELVELI – 627002 
BRANCH – III SIRAPPU MARUTHUVAM 
A PILOT STUDY TO EVALUATE THE THERAPEUTIC EFFICACY OF SIDDHA 
FORMULATION “PANJA LAVANA PARPAM” INTERNAL & “LAHU VATHA KESARI 
THYLAM” EXTERNAL IN “AZHAL KEEL VAYU” (OSTEOARTHRITIS). 
FORM IV – B  - WITHDRAWAL FORM 
 
1. SL.NO    : ___________ 
2. OP / IP NO    : ___________ 
3. NAME   : ___________ 
4. RELIGION    : H / C / M / O 
5. AGE / GENDER  : ___________ 
6. OCCUPATION  : ___________ 
7. SOCIAL STATUS  : ___________ 
8. CONTACT NO  : ___________ 
9. DATE OF TRIAL COMMENCEMENT  : ___________ 
10. DATE OF WITHDRAWAL FROM TRIAL : ___________ 
11. REASONS FOR WITHDRAWAL   : ___________ 
 Long absence at reporting   :  Yes / No 
 Irregular treatment    :  Yes / No 
 Shift of locality    :  Yes / No 
 Increase in severity of symptoms  :  Yes / No 
 Development of severe adverse drug reactions:  Yes / No 
 
Date  :  
Station: 
Signature of the Investigator : 
Signature of the Lecturer :    Signature of the HOD 
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GOVERNMENTSIDDHAMEDICALCOLLEGE& HOSPITAL 
POST GRADUATE DEPARTMENT 
PALAYAMKOTTAI, TIRUNELVELI – 627002 
BRANCH – III (SIRAPPU MARUTHUVAM) 
 
A PILOT STUDY TO EVALUATE THE THERAPEUTIC EFFICACY OF SIDDHA 
FORMULATION “PANJA LAVANA PARPAM” INTERNAL & “LAHU VATHA KESARI 
THYLAM” EXTERNAL IN “AZHAL KEEL VAYU” (OSTEOARTHRITIS). 
 
FORM – IV C  DRUG COMPLIANCE FORM 
 
Name of the Drug : SIVATHAI  CHOORANAM 
Drugs issued  : (Mg / Gram) 
Drugs returned : (Mg / Gram) 
 
S. NO DATE DRUG TAKEN TIME 
MORNING / TIME EVENING / TIME 
Day 1    
Day 2    
Day 3    
Day 4     
Day 5    
Day 6    
Day 7    
Day 13    
Day 14    
Day 15    
Day 16    
Day 17    
Day 18    
Day 19    
Day 25    
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Day 26    
Day 27    
Day 28    
Day 29    
Day 30    
Day 31    
Day 37    
Day 38    
Day 39    
Day 40    
Day 41    
Day 42    
Day 43    
Day 44    
Day 45    
Day 46    
Day 47    
Day 48     
 
 
Date  :  
Station: 
Signature of the Investigator : 
Signature of the Lecturer :    Signature of the HOD 
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SCHEMATIC VIEW OF THE MAIN STRUCTURES OF 
A HEALTHY (LEFT) AND DEGENERATE OA 
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